

FILE 'HOME' ENTERED AT 14:46:31 ON 24 SEP 2008

=> fil reg  
COST IN U.S. DOLLARS  
SINCE FILE  
ENTRY  
SESSION  
0.84  
0.84  
FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 14:48:53 ON 24 SEP 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 SEP 2008 HIGHEST RN 1052062-90-4  
DICTIONARY FILE UPDATES: 23 SEP 2008 HIGHEST RN 1052062-90-4

New CAS Information Use Policies, enter **HELP USAGETERMS** for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stnqgen/stndoc/properties.html>

```
=> s
[idek] [eaq] l[lra] [nds] [alki] [ly] [rnlk] [yn] h[mig] [vlqg] [gktd] [rsle] [raei] [vmtl] [lcv] [t
ags] /scsp
```

## INVALID BRACKET EXPRESSION

=> fil reg  
COST IN U.S. DOLLARS  
SINCE FILE ENTRY SESSION  
FULL ESTIMATED COST 1.38 2.22

FILE 'REGISTRY' ENTERED AT 14:50:57 ON 24 SEP 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 SEP 2008 HIGHEST RN 1052062-90-4  
DICTIONARY FILE UPDATES: 23 SEP 2008 HIGHEST RN 1052062-90-4

New CAS Information Use Policies. enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stn/stndoc/properties.html>

```
=> s
[idek][eqq]l[lra][nds][alki][ly][rnlk][yn]h[mig][vlqg][gktd][rsle][raei][vmtl][lcv][tags]/sqsp
```

```
L1      125 [IDEK][EAQ]L[LRA][NDS][ALKI][LY][RNLK][YN]H[MIG][VLQG][GKTD][RSL
E][RAEI][VMTL][LCV][TAGS]/SQSP
```

```
=> fil caplus
COST IN U.S. DOLLARS                               SINCE FILE      TOTAL
                                                    ENTRY      SESSION
FULL ESTIMATED COST                           30.86      33.08
```

FILE 'CAPLUS' ENTERED AT 14:51:08 ON 24 SEP 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Sep 2008 VOL 149 ISS 13  
FILE LAST UPDATED: 23 Sep 2008 (20080923/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>  
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

```
=> s 11
L2      78 L1
=> s 11/thu
L3      26 L1/THU
```

=> d ti 1-26

```
L3      ANSWER 1 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
TI      Use of βig-h3 protein comprising fas-1 domains, EMI domain and RGD
motifs for treatment and prevention of angiogenesis-related disorders
```

L3 ANSWER 2 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

TI Prevention and treatment of inflammation by inhibiting FEX-2-dependent adhesion of lymphocytes to the endothelium

L3 ANSWER 3 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Differentially expressed nucleic acids and encoded polypeptides for use in liver disorders and epithelial cancer

L3 ANSWER 4 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Expression profile of colon cancer specific genes and their use as biomarkers for diagnosis, therapy and drug screening

L3 ANSWER 5 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Genes showing altered patterns of expression in colon cancer and their use in diagnosis and therapy

L3 ANSWER 6 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI TAT (Tumor-associated Antigenic Target) polypeptides and methods for diagnosis and treatment of tumors of glial origin

L3 ANSWER 7 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Novel human genes and gene expression products and their use in diagnosis and treatment of colon cancer

L3 ANSWER 8 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Specific protein markers useful for diagnosis of pancreatic cancer and screening methods

L3 ANSWER 9 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Gene expression profile in activated human CD4+ T cells useful for the diagnosis and treatment of immune-related diseases

L3 ANSWER 10 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Differentially expressed nucleic acids and their encoded proteins and their uses for the diagnosis and treatment of tumor

L3 ANSWER 11 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Nucleic acid and encoded protein sequences that are differentially expressed in psoriatic skin and their use for diagnosis and treatment of psoriasis

L3 ANSWER 12 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Human protein and cDNA sequences for diagnostics and therapeutics

L3 ANSWER 13 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Methods of testing for bronchial asthma or chronic obstructive pulmonary disease, and drug screening for the same, using identified differentially expressed IL-13-stimulated marker genes

L3 ANSWER 14 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Genetic and protein manipulation of  $\beta$ ig-H3 for the treatment and cure of muscular dystrophies

L3 ANSWER 15 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer

L3 ANSWER 16 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Gene expression profiles useful for methods of diagnosis of cancer and screening for modulators of cancer

L3 ANSWER 17 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

L3 Nucleic acid markers for use in determining predisposition to neoplasm and/or adenoma

L3 ANSWER 18 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Gene expression profiles useful in methods of diagnosis of cancer compositions and methods of screening for modulators of cancer

L3 ANSWER 19 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer

L3 ANSWER 20 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Human cDNA sequences and their encoded proteins and diagnostic and therapeutic uses

L3 ANSWER 21 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Protein-protein interactions in human adipocyte cells and method for selecting modulators of these interactions

L3 ANSWER 22 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer

L3 ANSWER 23 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Tumor-associated proteins and their cDNA sequences and uses for immunotherapy and diagnosis of colon cancer

L3 ANSWER 24 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Nucleic acids and their encoded polypeptides from human tissues

L3 ANSWER 25 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Identification of colon cancer-associated proteins for immunotherapy and diagnosis

L3 ANSWER 26 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Colon tumor-specific nucleic acids and proteins and their use for immunotherapy and diagnosis of colon cancer

=> fil reg  
COST IN U.S. DOLLARS  
SINCE FILE  
ENTRY SESSION  
11.96 45.04  
FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 14:51:35 ON 24 SEP 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 SEP 2008 HIGHEST RN 1052062-90-4  
DICTIONARY FILE UPDATES: 23 SEP 2008 HIGHEST RN 1052062-90-4

New CAS Information Use Policies, enter **HELP USAGETERMS** for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> s l1 and sql<30

L4 0 L1 AND SQL<30

=> d his

(FILE 'HOME' ENTERED AT 14:46:31 ON 24 SEP 2008)

FILE 'REGISTRY' ENTERED AT 14:48:53 ON 24 SEP 2008

FILE 'REGISTRY' ENTERED AT 14:50:57 ON 24 SEP 2008

L1 125 S [IDEK][EAQ]L[LRA][NDS][ALKI][LY][RNLK][YN]H[MIG][VLQG][GKTD][

FILE 'CAPLUS' ENTERED AT 14:51:08 ON 24 SEP 2008

L2 78 S L1

L3 26 S L1/THU

FILE 'REGISTRY' ENTERED AT 14:51:35 ON 24 SEP 2008

L4 0 S L1 AND SQL<30

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

FULL ESTIMATED COST

6.07

SESSION

51.11

FILE 'CAPLUS' ENTERED AT 14:52:33 ON 24 SEP 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Sep 2008 VOL 149 ISS 13

FILE LAST UPDATED: 23 Sep 2008 (20080923/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> s US20070004622/pn

L5 1 US20070004622/PN

=> analyze 15 1 rn  
L6 ANALYZE L5 1 RN : 10 TERMS

=> fil reg  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
FULL ESTIMATED COST ENTRY SESSION  
14.25 65.36

FILE 'REGISTRY' ENTERED AT 14:52:50 ON 24 SEP 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 23 SEP 2008 HIGHEST RN 1052062-90-4  
DICTIONARY FILE UPDATES: 23 SEP 2008 HIGHEST RN 1052062-90-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> s 16  
L7 10 L6

=> s 11 and 16

L9 10 L1 AND L8

=> d scan

L9 10 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
IN 8: PN: WO2004087193 SEQID: 8 unclaimed protein (9CI)  
SQL 113  
MF Unspecified  
CI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L9 10 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
IN 5: PN: WO2004087193 SEQID: 5 unclaimed protein (9CI)  
SQL 131  
MF Unspecified  
CI MAN

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L9 10 ANSWERS  REGISTRY COPYRIGHT 2008 ACS on STN  
IN 2: PN: WO2004087193 SEQID: 2 unclaimed protein (9CI)  
SQL 103  
MF Unspecified  
CI MAN

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L9 10 ANSWERS  REGISTRY COPYRIGHT 2008 ACS on STN  
IN 9: PN: WO2004087193 SEQID: 9 unclaimed protein (9CI)  
SQL 73  
MF Unspecified  
CI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L9 10 ANSWERS  REGISTRY COPYRIGHT 2008 ACS on STN  
IN 6: PN: WO2004087193 SEQID: 6 unclaimed protein (9CI)  
SQL 85  
MF Unspecified  
CI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L9 10 ANSWERS  REGISTRY COPYRIGHT 2008 ACS on STN  
IN 3: PN: WO2004087193 SEQID: 3 unclaimed protein (9CI)  
SQL 131  
MF Unspecified  
CI MAN

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L9 10 ANSWERS  REGISTRY COPYRIGHT 2008 ACS on STN  
IN 10: PN: WO2004087193 SEQID: 10 unclaimed protein (9CI)  
SQL 67  
MF Unspecified  
CI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L9 10 ANSWERS  REGISTRY  COPYRIGHT 2008 ACS on STN  
IN 7: PN: WO2004087193 SEQID: 7 unclaimed protein (9CI)  
SQL 119  
MF Unspecified  
CI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L9 10 ANSWERS  REGISTRY  COPYRIGHT 2008 ACS on STN  
IN 4: PN: WO2004087193 SEQID: 4 unclaimed protein (9CI)  
SQL 129  
MF Unspecified  
CI MAN

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L9 10 ANSWERS  REGISTRY  COPYRIGHT 2008 ACS on STN  
IN 1: PN: WO2004087193 SEQID: 1 unclaimed protein (9CI)  
SQL 683  
MF Unspecified  
CI MAN

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> 1  
1 IS NOT A RECOGNIZED COMMAND  
The previous command name entered was not recognized by the system.  
For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (>).

=> d his

(FILE 'HOME' ENTERED AT 14:46:31 ON 24 SEP 2008)

FILE 'REGISTRY' ENTERED AT 14:48:53 ON 24 SEP 2008

FILE 'REGISTRY' ENTERED AT 14:50:57 ON 24 SEP 2008  
L1       125 S [IDEK] [EAQ] L[LRA] [NDS] [ALKI] [LY] [RNLK] [YNJ] H[MIG] [VLQG] [GKTD] [

FILE 'CAPLUS' ENTERED AT 14:51:08 ON 24 SEP 2008  
L2       78 S L1

```

L3          26 S L1/THU
L4          FILE 'REGISTRY' ENTERED AT 14:51:35 ON 24 SEP 2008
          0 S L1 AND SQL<30

L5          FILE 'CAPLUS' ENTERED AT 14:52:33 ON 24 SEP 2008
          1 S US20070004622/PN
L6          ANALYZE L5 1 RN :      10 TERMS

L7          FILE 'REGISTRY' ENTERED AT 14:52:50 ON 24 SEP 2008
          10 S L6
L8          10 S L6
L9          10 S L1 AND L8

=> fil caplus
COST IN U.S. DOLLARS                               SINCE FILE      TOTAL
                                                    ENTRY      SESSION
FULL ESTIMATED COST                               0.46      65.82

FILE 'CAPLUS' ENTERED AT 14:53:35 ON 24 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Sep 2008 VOL 149 ISS 13  
FILE LAST UPDATED: 23 Sep 2008 (20080923/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

081 IS DEFAULT SEARCH FIELD FOR CAFESOS FILE

L10 297112 TUMOR/OBI OR TUMOUR/OBI

→ 8 ONCO:

=> s neoplasm  
L12 525362 NEOPLASM/OBI

=> s cancer  
L13 246205 CANCER/OBI

=> s carcino?  
L14 223599 CARCINO?/OBI

=> s 110-114  
L15 782082 (L10 OR L11 OR L12 OR L13 OR L14)

=> d his

  (FILE 'HOME' ENTERED AT 14:46:31 ON 24 SEP 2008)

  FILE 'REGISTRY' ENTERED AT 14:48:53 ON 24 SEP 2008

  FILE 'REGISTRY' ENTERED AT 14:50:57 ON 24 SEP 2008  
L1      125 S [IDEK][EAQ]L[LRA][NDS][ALKI][LY][RNLK][YN]H[MIG][VLQG][GKTD][

  FILE 'CAPLUS' ENTERED AT 14:51:08 ON 24 SEP 2008  
L2      78 S L1  
L3      26 S L1/THU

  FILE 'REGISTRY' ENTERED AT 14:51:35 ON 24 SEP 2008  
L4      0 S L1 AND SQL<30

  FILE 'CAPLUS' ENTERED AT 14:52:33 ON 24 SEP 2008  
L5      1 S US20070004622/PN  
L6      ANALYZE L5 1 RN :            10 TERMS

  FILE 'REGISTRY' ENTERED AT 14:52:50 ON 24 SEP 2008  
L7      10 S L6  
L8      10 S L6  
L9      10 S L1 AND L8

  FILE 'CAPLUS' ENTERED AT 14:53:35 ON 24 SEP 2008  
L10     297112 S TUMOR OR TUMOUR  
L11     45619 S ONCO?  
L12     525362 S NEOPLASM  
L13     246205 S CANCER  
L14     223599 S CARCINO?  
L15     782082 S L10-L14

=> s 13 (1) 115  
L16     16 L3 (L) L15

=> d ti 1-16

L16 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Differentially expressed nucleic acids and encoded polypeptides for use in  
liver disorders and epithelial cancer

L16 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Expression profile of colon cancer specific genes and their use as  
biomarkers for diagnosis, therapy and drug screening

L16 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Genes showing altered patterns of expression in colon cancer and their use  
in diagnosis and therapy

L16 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN  
TI TAT (Tumor-associated Antigenic Target) polypeptides and methods for  
diagnosis and treatment of tumors of glial origin

L16 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Novel human genes and gene expression products and their use in diagnosis  
and treatment of colon cancer

L16 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Specific protein markers useful for diagnosis of pancreatic cancer and screening methods

L16 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Differentially expressed nucleic acids and their encoded proteins and their uses for the diagnosis and treatment of tumor

L16 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer

L16 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Gene expression profiles useful for methods of diagnosis of cancer and screening for modulators of cancer

L16 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Nucleic acid markers for use in determining predisposition to neoplasm and/or adenoma

L16 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Gene expression profiles useful in methods of diagnosis of cancer compositions and methods of screening for modulators of cancer

L16 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer

L16 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer

L16 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Tumor-associated proteins and their cDNA sequences and uses for immunotherapy and diagnosis of colon cancer

L16 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Identification of colon cancer-associated proteins for immunotherapy and diagnosis

L16 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Colon tumor-specific nucleic acids and proteins and their use for immunotherapy and diagnosis of colon cancer

=> d ti 15

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Use of a peptide that interacts with alphav beta3 integrin of endothelial cell

=> s 116 or 15  
L17 17 L16 OR L5

=> d ti 1-17

L17 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Differentially expressed nucleic acids and encoded polypeptides for use in liver disorders and epithelial cancer

L17 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Expression profile of colon cancer specific genes and their use as biomarkers for diagnosis, therapy and drug screening

L17 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Genes showing altered patterns of expression in colon cancer and their use in diagnosis and therapy

L17 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN  
TI TAT (Tumor-associated Antigenic Target) polypeptides and methods for diagnosis and treatment of tumors of glial origin

L17 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Use of a peptide that interacts with alphav beta3 integrin of endothelial cell

L17 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Novel human genes and gene expression products and their use in diagnosis and treatment of colon cancer

L17 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Specific protein markers useful for diagnosis of pancreatic cancer and screening methods

L17 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Differentially expressed nucleic acids and their encoded proteins and their uses for the diagnosis and treatment of tumor

L17 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer

L17 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Gene expression profiles useful for methods of diagnosis of cancer and screening for modulators of cancer

L17 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Nucleic acid markers for use in determining predisposition to neoplasm and/or adenoma

L17 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Gene expression profiles useful in methods of diagnosis of cancer compositions and methods of screening for modulators of cancer

L17 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer

L17 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer

L17 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Tumor-associated proteins and their cDNA sequences and uses for immunotherapy and diagnosis of colon cancer

L17 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Identification of colon cancer-associated proteins for immunotherapy and diagnosis

L17 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Colon tumor-specific nucleic acids and proteins and their use for  
immunotherapy and diagnosis of colon cancer

=> d ibib abs hitseq 17

L17 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2000:441937 CAPLUS <<LOGINID::20080924>>  
DOCUMENT NUMBER: 133:85149  
TITLE: Colon tumor-specific nucleic acids and proteins and  
their use for immunotherapy and diagnosis of colon  
cancer  
INVENTOR(S): Xu, Jiangchun; Lodes, Michael J.; Sechrist, Heather;  
Benson, Darin R.; Meagher, Madeleine Joy; Stolk, John;  
Wang, Tongtong; Jiang, Yuqiu  
PATENT ASSIGNEE(S): Corixa Corporation, USA  
SOURCE: PCT Int. Appl., 229 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 7  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000037643	A2	20000629	WO 1999-US30909	19991223
WO 2000037643	A3	20010809		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6284241	B1	20010904	US 1998-221298	19981223
US 6623923	B1	20030923	US 1999-401064	19990922
CA 2356987	A1	20000629	CA 1999-2356987	19991223
EP 1144632	A2	20011017	EP 1999-967625	19991223
EP 1144632	A3	20011107		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002533082	T	20021008	JP 2000-589697	19991223
US 20020110547	A1	20020815	US 2001-833263	20010410
US 20020076414	A1	20020620	US 2001-922217	20010803
US 20020182191	A1	20021205	US 2001-25380	20011219
US 20050260177	A1	20051124	US 2005-108172	20050415
PRIORITY APPLN. INFO.:				
		US 1998-221298	A	19981223
		US 1999-347496	A	19990702
		US 1999-401064	A	19990922
		US 1999-444242	A	19991119
		US 1999-454150	A	19991202
		US 1999-444252	A2	19991119
		WO 1999-US30909	W	19991223
		US 1999-476296	A2	19991230
		US 2000-480321	A2	20000110
		US 2000-504629	A2	20000215
		US 2000-519444	A2	20000306
		US 2000-444252	A2	20000410
		US 2000-575251	A2	20000519

US 2000-609448	A2 20000629
US 2000-649811	A2 20000828
US 2001-833263	A2 20010410
US 2001-922217	A2 20010803
US 2001-25380	B1 20011219

AB Over 470 nucleic acids that are overexpressed  $\geq 2$ -fold in human colon tumor tissues are provided. Complementary DNA libraries were constructed by subtracting a pool of colon tumors with a pool of normal colon and other tissues using PCR subtraction methodologies; clones from the cDNA subtracted library were submitted to PCR amplification, and mRNA expression levels for representative clones determined by microarray technol. This method recovers rare transcripts that are over-expressed in colon tumor tissue. Addnl. colon tumor-specific transcripts were obtained by (1) conventional cDNA subtraction, (2) use of mouse antisera to identify DNA sequences encoding colon tumor antigens, (3) and isolation of tumor polypeptides using SCID-passaged tumor RNA. Compns. and methods for the therapy and diagnosis of cancer, such as colon cancer, are disclosed. Compns. may comprise one or more colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen-presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a protein. Such compns. may be used, for example, for the prevention and treatment of diseases such as colon cancer. Diagnostic methods based on detecting a colon tumor protein, or mRNA encoding such a protein, in a sample are also provided.

IT 148710-76-3, Protein (human clone  $\beta$ ig-h3 transforming growth factor  $\beta$ -induced precursor reduced)

RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)

(amino acid sequence; colon tumor-specific nucleic acids and proteins and their use for immunotherapy and diagnosis of colon cancer)

RN 148710-76-3 CAPLOS

CN Protein (human clone  $\beta$ ig-h3 transforming growth factor  $\beta$ -induced precursor reduced) (9CI) (CA INDEX NAME)

SEQ

1	MALFVRLAL	ALALALGPAA	TLAGPAKSPY	QLVLQHSRLR	GRQHGPNVCA
51	VQKVIGTNRK	YFTNCCKQWYQ	RKICGKSTVI	SYECCPGYEK	VPGEKGCPA
101	LPLSNLYETL	GVVGSTTQL	YTDRTEKLRP	EMEGPGSFTI	FAPSNEAWAS
151	LPAEVLDLSV	SNVNIELLLNA	LRYHMVGRVV	LTDDELKHGMT	LTSMYQNSNI
201	QIHYPNGIV	TVCARLLKA	DHATNGVVH	LIDKVISTIT	NNIQQIIIEIE
251	DTFETLRAAV	AASGLNTMLE	GNGQYTLAP	TNEAFEKIPS	ETLNRLIGDP
301	EALRDLNNHH	ILKSAMCAEA	IVAGLSVETL	EGTTLEVGCS	GDLMLTINGKA
351	IISNKKDILAT	NGVIHYIDEL	LIPDSAKTLE	ELAAEESDVST	AIDLFRQAGL
401	GNHLSGSERL	TLLAPLNSVF	KDGTPIDAH	TRNLLRNHII	KDQLASKYLY
451	HQQTLETLGG	KKLRLRVFVYRN	SLCIENSCIA	AHDKRGRYGT	LFTMDRVLTP
501	PMGTVMDVLK	GDNRFMSMLVA	AIQSAGLTET	LNREGVYTVF	APTNEAFRAL
551	PPRERSRLLG	DAKELANILK	YHIGDEILVS	GGIGALVRLK	SLQGDKLEVS
601	LKNNVSVSNK	EPVAEPDIMA	TNGVHVITN	VLOPPANRPQ	ERGDELADSA
651	LEIFKQASAF	SRASQRSVRL	APVYQKLLER	MKH	

=> fil stng  
COST IN U.S. DOLLARS

SINCE ENTRY	TOTAL SESSION
-------------	---------------

FULL ESTIMATED COST	35.15	100.97
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.80	-0.80

FILE 'STNGUIDE' ENTERED AT 14:55:58 ON 24 SEP 2008  
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.  
 LAST RELOADED: Sep 19, 2008 (20080919/UP).

=> fil caplus		
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.72	101.69
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.80

FILE 'CAPLUS' ENTERED AT 15:02:52 ON 24 SEP 2008  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Sep 2008 VOL 149 ISS 13  
 FILE LAST UPDATED: 23 Sep 2008 (20080923/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>  
 'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> d ibib abs hitseq 6-16

L17 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:609831 CAPLUS <<LOGINID::20080924>>  
 DOCUMENT NUMBER: 141:155365  
 TITLE: Novel human genes and gene expression products and  
 their use in diagnosis and treatment of colon cancer  
 INVENTOR(S): Astle, Jon H.; Boardman, Lisa Allyn; Burgart, Lawrence  
 J.; Burgess, Christopher C.; Catino, Theodore J.;  
 Dwivedi, Poornima; Lewis, Marcia E.; Molino, Gary A.;  
 Myerow, Susan H.; Thiagalingam, Arunthathi; Thibodeau,

Stephen N.  
 PATENT ASSIGNEE(S): Bayer Healthcare LLC, USA; Mayo Foundation for Medical Education & Research  
 SOURCE: U.S. Pat. Appl. Publ., 58 pp., Cont.-in-part of U.S. Ser. No. 871,161.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 5  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040146879	A1	20040729	US 2003-610049	20030630
US 6262333	B1	20010717	US 1999-328111	19990608
US 6262334	B1	20010717	US 1999-385982	19990830
US 20030097666	A1	20030522	US 2001-871161	20010531
US 20020144298	A1	20020103	US 2001-879536	20010611
EP 1494031	A2	20050105	EP 2004-253880	20040629
EP 1494031	A3	20071121		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
JP 2005046137	A	20050224	JP 2004-191089	20040629
			US 1998-98639P	P 19980831
			US 1999-117393P	P 19990127
			US 1999-328111	A2 19990608
			US 1999-385982	A1 19990830
			US 2001-871161	A2 20010531
			US 1998-88801P	P 19980610
			US 2003-610049	A 20030630

PRIORITY APPLN. INFO.:

AB This invention relates to novel human genes, to proteins expressed by the genes, and to variants of the proteins. The invention also relates to diagnostic assays and therapeutic agents related to the genes and proteins, including probes, antisense constructs, and antibodies. The subject nucleic acids have been found to be differentially regulated in tumor cells, particularly in colon cancer tissue.

IT 727761-71-9

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (amino acid sequence; human genes and gene expression products and their use in diagnosis and treatment of colon cancer)

RN 727761-71-9 CAPLUS

CN Protein (human colon cancer-specific gene) (9CI) (CA INDEX NAME)

SEQ 1 MALFVRLLL ALALALGPAA TLAGPAKSPY QLVLQHSRLR GRQHGPNVCA  
 51 VQKVIGTNRK YFTNCKQWYQ RKICGKSTVI SYECCPGYEK VPGEKGCPAA  
 101 LPLSNLYETL GVGVSTTQL YTDRTEKLRP EMEGPGSFTI FAPSNEAWAS  
 151 LPAAVLDSLV SNVNIELLNA LRYHMVGRVV LTDELKHGMT LTSMYQNSNI  
 201 QIHHYPNIGV TVNCARLLKA DHATNGVHV LIDKVISTIT NNIQQIEIE  
 251 DTFETLRAAV AASGLNTMLE GNGQYTLAP TNEAEFKIPS ETLNRLIGDP  
 301 EAALRDLNNH ILKSAAMCAA IVAGLSVETL EGTTILEVGCS GDMLTINGKA  
 351 IISNKKDILAT NGVIHYIDEL LIPDSAKTLE ELAAEESDVT AIDLFRQAGL  
 401 GNHLSGSERL TLLAPLNSVF KDGTPPIDAH TRNLLRNHII KDLQASKYLY  
 451 HGQTLLETLLGG KKLRFVYVRN SLCIENSCIA AHDKRRGRYGT LFTMDRVLTP  
 501 PMGTVMDVLK GDNRFSMLVA AIQOSAGLTET LNREGVYTVF APTNEAFRAL  
 551 PPRERSRLLG DAKELANILK YHIGDEILVS GGIAGLVRK SLQGDKLEVS  
 601 LKNNVSVNK EPVAEPDIMA TNGVVHVITN VLQPPANRPQ ERGDELADSA  
 651 LEIFKQASAF SRASQRSVRL APVYQKLLER MKH

L17 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:534405 CAPLUS <<LOGINID::20080924>>  
 DOCUMENT NUMBER: 141:69775  
 TITLE: Specific protein markers useful for diagnosis of  
 pancreatic cancer and screening methods  
 INVENTOR(S): Chen, Jie; Hu, Liping; Liu, Tong Hua; Lu, Zhao Hui;  
 Shen, Yan  
 PATENT ASSIGNEE(S): F. Hoffmann-La Roche Ag, Switz.; Sinogenomax Co. Ltd.  
 Chinese National Human Genomecenter  
 SOURCE: PCT Int. Appl., 381 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004055519	A2	20040701	WO 2003-EP14057	20031211
WO 2004055519	A3	20041104		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003294828	A1	20040709	AU 2003-294828	20031211
US 20040219572	A1	20041104	US 2003-733969	20031211
CN 1726395	A	20060125	CN 2003-80106539	20031211
PRIORITY APPLN. INFO.:			EP 2002-28058 EP 2003-25237 WO 2003-EP14057	A 20021217 A 20031105 W 20031211

AB The present invention provides polypeptides which are up- or down-regulated in pancreatic cancer and which can be used as markers for diagnosis of pancreatic cancer. Thus, 110 protein markers are identified in pancreatic adenocarcinoma patients by 2-dimensional electrophoresis and MALDI-TOF mass spectrometry. The invention also provides an in vitro method for the diagnosis of pancreatic cancer and/or the susceptibility to pancreatic cancer comprising the steps of (a) obtaining a biol. sample; and (b) detecting and/or measuring the increase of one or more polypeptides as disclosed herein. Furthermore, screening methods relating to inhibitors and antagonists of the specific polypeptides disclosed herein are provided.

IT 712410-93-0

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study);

USES (Uses)

(amino acid sequence; specific protein markers useful for diagnosis of pancreatic cancer and screening methods)

RN 712410-93-0 CAPLUS

CN Cell adhesion molecule  $\beta$ ig-h3 (TGF- $\beta$ -induced gene h3 (human precursor) (9CI) (CA INDEX NAME)

SEQ 1 MALFVRLAL ALALALGPA A TLAGPAKSPY QLVLQHSRLR GRQHGPNVCA  
 51 VQKVGITNRK YFTNCQWYQ RKICGKSTVI SYECCPGYEK VPGEKGCPAA  
 101 LPLSNLYETL GVGSTTTQL YTDRTEKLRP EMEGPGSFTI FAPSNEAWAS  
 151 LPAEVLDLSV SNVNIELNA LRYHMVGRV L TDELKHGML LTSMYQNSNI  
 201 QIHHYPNGIV TVNCARLLKA DHAHTNGVH LIDKVISTIT NNIIQOIIIEIE  
 251 DTTFETLRAAV AASGLNTMLE GNGQYTLLAP TNEAEFKIPS ETLNRIILGDP  
 301 EALRDLNNH ILKSAMCABA IVAGLSVETL EGTTLEVGC S GDMLTINGKA  
 351 IISNKKDILAT NGVIVHYIDEL LIPDASKTLE ELAAESDVT AIDLFRQAGL  
 401 GNHLSGSERL TLLAPLNSVF KDGTPPIDAH TRNLLRNHII K DQQLASKYLY  
 451 HQQTLETLLGG KKLRLRVFVYRN SLCIENSCIA AHDKRGRYGT LFTMDRVLTP  
 501 PMGTVMDVLK GDNRFSMLVA AIQSGALLTET LNREGVYTVF APTNEAFLR  
 551 PPRERSRLLG DAKELANILK YHIGDEILVS GGIGALVRLK SLOQDKLEVS  
 601 LKNNVVSVNK EPVVAEPDIMA TNQGVVHWITN VLQOPPANRQ ERGDELADSA  
 651 LEIFKQASAF SRASQRSVRL APVYQKLLER MKH

L17 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:308357 CAPLUS <<LOGINID::20080924>>  
 DOCUMENT NUMBER: 140:333596  
 TITLE: Differentially expressed nucleic acids and their  
 encoded proteins and their uses for the diagnosis and  
 treatment of tumor  
 INVENTOR(S): Wu, Thomas D.; Zhang, Zemin; Zhou, Yan  
 PATENT ASSIGNEE(S): Genentech, Inc., USA  
 SOURCE: PCT Int. Appl., 7273 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004030615	A2	20040415	WO 2003-US28547	20030929
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2500687	A1	20040415	CA 2003-2500687	20030929
WO 2004030615	A2	20040415	WO 2003-XA28547	20030929
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003295328	A1	20040423	AU 2003-295328	20030929
EP 1594447	A2	20051116	EP 2003-786510	20030929
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 JP 2006516089 T 20060622 JP 2004-541530 20030929  
 US 20070224201 A1 20070927 US 2005-529351 20050325  
 PRIORITY APPLN. INFO.: US 2002-414971P P 20021002  
 WO 2003-US28547 W 20030929

AB The present invention provides a large number of specific cDNA sequences which are upregulated in certain tumor tissues as compared to their normal tissue counterparts and therefore useful for the diagnosis and treatment of tumor in mammals. An expressed sequence tag (EST) DNA database was searched and interesting EST sequences identified by GEPIS (gene expression profiling in silico), a bioinformatics tool that characterizes genes of interest for new cancer therapeutic targets. Using this type of screening bioinformatics, various tumor-associated antigenic target (TAT) proteins (and their encoding nucleic acid mols). were identified as being significantly overexpressed in particular type of cancer or certain cancers as compared to other cancers and/or normal non-cancerous tissues. [This abstract record is one of two records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints].

IT 677367-06-5P, Tumor-associated antigen PRO2561 (human)

RL; ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (amino acid sequence; differentially expressed nucleic acids and their encoded proteins and their uses for the diagnosis and treatment of tumor)

RN 677367-06-5 CAPLUS

CN Tumor-associated antigen PRO2561 (human) (9CI) (CA INDEX NAME)

SEQ 1 MMALFVRLLA LALALALGPA ATLAGPAKSP YQLVLQHSRL RGROHGPNV  
 51 AVQKVGITNR KYFVNCKQWY QRKICGKSTV ISYECPCGYE KVPGEGCPA  
 101 ALAPLNSNLYET LGVVGSTTTQ LYTDRTKEPLR PEMEGPGSFT IFAPFSNEAWA  
 151 SLPAEVLDSL VSNVNIELLN ALRYHMVGRV VLTDDELKHM TLTSMYQNSN  
 201 IQIHHYPNGI VTVNCARLLK ADHHATNGVV HLIDKVISTI TNNIQQIIEI  
 251 EDTFETLRAA VAASGLNTML EGNGQYTLLA PTNEAFEKIP SETLNRLRIL  
 301 PEALRDLNN HILKSAMCAE AIVAGLSVET LEGTTLEVGC SGDMLTINGK  
 351 AIISNKDLA TNQVIHYIDE LLIPDSAKTL FELAAESDVS TAIDLFRQAG  
 401 LGNHLGSGER LTLALPLNSV FKDGTPPIDA HTRNLLRNHI IKDQLASKYL  
 451 YHGGQTLETLG GKKLRFVYR NSLCIENSCI AAHDKRGRRYRG TLFTMDRVL  
 501 FPMGTVMDVL KGDNRFSLMV AAQASAGLITE TLNRREGVYTV FAPTNNEAFRA  
 551 LPPRERSRLR GDAAKELANIL KYHIGDEILV SGIGALVRL KSLQGDKLEV  
 601 SLKNNVVSVN KEPVAEPDIM ATNGVHVIT NVLQPANRE QERGDELADS  
 651 ALEIFKQASA FSRASQRSRV LAPVYQKLLE RMKH

L17 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2003:747872 CAPLUS <<LOGINID::20080924>>  
 DOCUMENT NUMBER: 139:256367  
 TITLE: Tumor-associated nucleic acids and proteins for  
 immunotherapy and diagnosis of colon cancer  
 INVENTOR(S): Xu, Jiangchun; Lodes, Michael J.; Sechrist, Heather;  
 Meagher, Madeleine Joy; Stolk, John; Benson, Darin R.;  
 Wang, Tongtong  
 PATENT ASSIGNEE(S): Corixa Corporation, USA  
 SOURCE: U.S., 140 pp., Cont.-in-part of U.S. Ser. No. 347,496.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent

LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 7  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6623923	B1	20030923	US 1999-401064	19990922
US 6284241	B1	20010904	US 1998-221298	19981223
CA 2356987	A1	20000629	CA 1999-2356987	19991223
WO 2000037643	A2	20000629	WO 1999-US30909	19991223
WO 2000037643	A3	20010809		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1144632	A2	20011017	EP 1999-967625	19991223
EP 1144632	A3	20011107		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002533082	T	20021008	JP 2000-589697	19991223
EP 1715043	A2	20061025	EP 2006-2432	19991223
EP 1715043	A3	20070110		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
EP 1767636	A2	20070328	EP 2006-25304	19991223
EP 1767636	A3	20070613		
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, AL, LT, LV, MK, RO, SI				
US 20020110547	A1	20020815	US 2001-833263	20010410
US 20020076414	A1	20020620	US 2001-922217	20010803
US 20020182191	A1	20021205	US 2001-25380	20011219
US 20050260177	A1	20051124	US 2005-108172	20050415
PRIORITY APPLN. INFO.:				
		US 1998-221298	A2 19981223	
		US 1999-347496	A2 19990702	
		US 1999-401064	A 19990922	
		US 1999-444242	A 19991119	
		US 1999-444252	A2 19991119	
		US 1999-454150	A 19991202	
		EP 1999-967625	A3 19991223	
		WO 1999-US30909	W 19991223	
		US 1999-476296	A2 19991230	
		US 2000-480321	A2 20000110	
		US 2000-504629	A2 20000215	
		US 2000-519444	A2 20000306	
		US 2000-444252	A2 20000410	
		US 2000-575251	A2 20000519	
		US 2000-609448	A2 20000629	
		US 2000-649811	A2 20000828	
		US 2001-833263	A2 20010410	
		US 2001-922217	A2 20010803	
		US 2001-25380	B1 20011219	

AB Compns. and methods for the therapy and diagnosis of cancer, such as colon cancer, are disclosed. Compns. may comprise one or more colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a protein. Thus, polypeptides

differentially expressed in colon tumors are isolated and characterized by PCR-based subtraction and microarray anal. of cDNA libraries, as well as mouse antisera. Such compns. may be used, for example, for the prevention and treatment of diseases such as colon cancer. Diagnostic methods based on detecting a colon tumor protein, or mRNA encoding such a protein, in a sample are also provided.

IT 603206-84-4P

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(amino acid sequence; tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer)

RN 603206-84-4 CAPLUS

CN Colon tumor-associated protein (human clone US6623923-SEQID-121) (9CI)  
(CA INDEX NAME)

SEQ 1 MALFVRLAL ALALALGPAA TLAGPAKSPY QLVLQHSRLR GRQHGPNVCA  
51 VQKVIGTNRK YFTNCKQWYQ RKICGKSTVI SYECCPGYEK VPGEKGCPAA  
101 LPALSNLYETL GVGSTTQL YTDRTEKLRP EMEPGFGSFTI FAPSNEAWAS  
151 LPAAEVLDLSV SNNVNIELLNA LRYHMVGRRV LTDELKHGMT LTSMYQNSNI  
201 QIHYPNGIV TVNCARLLKA DHATNGVVH LIDKVISTIT NNIQQIIEIE  
251 DTFFETLRAAV AASGLNTMLE GNGQYTLAP TNEAFEKIPS ETLNRILGDP  
301 EALARDLNNH ILKSAMCMEA IVAGLSVETL EGTTLEVGCS GDLMLTINGKA  
351 IIISNKDILAT NGVIYHIDEL LIPDASAKTFL ELAAEESDVT AIDLFRQAGL  
401 GNHLSGSERL TLLAPLNSVF KDGTPPIDAH TRNLLRNHHI KDQLASKIYL  
451 HQQTLETLLGG KKLRVFWYRN SLCIENSCIA AHDKRGRYGT LFMDRVLTP  
501 PMGTVMDVLK GDNRFSMLVA AIQSAGLTET LNREGVYTFV APTNEAFRAL  
551 PPRERSRLLG DAKELANILK YHIGDEILVS GGIGALVRLK SLQGDKLEVS  
601 LKNNNVSVNK EPVAPEDIMA TNGVVHVITN VLQPANRPQ ERGDELADSA  
651 LEIFKQASAF SRASQRSVRL APVYQKLLER MKH

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2003:442069 CAPLUS <<LOGINID::20080924>>  
DOCUMENT NUMBER: 139:18315  
TITLE: Gene expression profiles useful for methods of diagnosis of cancer and screening for modulators of cancer  
INVENTOR(S): Afar, Daniel; Aziz, Natasha; Ginsburg, Wendy M.; Gish, Kurt C.; Glynne, Richard; Hevezsi, Peter A.; Mack, David H.; Murray, Richard; Watson, Susan R.; Wilson, Keith E.; Zlotnik, Albert  
PATENT ASSIGNEE(S): Eos Biotechnology, Inc., USA  
SOURCE: PCT Int. Appl., 1385 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 38  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003042661	A2	20030522	WO 2002-XK36810	20021113
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,			

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,  
 PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT,  
 TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,  
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,  
 PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
 NE, SN, TD, TG  
 EP 1721977 A2 20061115 EP 2006-7721 20020917  
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT,  
 LI, LU, MC, NL, PT, SE, SK, TR  
 US 20070042360 A1 20070222 US 2002-245882 20020917  
 WO 2003042661 A2 20030522 WO 2002-US36810 20021113  
 WO 2003042661 A3 20041028  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KE, KR, KZ, LC, LK, LR,  
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,  
 PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT,  
 TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,  
 CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 US 20040197325 A1 20041007 US 2003-741657 20031219  
 US 7276372 B2 20071002  
 US 20070059748 A1 20070315 US 2006-516476 20060906  
 US 20070154928 A1 20070705 US 2007-625458 20070122  
 PRIORITY APPLN. INFO.:  
 US 2001-350666P P 20011113  
 US 2001-335394P P 20011115  
 US 2001-332464P P 20011121  
 US 2001-334393P P 20011129  
 US 2001-340376P P 20011214  
 US 2002-347211P P 20020108  
 US 2002-347349P P 20020110  
 US 2002-356714P P 20020213  
 US 2002-359077P P 20020220  
 US 2002-368809P P 20020329  
 US 2002-370110P P 20020404  
 US 2002-372246P P 20020412  
 US 2002-386614P P 20020605  
 US 2002-396839P P 20020716  
 US 2002-397775P P 20020722  
 US 2002-397845P P 20020722  
 US 2002-409450P P 20020909  
 WO 2002-US36810 W 20021113  
 US 2001-299234P P 20010618  
 US 2001-315287P P 20010827  
 US 2001-323469P P 20010917  
 US 2001-323887P P 20010920  
 US 2001-325114P P 20010925  
 US 2001-340944P P 20011029  
 US 2002-355145P P 20020208  
 US 2002-355257P P 20020208  
 US 2002-369899P P 20020404  
 US 2002-173999 A 20020617  
 EP 2002-766297 A3 20020917  
 US 2002-245882 A1 20020917  
 US 2002-435618P P 20021220

AB Described herein are genes whose expression are up-regulated or  
 down-regulated in specific cancers or other diseases, or are otherwise  
 regulated in disease. Mol. profiles of various normal and cancerous

tissues were determined and analyzed using the Affymetrix/Eos Hu3 GeneChip array comprising .apprx.58,680 probesets. Related methods and compns. that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of these selected conditions. [This abstract record is one of twelve records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 537729-48-9  
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(amino acid sequence; gene expression profiles useful for methods of  
diagnosis of cancer and screening for modulators of  
cancer)

RN 537729-48-9 CAPLUS

CN Tumor-associated protein (human clone WO03042661-SEQID-C295) (9CI) (CA  
INDEX NAME)

SEQ 1 MALFVRLAL ALALALGPAA TLAGPAKSPY QLVLQHSLRL GRQHGPNVCA  
51 VQKVIGTNRK YFTNCQWYQ RKIGCKSTVI SYECCPGYEK VPGEKGCPAA  
101 LPLSNLYETL GVGSTTTQL YTDRTEKLRP EMEPGPSFTI FAPSNEAWAS  
151 LPAEVLDLSV SNVNIELLKA LRYHMVGRRV LTDELKHGMT LTSMYQNSNI  
201 QIHHYPNGIV TVNCARLLNA DHAATNGVHH LIDKVISTIT NNHQIIEIE  
251 DTFETLRAAV AASGLNTMLE GNGQYTLLAP TNEAEFKIPS ETLNRLGDP  
301 EALRDLNNNH ILKSAMCAEA IVAGLSVETL EGTTILEVGC5 GDMLTINGKA  
351 IISNNDILAT NGVVIHYIDEL LIPDASAKTLE ELAAESDVT AIDLFRQAGL  
401 GHNLGSERL TLALPRLNSVF KDGTTPIDAH TRNLLRNHII KDQLASKYLY  
451 HQQTLTLLGG KKLRLVFVYRN SLCIENSCIA AHDKRGRYGT LFTMDRVLTP  
501 PMGTVMDVLK GDNRFSMLVA AIQSGAGLTET LNREGVYTFV APTNEAFRAL  
551 PPRERSRLLG DAKELANILK YHIGDEILVS GGIGALVRLK SLQGDKLEVS  
601 LKNNVVSVNK EPVVAEPDIMA TNQGVVHVTIN VLQPPANRPQ ERGDELADSA  
651 LEIFKQASAF SRASQRSVRL APVIQKLLER MKH

L17 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2003:242516 CAPLUS <>LOGINID::20080924>>  
DOCUMENT NUMBER: 138:266955  
TITLE: Nucleic acid markers for use in determining  
predisposition to neoplasm and/or adenoma  
INVENTOR(S): James, Robert; Henry, Julianne; Kazenwadel, Jan; Van  
Host, Pellekaan Nick; MacPherson, Anne; O'Connor,  
Susan  
PATENT ASSIGNEE(S): Medicomolecular Pty. Ltd., Australia  
SOURCE: PCT Int. Appl., 430 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003025214	A1	20030327	WO 2002-AU1258	20020913
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,			

UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002325088	A1 20030401	AU 2002-325088	20020913
AU 2002325088	B2 20070809		
EP 1438427	A1 20040721	EP 2002-757979	20020913
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
US 20050053967	A1 20050310	US 2004-800322	20040312
AU 2007201611	A1 20070503	AU 2007-201611	20070412
PRIORITY APFLN. INFO.:		US 2001-322288P	P 20010514
		AU 2002-325088	A3 20020913
		WO 2002-AU1258	W 20020913

AB The present invention relates generally to novel nucleic acid mols., the levels and/or patterns of expression of which are indicative of the onset, predisposition to the onset and/or progression of a neoplasm and to derivs., homologs or analogs of said mols. More particularly, the present invention is directed to novel nucleic acid mols., the levels of expression of which are indicative of the onset and/or progression of a gastrointestinal tract neoplasm, such as an adenoma, and to derivs., homologs or analogs of said mols. The present invention is further directed to isolated proteins encoded thereby and to derivs., homologs, analogs, chemical equivalent and mimetics thereof. The identification of adenoma

markers and adenoma markers together with identification of their expression uplift levels and expression profile can now be correlated to disease stage and/or cancer invasiveness. The mols. of the present invention are useful in a range of prophylactic, therapeutic, and/or diagnostic applications including, but not limited to, those relating to the diagnosis and/or treatment of colorectal neoplasms such as colorectal adenomas. In a related aspect, the present invention is directed to a method of screening a subject for the onset, predisposition to the onset, and/or progression of a neoplasm by screening for modulation in the level of expression of one or more nucleic acid mol. markers.

IT 503193-38-2

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(amino acid sequence; nucleic acid markers for use in determining predisposition to neoplasm and/or adenoma)

RN 503193-38-2 CAPLUS

CN Adenoma-associated protein (human clone 4-1le) (9CI) (CA INDEX NAME)

SEQ 1 MALFVRLLL ALALALGPAA TLAGPAKSPY QLVLQHSRLR GRQHGPNVCA  
 51 VQKVIGTNRK YFTNCKQWYQ RKICGKSTVI SYECCPGYEK VPGEKGCPAA  
 101 LPLSNLYETL GVGVSTTQL YTDRTKELRP EMEGPGSFTI FAPSNEAWAS  
 151 LPAAVLSDLV SNVNIELLNA LRYHMVGRVV LTDELKHGMT LTSMYQNSNI  
 201 QIHHYHNGIV TVNCARLLKA DHATNGVHV LIDKVISTIT NNIIQIIIEIE  
 251 DTFETLRAAV AASGLNTMLE GNGQYTLAPP TNEAEFKIPS ETLNRLILGDP  
 301 EAALRDLNNH ILKSAMCAEA IVAGLSVETL EGTTILEVGCS GDMLTINGKA  
 351 IISNKKDILAT NGVIHYIDEL LIPDSAKTLE ELAAEESDVST AIDLFRQAGL  
 401 GNHLSGSERL TLLAPLNSVF KDGTPPIDAH TRNLLRNHII KQQLASKYLY  
 451 HGQTLLETLLGG KKLRFVSYRN SLCIENSCIA AHDRGRGRYGT LFTMDRVLTP  
 501 PMGTVMDVLK GDNRFSMVLVA AIQOSAGLTT LNREGVYTVF APTNEAFRAL  
 551 PPRERSRLLG DAKELANILK YHIGDEILVS GGIAGLVRK SLQGDKLEVS  
 601 LKNNVVSVNK EPVAEPDIMA TNGVVHVITN VLQPPANRPQ ERGDELADSA  
 651 LEIFKQASAF SRASQRSVRL APVYQKLLER MKH

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2003:242452 CAPLUS <<LOGINID::20080924>>  
DOCUMENT NUMBER: 138:282427  
TITLE: Gene expression profiles useful in methods of diagnosis of cancer compositions and methods of screening for modulators of cancer  
INVENTOR(S): Afar, Daniel; Aziz, Natasha; Gish, Kurt C.; Hevez, Peter A.; Mack, David H.; Wilson, Keith E.; Zlotnik, Albert  
PATENT ASSIGNEE(S): EOS Biotechnology, Inc., USA  
SOURCE: PCT Int. Appl., 767 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 38  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003025138	A2	20030327	WO 2002-US29560	20020917
WO 2003025138	A3	20030508		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2459219	A1	20030327	CA 2002-2459219	20020917
WO 2003025138	A2	20030327	WO 2002-XA29560	20020917
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2003025138	A2	20030327	WO 2002-XB29560	20020917
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2003025138	A2	20030327	WO 2002-XC29560	20020917
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,  
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,  
 UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,  
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,  
 PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
 NE, SN, TD, TG

WO 2003025138 A2 20030327 WO 2002-XD29560 20020917  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,  
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,  
 UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,  
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,  
 PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
 NE, SN, TD, TG

WO 2003025138 A2 20030327 WO 2002-XE29560 20020917  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,  
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,  
 UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,  
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,  
 PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
 NE, SN, TD, TG

WO 2003025138 A2 20030327 WO 2002-XF29560 20020917  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,  
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,  
 UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,  
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,  
 PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
 NE, SN, TD, TG

WO 2003025138 A2 20030327 WO 2002-XG29560 20020917  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,  
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,  
 UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,  
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,  
 PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
 NE, SN, TD, TG

WO 2003025138 A2 20030327 WO 2002-XH29560 20020917  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,  
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,  
 UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,

CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002330039	A1	20030401	AU 2002-330039	20020917
EP 1434881	A2	20040707	EP 2002-766297	20020917
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005518782	T	20050630	JP 2003-529912	20020917
EP 1721977	A2	20061115	EP 2006-7721	20020917
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SK, TR				
US 20070042360	A1	20070222	US 2002-245882	20020917
US 20040197325	A1	20041007	US 2003-741657	20031219
US 7276372	B2	20071002		
US 20070059748	A1	20070315	US 2006-516476	20060906
US 20070154928	A1	20070705	US 2007-625458	20070122

AB Described herein are genes whose expression are up-regulated or down-regulated in specific cancers, including acute lymphocytic leukemia, glioblastoma, glioblastoma multiforme, glioma, kidney cancer, stomach cancer, melanoma, and benign nevi. Mol. profiles of various normal and cancerous tissues were determined and analyzed using the Affymetrix/Bos Hu01 and Hu03 GeneChip microarrays containing 35,403 and 59,680 probe sets, resp. Related methods and compns. that can be used for diagnosis and treatment of those cancers are disclosed. Also described herein are methods that can be used to identify modulators of selected cancers. [This abstract record is one of nine records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT 503636-40-6

RL: ANT (Analyte); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(amino acid sequence; gene expression profiles useful in methods of diagnosis of cancer compns. and methods of screening for modulators of cancer)

RN 503636-40-6 CAPLUS

CN Tumor-associated protein (human clone WO03025138-SEQID-279) (9CI) (CA INDEX NAME)

SEQ	1	MALEFVRLLAL	ALALALGPA	TLAGPKAPS	YQLVLOHSLR	GRQHGPNVCA
	51	VQKVIGTNRK	YFTNCKQWYQ	RKICGKSTVI	SYECPGKEY	VPGEKGCPAA
101		TSPLNSLYETL	VGUVGTTQ	YTDTRKELRP	EMEPGGSFTI	LTSMSEWAAS
151		LPAEVFLSDLV	SNVNIELLNA	LYRHWMGRVRL	LTDDELKHGM	LTSMQNSYNI
201		OIIHYPNGIV	TVCNARLLKA	DHHATNGVHV	LIDKVISTIT	NNIQOIIIELE

251 DTFETLRAAV AASGLNTMLE GNGQYTLAP TNEAFEKIPS ETLNRLIGDP  
 301 EALRDLNNH ILKSAMCAEA IVAGLSVETL EGTTLEVGC GDLMLTINGKA  
 351 IISNKDILAT NGVIHYIDEL LIPDSAKTLE ELAAEESDVT AIDLFRQAGL  
 401 GNHLSGSERL TLLAPLNSV KGDTTPIDAH TRNLLRNHII KDQLASKYLY  
 451 HQQTLETLLGG KKLRLVVFYRN SLCIENCIA AHDKRGRYGT LFTMDRVLTP  
 501 PMGTVMDVLK GDNRFSMLVA AIQSGALTET LNREGVYTFV APTNEAFRAL  
 551 PRERSRLLG DAKELANILK YHIGDEILVS GGIGALVRLK SLQGDKLEVS  
 601 LKNNVSVNK EPVAEPDIMA TNGVHVITN VLQPPANRPQ ERGDELADSA  
 651 LEIFKQASAF SRASQRSVRL APVYQKLLER MKH

L17 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2002:928019 CAPLUS <>LOGINID::20080924>>  
 DOCUMENT NUMBER: 138:1132  
 TITLE: Tumor-associated nucleic acids and proteins for  
 immunotherapy and diagnosis of colon cancer  
 INVENTOR(S): Xu, Jiangchun; Lodes, Michael J.; Sechrist, Heather;  
 Benson, Darin R.; Meagher, Madeleine Joy; Stolk, John  
 A.; Wang, Tongtong; Jiang, Yuqiu; Smith, Carole L.;  
 King, Gordon E.; Wang, Aijun; Clapper, Jonathan D.;  
 Skeiky, Yasir A. W.; Fanger, Gary R. C.; Vedrick,  
 Thomas S.; Carter, Darrick  
 PATENT ASSIGNEE(S): Corixa Corporation, USA  
 SOURCE: U.S. Pat. Appl. Publ., 52 pp., Cont.-in-part of U.S.  
 Ser. No. 922,217.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 7  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020182191	A1	20021205	US 2001-25380	20011219
US 6284241	B1	20010904	US 1998-221298	19981223
US 6623923	B1	20030923	US 1999-401064	19990922
WO 2000037643	A2	20000629	WO 1999-US30909	19991223
WO 2000037643	A3	20010809		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 20020110547	A1	20020815	US 2001-832363	20010410
US 20020076414	A1	20020620	US 2001-922217	20010803
WO 2002083070	A2	20021024	WO 2002-US11475	20020409
WO 2002083070	A3	20041111		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

AU 2002256186	A1 20021028	AU 2002-256186	20020409
US 20050260177	A1 20051124	US 2005-108172	20050415
PRIORITY APPLN. INFO.:			
		US 1998-221298	A2 19981223
		US 1999-347496	A2 19990702
		US 1999-401064	A2 19990922
		US 1999-444252	A2 19991119
		US 1999-454150	B2 19991202
		WO 1999-US30909	W 19991223
		US 1999-476296	B2 19991230
		US 2000-480321	B2 20000110
		US 2000-504629	B2 20000215
		US 2000-519444	B2 20000306
		US 2000-575251	B2 20000519
		US 2000-609448	A2 20000629
		US 2000-649811	A2 20000828
		US 2001-833263	A2 20010410
		US 2001-922217	A2 20010803
		US 1999-444242	A 19991119
		US 2000-444252	A2 20000410
		US 2001-25380	A 20011219
		WO 2002-US11475	W 20020409

AB Compns. and methods for the therapy and diagnosis of cancer, such as colon cancer, are disclosed. Compns. may comprise one or more colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a protein. Thus, polypeptides differentially expressed in colon tumors are isolated and characterized by PCR-based subtraction and microarray anal. of cDNA libraries, as well as mouse antisera. Such compns. may be used, for example, for the prevention and treatment of diseases such as colon cancer. Diagnostic methods based on detecting a colon tumor protein, or mRNA encoding such a protein, in a sample are also provided.

IT 476595-10-5P

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(amino acid sequence; tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer)

RN 476595-10-5 CAPLUS

CN Colon tumor-associated protein (human clone US20020182191-SEQID-121) (9CI)  
(CA INDEX NAME)

SEQ 1 MALEVRLAL ALALALGPA A TLAGPAKSPY QLVLQHSLR GRQHGPNVCA  
 51 VQKVIGTNRK YFTNCQWYQ RKICGKSTVI SYECCPGYEK VPGEKGPAA  
 101 LPLSNLYETL GVGSTTTQL YTDRTEKLRP EMEGPGSFTI FAPSNEAWAS  
 151 LPAEVLDLSV SNVNIELLLNA LRYHMVGRRV LTDELKHGMT LTSMYQNSNI  
 201 QIHHYPNGIV TVNCARLLKA DHATNGVH LIDKVISTIT NNIIQOIIIEIE  
 251 DTFETLRAAV AASGLNTMLE GNGQYTLLAP TNEAEFKIPS ETILNRLILGDP  
 301 EAIRDLLNNH ILKSAMCABA IVAGLSVETL EGTTILEVGCS GDMLTINGKA  
 351 IISNKKDILAT NGVIHYIDEL LIPDSAKTLE ELAAEESDVST AIDLFRQAGL  
 401 GNHLHSGSERL TLLAPLNSVF KDGTPPIDAH TRNLLRNHII KDQLASKYLY  
 451 HQQTLETLGG KKLRVFVYRN SLCIENSCIA AHDKRGRYGT LFTMDRVLTP  
 501 PMGTVMDVLK GDNRFSMLVA AIQSAGLTET LNREGVYTVF APTNEAFRAL  
 551 PRPERSRLLG DAKELANILK YHIGDEILVS GGIGALVRLK SLQGDKLEVS  
 601 LKNNNVSVNK EPVVAEPDIMA TNQGVVHVTIN VLQPPANRPQ ERGDELADSA  
 651 LEIFKQASAF SRASQRSVRL APVYQKLLER MKH

L17 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2002:616199 CAPLUS <<LOGINID::20080924>>  
 DOCUMENT NUMBER: 137:151147  
 TITLE: Tumor-associated nucleic acids and proteins for  
 immunotherapy and diagnosis of colon cancer  
 INVENTOR(S): Wang, Aijun; Clapper, Jonathan D.; Stolk, John A.;  
 Meagher, Madeleine Joy  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 46 pp., Cont.-in-part of U.S.  
 Ser. No. 649,811.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 7  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020110547	A1	20020815	US 2001-833263	20010410
US 6284241	B1	20010904	US 1998-221298	19981223
US 6623923	B1	20030923	US 1999-401064	19990922
WO 2000037643	A2	20000629	WO 1999-US30909	19991223
WO 2000037643	A3	20010809		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TT, TZ, UA, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 20020076414	A1	20020620	US 2001-922217	20010803
US 20020182191	A1	20021205	US 2001-25380	20011219
WO 2002083070	A2	20021024	WO 2002-US11475	20020409
WO 2002083070	A3	20041111		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002256186	A1	20021028	AU 2002-256186	20020409
US 20050260177	A1	20051124	US 2005-108172	20050415
PRIORITY APPLN. INFO.:				
		US 1998-221298	A2 19981223	
		US 1999-347496	A2 19990702	
		US 1999-401064	A2 19990922	
		US 1999-454150	A2 19991202	
		WO 1999-US30909	A2 19991223	
		US 1999-476296	A2 19991230	
		US 2000-480321	A2 20000110	
		US 2000-504629	A2 20000215	
		US 2000-519444	A2 20000306	
		US 2000-444252	A2 20000410	
		US 2000-575251	A2 20000519	
		US 2000-609448	A2 20000629	
		US 2000-649811	A2 20000828	
		US 1999-444242	A 19991119	

US 1999-444252 A2 19991119  
US 2001-833263 A2 20010410  
US 2001-922217 A2 20010803  
US 2001-25380 A 20011219  
WO 2002-US11475 W 20020409

AB Compns. and methods for the therapy and diagnosis of cancer, such as colon cancer, are disclosed. Compns. may comprise one or more colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a protein. Thus, polypeptides differentially expressed in colon tumors are isolated and characterized by PCR-based subtraction and microarray anal. of cDNA libraries, as well as mouse antisera. Such compns. may be used, for example, for the prevention and treatment of diseases such as colon cancer. Diagnostic methods based on detecting a colon tumor protein, or mRNA encoding such a protein, in a sample are also provided.

IT 444969-60-2P  
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(amino acid sequence; tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer)

IT 444969-60-2 CAPLUS

CN Colon tumor-associated protein (human clone US20020110547-SEQID-121) (9CI)  
(CA INDEX NAME)

SEQ 1 MALFVRLAL ALALALGPAA TLAGPAKSPY QLVQHSLRL GRQHGPNVCA  
51 VQKVIGTNRK YFTNCQWYQ RKIGKSTVI SYECCPGYEK VPGEKGCPAA  
101 LPALSNLYETL GVVGSTTQL YTDRTEKLRP EMEGGPGSFTI FAPSNEAWAS  
151 LPAAEVLDLSV SNVNIELLNA LRYHMVGRRV LTDELKHGMT LTSMYQNSNI  
201 QIHYPNGIV TVNCARLLKA DHATNGVHV LIDKVISTIT NNIIQIIIEIE  
251 DTFFETLRAAV AASGLNTMLE GNGQYTTLLAP TNEAFEKIPS ETLNRLIGD  
301 EAALRDLNNH ILKSAAMCAEA IVAGLSVETL EGTTLEVGCS GDMLTINGKA  
351 IISNKDILAT NGVIHYIDEL LIPDSAKTFL ELAAESDVT AIDLFRQAGL  
401 GNHLSGSERL TLLAPLNSVF KDGTPPIDAH TRNLLRNHII KDQLASKYLY  
451 HQQTLETLLGG KKLRLRVFYVRN SLCIENCIA AHDKRGRYGT LFTMDRVLTP  
501 PMGTVMDVLK GDNRFSMLVA AIQSAGLTET LNREGVYTVF APTNEAFLAL  
551 PPRERSRLVG DAKELANILK YHIGDEILVS GGIGALVRLK SLQGDKLEVS  
601 LKNNNVSVNKK EPVAPEDIMA TNGVVHVITN VLQPPANRPQ ERGDELADSA  
651 LEIFKQASAF SRASQRSVRL APVYQKLLER MKH

L17 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2002:466537 CAPLUS <<LOGINID::20080924>>  
DOCUMENT NUMBER: 137:42650  
TITLE: Tumor-associated proteins and their cDNA sequences and  
uses for immunotherapy and diagnosis of colon cancer  
INVENTOR(S): Xu, Jiangchun; Lodes, Michael J.; Sechrist, Heather;  
Benson, Darin R.; Meagher, Madeleine Joy; Stolk, John  
A.; Wang, Tongtong; Jiang, Yiqiu; Smith, Carole L.;  
King, Gordon E.; Wang, Aijun; Clapper, Jonathan D.  
PATENT ASSIGNEE(S): Corixa Corporation, USA  
SOURCE: U.S. Pat. Appl. Publ., 50 pp., Cont.-in-part of U.S.  
Ser. No. 833,263.  
DOCUMENT TYPE: Patent  
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020076414	A1	20020620	US 2001-922217	20010803
US 6284241	B1	20010904	US 1998-221298	19981223
US 6623923	B1	20030923	US 1999-401064	19990922
WO 2000037643	A2	20000629	WO 1999-US30909	19991223
WO 2000037643	A3	20010809		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, LZ, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 20020110547	A1	20020815	US 2001-833263	20010410
US 20020182191	A1	20021205	US 2001-25380	20011219
WO 2002083070	A2	20021024	WO 2002-US11475	20020409
WO 2002083070	A3	20041111		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, LZ, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, NO, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002255186	A1	20021028	AU 2002-255186	20020409
US 20050260177	A1	20051124	US 2005-108172	20050415
PRIORITY APPLN. INFO.:				
		US 1998-221298	A2 19981223	
		US 1999-347496	A2 19990702	
		US 1999-401064	A2 19990922	
		US 1999-454150	B2 19991202	
		WO 1999-US30909	W 19991223	
		US 1999-476296	A2 19991230	
		US 2000-480321	B2 20000110	
		US 2000-504629	A2 20000215	
		US 2000-519444	A2 20000306	
		US 2000-444252	A2 20000410	
		US 2000-575251	A2 20000519	
		US 2000-609448	A2 20000629	
		US 2000-649811	A2 20000828	
		US 2001-833263	A2 20010410	
		US 1999-444242	A 19991119	
		US 1999-444252	A2 19991119	
		US 2001-922217	A2 20010803	
		US 2001-25380	A 20011219	
		WO 2002-US11475	W 20020409	

AB Compns. and methods for the therapy and diagnosis of cancer, such as colon cancer, are disclosed. Thus, colon tumor-associated proteins are isolated by PCR-based subtraction and microarray anal., use of SCID mouse antisera, and conventional subtraction. Compns. may comprise one or more colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a protein. Such compns. may be used, for example, for the prevention and treatment of diseases such as

colon cancer. Diagnostic methods based on detecting a colon tumor protein, or mRNA encoding such a protein, in a sample are also provided.

IT 438430-54-7P  
 RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (amino acid sequence; tumor-associated proteins and their cDNA sequences and uses for immunotherapy and diagnosis of colon cancer)

RN 438430-54-7 CAPLUS  
 CN Colon tumor-associated protein (human clone US20020076414-SEQID-121) (9CI)  
 (CA INDEX NAME)

SEQ 1 MALFVRLAL ALALALGPAA TLAGPAKSPY QLVLQHSRLR GRQHGPNVCA  
 51 VQKVGITNRK YFTNCKQWYQ RKICGKSTVI SYECCPGYEK VPGEKGCPAA  
 101 LPLSNLYETL GVVGSTTQL YTDTRTEKLRP EMEGPGSFTI FAPSNEAWAS  
 151 LPAAEVLDLSV SNVNIELLNA LRYHMVGRRV LTDELKHGMT LTSMYQNSNI  
 201 QIHHYPPNGIV TVNCARLLKA DHATNGVHH LIDKVISTIT NNIIQOIIIEIE  
 251 DTFETLRAAV AASGLNTMLE GNGQYTLAP TNEAEFKIPS ETLNRILGDP  
 301 EAIRDLLNNH ILKSAMCAEA IVAGLSVETL EGTTLEVGCS GDMLTINGKA  
 351 IISNKKDILAT NGVIIHYIDEL LIPDSAKTLF ELAAEESDVST AIDLFRQAGL  
 401 GNHLSGSERL TLLAPLNSVF KDGTPPIDAH TRNLLRNHII KDLQASKYLY  
 451 HQGQTLETLLGG KKLRVVFVYRN SLCIENSCIA AHDKRGRGRTG LFTMDRVLTP  
 501 PMGTVMDVVK GDNRFSMLVA AIQSAGLTET LNREGVYTFV APTNEAFRAL  
 551 PPRERSRLLG DAKELANILK YHIGDEILVS GIGALVRLK SLQGDKLEVS  
 601 LKNNVSVSNK EPVVAEPDIMA TNGVVHVITN VLQPPANRPQ ERGDELADSA  
 651 LEIFKQASAF SRASQRSVRL APVYQKLLER MKH

L17 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2001:507728 CAPLUS <>LOGINID::20080924>>  
 DOCUMENT NUMBER: 135:121178  
 TITLE: Identification of colon cancer-associated proteins for immunotherapy and diagnosis  
 INVENTOR(S): Xu, Jiangchun; Lodes, Michael J.; Secrist, Heather; Benson, Darin R.; Meagher, Madeleine Joy; Stolk, John A.; King, Gordon E.; Wang, Tongtong; Jiang, Yuqiu  
 PATENT ASSIGNEE(S): Corixa Corporation, USA  
 SOURCE: PCT Int. Appl., 472 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 7  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001049716	A2	20010712	WO 2000-US35596	20001229
WO 2001049716	A3	20020131		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,			

BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2396036	A1 20010712	CA 2000-2396036	20001229
EP 1242598	A2 20020925	EP 2000-989592	20001229
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRIORITY APPLN. INFO.:			
	US 1999-476296	A 19991230	
	US 2000-480321	A 20000110	
	US 2000-504629	A 20000215	
	US 2000-519444	A 20000306	
	US 2000-575251	A 20000519	
	US 2000-609448	A 20000629	
	US 2000-649811	A 20000828	
	WO 2000-US35596	W 20001229	

AB The authors disclose the use of a cDNA library and subtractive PCR to identify a number of genes, and their proteins, which are overexpressed in human colon tumors. In addition, soluble tumor proteins expressed in serum of colon tumor-bearing SCID mice were used to generate polyclonal antibodies for probing a cDNA expression library.

IT 148710-76-3, Protein (human clone  $\beta$ ig-h3 transforming growth factor  $\beta$ -induced precursor reduced)

RL: ANT (Analyte); ARG (Analytical reagent use); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)

(amino acid sequence; identification and immunogenicity of human colon tumor-associated antigens)

RN 148710-76-3 CAPLUS

CN Protein (human clone  $\beta$ ig-h3 transforming growth factor  $\beta$ -induced precursor reduced) (9CI) (CA INDEX NAME)

SEQ	1 MALFVRLAL ALALALGPA TLAGPAKSPY QLVQHSRLR GRQHGPNVCA
	51 VKVIGTNRK YFTNCKQWYQ RKIGKSTVI SYECCPGIEK VPGEKGCPAA
101	LPLSNLYETL GVVGTTTQL YTDRTEKLRP EMEGPGSFTI FAPSNEAWAS
151	LPAEVLDLSV SNNVIELLLNA LRYHMVGRV LTDELKHGMT LTSMYQNSNI
201	QIHYPNGIV TVNCARLLKA DHATNGVHH LIDKVISTIT NNIIQQIEIE
251	DTFETLRAAV AASGLNTMLE GNGQYTLLAP TNEAFEKIPS ETLNRLGKD
301	EALRDLNNNH ILKSAMCAEA IVAGLSVETL EGTTLEVGCs GDMLTINGKA
351	IIISNKDILAT NGVIHYIDEL LIPDSAKTLE ELAAEESDVST AIDLFRQAGL
401	GNHLSGSERL TLLAPLNSVF KDGTPPIDAH TRNLLRNHII KDQLASKYLY
451	HGQTLTETLGG KKLRVFEVYN SLCIENSCIA AHDKRGRYGT LFTMDRVLTP
501	PMGTVMDVLUK GDNRFSMLVA AIIQASAGLTET LNREGVYTFV APTNEAFRAL
551	PPRERSRLLG DAKELANILK YHIGDEILVS GGIGALVRLK SLQGDKLEVS
601	LKNNVSVN EPVAEPDIMA TNGVVHVITN VLQPPANRPQ ERGDELADSA
651	LEIFKQASAF SRASQRSVRL APVYQKLLER MKH

=> fil stng  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FULL ESTIMATED COST

91.93 193.62

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION

CA SUBSCRIBER PRICE

-8.80 -9.60

FILE 'STNGUIDE' ENTERED AT 15:03:50 ON 24 SEP 2008  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Sep 19, 2008 (20080919/UP).

=> d his

(FILE 'HOME' ENTERED AT 14:46:31 ON 24 SEP 2008)  
FILE 'REGISTRY' ENTERED AT 14:48:53 ON 24 SEP 2008  
FILE 'REGISTRY' ENTERED AT 14:50:57 ON 24 SEP 2008  
L1 125 S [IDEK][EAQ][L][LRA][NDS][ALKI][LY][RNLK][YNJH][MIG][VLQG][GKTD][  
FILE 'CAPLUS' ENTERED AT 14:51:08 ON 24 SEP 2008  
L2 78 S L1  
L3 26 S L1/THU  
FILE 'REGISTRY' ENTERED AT 14:51:35 ON 24 SEP 2008  
L4 0 S L1 AND SQL<30  
FILE 'CAPLUS' ENTERED AT 14:52:33 ON 24 SEP 2008  
L5 1 S US20070004622/PN  
L6 ANALYZE L5 1 RN : 10 TERMS  
FILE 'REGISTRY' ENTERED AT 14:52:50 ON 24 SEP 2008  
L7 10 S L6  
L8 10 S L6  
L9 10 S L1 AND L8  
FILE 'CAPLUS' ENTERED AT 14:53:35 ON 24 SEP 2008  
L10 297112 S TUMOR OR TUMOUR  
L11 45619 S ONCO?  
L12 525362 S NEOPLASM  
L13 246205 S CANCER  
L14 223599 S CARCINO?  
L15 782082 S L10-L14  
L16 16 S L3 (L) L15  
L17 17 S L16 OR L5  
FILE 'STNGUIDE' ENTERED AT 14:55:58 ON 24 SEP 2008  
FILE 'CAPLUS' ENTERED AT 15:02:52 ON 24 SEP 2008  
FILE 'STNGUIDE' ENTERED AT 15:03:50 ON 24 SEP 2008

=> fil caplus  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 0.54 194.16  
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL  
ENTRY SESSION  
CA SUBSCRIBER PRICE 0.00 -9.60

FILE 'CAPLUS' ENTERED AT 15:09:15 ON 24 SEP 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Sep 2008 VOL 149 ISS 13  
FILE LAST UPDATED: 23 Sep 2008 (20080923/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>  
'OBI' IS DEFAULT SEARCH FIELD FOR 'CPLUS' FILE

```

=> fil stng
COST IN U.S. DOLLARS                               SINCE FILE      TOTAL
                                                ENTRY SESSION
FULL ESTIMATED COST                           0.48      194.64

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                ENTRY SESSION
CA SUBSCRIBER PRICE                            0.00      -9.60

```

FILE 'STNGUIDE' ENTERED AT 15:09:32 ON 24 SEP 2008  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Sep 19, 2008 (20080919/UP).

```

=> fil caplus
COST IN U.S. DOLLARS                               SINCE FILE      TOTAL
                                                    ENTRY        SESSION
FULL ESTIMATED COST                           0.06          194.70

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                    ENTRY        SESSION
CA SUBSCRIBER PRICE                           0.00          -9.60

```

FILE 'CAPLUS' ENTERED AT 15:10:07 ON 24 SEP 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is

strictly prohibited.

FILE COVERS 1907 - 24 Sep 2008 VOL 149 ISS 13  
FILE LAST UPDATED: 23 Sep 2008 (20080923/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>  
'OBI' IS DEFAULT SEARCH FIELD FOR 'CPLUS' FILE

=> help role

CAS roles are CAS indexing terms consisting of codes that describe the new or novel information reported about a substance or a class of compounds. Specific roles have 3-letter codes. Super roles have 4-letter codes. Super roles are automatically generated from the specific roles, and are upposed for searching. The PREP (Preparation) role is available for documents from 1907 to the present. Other roles are available for all indexed documents from 1967 to the present.

To search a role for a specific substance, append the CAS Registry Number or a Registry File L-number answer set with a slash and the code for the role, e.g., 67-68-5/THU. To search more than one role, separate a list of roles by commas and no spaces, e.g., 67-68-5/THU,ADV. Only one role may be appended to an L-number answer set. Use the OR operator to apply multiple roles to an L-number, e.g., S L1/THU OR L1/ADV.

To search roles assigned to index headings for classes of compounds, follow the heading with a slash and the role or roles separated by commas, e.g., PHENOLS/POL,REM.

Roles are displayed in the RL (Role) field within the IT (Index Term) field. Roles are included in any display format that contains the IT or RL field. Enter SET ROLES OFF at an arrow prompt (=>) to suppress display of codes and text for roles. Enter SET ROLES CODES to display only codes. Enter SET ROLES TEXT to return to default display (codes and names). Enter HELP SET ROLES at an arrow prompt for more information.

Enter HELP THESAURUS and HELP RCODE at an arrow prompt in this file for information on using the role thesaurus to find role definitions and narrower and broader terms.

The following is a hierarchical list of CAS roles. Under each super role are listed the specific roles that generate the super role.

List of CAS Roles (1)

ANST Analytical Study

ANT Analyte

AMX Analytical Matrix

ARG Analytical Reagent Use

ARU Analytical Role, Unclassified

BIOL	Biological Study
ADV	Adverse Effect, Including Toxicity
AGR	Agricultural Use
BAC	Biological Activity or Effector, Except Adverse (2)
BCP	Biochemical Process (3)
BMF	Bioindustrial Manufacture
BOC	Biological Occurrence (2)
BPN	Biosynthetic Preparation
BPR	Biological Process (2)
BSU	Biological Study, Unclassified
BUU	Biological Use, Unclassified
COS	Cosmetic Use (3)
DGN	Diagnostic Use (3)
DMA	Drug Mechanism of Action (3)
FFD	Food or Feed Use
MFM	Metabolic Formation (2)
NPO	Natural Product Occurrence (3)
PAC	Pharmacological Activity (3)
PKT	Pharmacokinetics (3)
THU	Therapeutic Use
CMBI	Combinatorial Study (3)
CPN	Combinatorial Preparation (3)
CRT	Combinatorial Reactant (3)
CRG	Combinatorial Reagent (3)
CST	Combinatorial Study (3)
CUS	Combinatorial Use (3)
FORM	Formation, Nonpreparative
FMU	Formation, Unclassified
GFM	Geological or Astronomical Formation
MFM	Metabolic Formation (2)
OCU	Occurrence
BOC	Biological Occurrence (2)
GOC	Geological or Astronomical Occurrence
NPO	Natural Product Occurrence (3)
OCU	Occurrence, Unclassified
POL	Pollutant
PREP	Preparation (4)
BMF	Bioindustrial Manufacture
BPN	Biosynthetic Preparation
BYP	Byproduct
CPN	Combinatorial Preparation (3)
IMF	Industrial Manufacture
PUR	Purification or Recovery
PNU	Preparation, Unclassified (5)
SPN	Synthetic Preparation
PROC	Process
BCP	Biochemical Process (3)
BPR	Biological Process (2)

GPR Geological or Astronomical Process  
PEP Physical, Engineering, or Chemical Process  
CPS Chemical Process (6)  
EPR Engineering Process (6)  
PYP Physical Process (6)  
REM Removal or Disposal

PRPH Prophetic Substance (7)

RACT Reactant or Reagent (2,6)

RCT Reactant (8)  
CRT Combinatorial Reactant (3)  
RGT Reagent (3)  
CRG Combinatorial Reagent (3)

USES Uses

AGR Agricultural Use  
ARG Analytical Reagent Use  
BUU Biological Use, Unclassified  
CAT Catalyst Use  
COS Cosmetic Use (3)  
CUS Combinatorial Use (3)  
DGN Diagnostic Use (3)  
FDI Food or Feed Use  
MOA Modifier or Additive Use  
NUU Other Use, Unclassified (9)  
POF Polymer in Formulation  
TEM Technical or Engineered Material Use  
THU Therapeutic Use

Specific roles that are not upposted to any super roles:

MSC Miscellaneous  
PRP Properties

- (1) Super roles have 4-letter codes. Specific roles have 3-letter codes. Under each super role are listed the corresponding specific roles that are retrieved when you search that super role.
- (2) Used from CA Vol. 66 (1967) to Vol. 135 (2001)
- (3) Used starting with CA Vol. 136 (2002)
- (4) The PREP super role has been added to records back to 1907.
- (5) Used from CA vol. 66 (1967) to vol. 145 (2006).
- (6) Used from CA vol. 136 (2002) to CA vol. 145 (2006).
- (7) Used starting with records from CA vol. 148 (2008).
- (8) Searching the RCT (Reactant) role retrieves references from CA Vol. 66 (1967) to the present. Searching the RACT (Reactant or Reagent) super role retrieves references with the CRT, CRG, RGT, or RCT references starting with CA Vol. 136 (2002).
- (9) Starting with CA Vol. 136 (2002), the searchable text for the NUU role changed from NONBIOLOGICAL USE, UNCLASSIFIED/RL to OTHER USE, UNCLASSIFIED/RL. Search the code NUU/RL to retrieve records from CA Vol. 66 (1967) to the present.

=> d his

(FILE 'HOME' ENTERED AT 14:46:31 ON 24 SEP 2008)

FILE 'REGISTRY' ENTERED AT 14:48:53 ON 24 SEP 2008

FILE 'REGISTRY' ENTERED AT 14:50:57 ON 24 SEP 2008

L1       125 S [IDEK] [EAQ] L [LRA] [NDS] [ALK1] [LY] [RNLK] [YN] H [MIG] [VLQG] [GKTD] |

FILE 'CAPLUS' ENTERED AT 14:51:08 ON 24 SEP 2008

L2       78 S L1

L3       26 S L1/THU

FILE 'REGISTRY' ENTERED AT 14:51:35 ON 24 SEP 2008

L4       0 S L1 AND SQL<30

FILE 'CAPLUS' ENTERED AT 14:52:33 ON 24 SEP 2008

L5       1 S US20070004622/PN

L6       ANALYZE L5 1 RN :           10 TERMS

FILE 'REGISTRY' ENTERED AT 14:52:50 ON 24 SEP 2008

L7       10 S L6

L8       10 S L6

L9       10 S L1 AND L8

FILE 'CAPLUS' ENTERED AT 14:53:35 ON 24 SEP 2008

L10      297112 S TUMOR OR TUMOUR

L11      45619 S ONCO?

L12      525362 S NEOPLASM

L13      246205 S CANCER

L14      223599 S CARCINO?

L15      782082 S L10-L14

L16      16 S L3 (L) L15

L17      17 S L16 OR L5

FILE 'STNGUIDE' ENTERED AT 14:55:58 ON 24 SEP 2008

FILE 'CAPLUS' ENTERED AT 15:02:52 ON 24 SEP 2008

FILE 'STNGUIDE' ENTERED AT 15:03:50 ON 24 SEP 2008

FILE 'CAPLUS' ENTERED AT 15:09:15 ON 24 SEP 2008

FILE 'STNGUIDE' ENTERED AT 15:09:32 ON 24 SEP 2008

FILE 'CAPLUS' ENTERED AT 15:10:07 ON 24 SEP 2008

=> d ti l3 1-26

L3      ANSWER 1 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

TI      Use of  $\beta$ ig-h3 protein comprising fas-1 domains, EM1 domain and RGD motifs for treatment and prevention of angiogenesis-related disorders

L3      ANSWER 2 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

TI      Prevention and treatment of inflammation by inhibiting FEX-2-dependent adhesion of lymphocytes to the endothelium

L3      ANSWER 3 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

TI      Differentially expressed nucleic acids and encoded polypeptides for use in liver disorders and epithelial cancer

L3      ANSWER 4 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

TI      Expression profile of colon cancer specific genes and their use as biomarkers for diagnosis, therapy and drug screening

L3 ANSWER 5 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Genes showing altered patterns of expression in colon cancer and their use in diagnosis and therapy

L3 ANSWER 6 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI TAT (Tumor-associated Antigenic Target) polypeptides and methods for diagnosis and treatment of tumors of glial origin

L3 ANSWER 7 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Novel human genes and gene expression products and their use in diagnosis and treatment of colon cancer

L3 ANSWER 8 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Specific protein markers useful for diagnosis of pancreatic cancer and screening methods

L3 ANSWER 9 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Gene expression profile in activated human CD4+ T cells useful for the diagnosis and treatment of immune-related diseases

L3 ANSWER 10 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Differentially expressed nucleic acids and their encoded proteins and their uses for the diagnosis and treatment of tumor

L3 ANSWER 11 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Nucleic acid and encoded protein sequences that are differentially expressed in psoriatic skin and their use for diagnosis and treatment of psoriasis

L3 ANSWER 12 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Human protein and cDNA sequences for diagnostics and therapeutics

L3 ANSWER 13 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Methods of testing for bronchial asthma or chronic obstructive pulmonary disease, and drug screening for the same, using identified differentially expressed IL-13-stimulated marker genes

L3 ANSWER 14 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Genetic and protein manipulation of  $\beta$ ig-H3 for the treatment and cure of muscular dystrophies

L3 ANSWER 15 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer

L3 ANSWER 16 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Gene expression profiles useful for methods of diagnosis of cancer and screening for modulators of cancer

L3 ANSWER 17 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Nucleic acid markers for use in determining predisposition to neoplasm and/or adenoma

L3 ANSWER 18 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Gene expression profiles useful in methods of diagnosis of cancer compositions and methods of screening for modulators of cancer

L3 ANSWER 19 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer

L3 ANSWER 20 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Human cDNA sequences and their encoded proteins and diagnostic and therapeutic uses

L3 ANSWER 21 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Protein-protein interactions in human adipocyte cells and method for selecting modulators of these interactions

L3 ANSWER 22 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer

L3 ANSWER 23 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Tumor-associated proteins and their cDNA sequences and uses for immunotherapy and diagnosis of colon cancer

L3 ANSWER 24 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Nucleic acids and their encoded polypeptides from human tissues

L3 ANSWER 25 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Identification of colon cancer-associated proteins for immunotherapy and diagnosis

L3 ANSWER 26 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Colon tumor-specific nucleic acids and proteins and their use for immunotherapy and diagnosis of colon cancer

=> d his

(FILE 'HOME' ENTERED AT 14:46:31 ON 24 SEP 2008)  
FILE 'REGISTRY' ENTERED AT 14:48:53 ON 24 SEP 2008  
FILE 'REGISTRY' ENTERED AT 14:50:57 ON 24 SEP 2008  
L1 125 S [IDEK][EAQ]L[LRA][NDS][ALKI][LY][RNLK][YN]H[MIG][VLQG][GKTD][  
FILE 'CAPLUS' ENTERED AT 14:51:08 ON 24 SEP 2008  
L2 78 S L1  
L3 26 S L1/THU  
FILE 'REGISTRY' ENTERED AT 14:51:35 ON 24 SEP 2008  
L4 0 S L1 AND SQL<30  
FILE 'CAPLUS' ENTERED AT 14:52:33 ON 24 SEP 2008  
L5 1 S US20070004622/PN  
L6 ANALYZE L5 1 RN : 10 TERMS  
FILE 'REGISTRY' ENTERED AT 14:52:50 ON 24 SEP 2008  
L7 10 S L6  
L8 10 S L6  
L9 10 S L1 AND L8  
FILE 'CAPLUS' ENTERED AT 14:53:35 ON 24 SEP 2008  
L10 297112 S TUMOR OR TUMOUR  
L11 45619 S ONCO?  
L12 525362 S NEOPLASM  
L13 246205 S CANCER  
L14 223599 S CARCINO?  
L15 782082 S L10-L14

L16 16 S L3 (L) L15  
L17 17 S L16 OR L5

FILE 'STNGUIDE' ENTERED AT 14:55:58 ON 24 SEP 2008  
FILE 'CAPLUS' ENTERED AT 15:02:52 ON 24 SEP 2008  
FILE 'STNGUIDE' ENTERED AT 15:03:50 ON 24 SEP 2008  
FILE 'CAPLUS' ENTERED AT 15:09:15 ON 24 SEP 2008  
FILE 'STNGUIDE' ENTERED AT 15:09:32 ON 24 SEP 2008  
FILE 'CAPLUS' ENTERED AT 15:10:07 ON 24 SEP 2008

=> s 13 or 15  
L18 27 L3 OR L5

=> d ti 1-27

L18 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Use of  $\beta$ ig-h3 protein comprising fas-1 domains, EM1 domain and RGD motifs for treatment and prevention of angiogenesis-related disorders

L18 ANSWER 2 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Prevention and treatment of inflammation by inhibiting FEX-2-dependent adhesion of lymphocytes to the endothelium

L18 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Differentially expressed nucleic acids and encoded polypeptides for use in liver disorders and epithelial cancer

L18 ANSWER 4 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Expression profile of colon cancer specific genes and their use as biomarkers for diagnosis, therapy and drug screening

L18 ANSWER 5 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Genes showing altered patterns of expression in colon cancer and their use in diagnosis and therapy

L18 ANSWER 6 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
TI TAT (Tumor-associated Antigenic Target) polypeptides and methods for diagnosis and treatment of tumors of glial origin

L18 ANSWER 7 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Use of a peptide that interacts with alphav beta3 integrin of endothelial cell

L18 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Novel human genes and gene expression products and their use in diagnosis and treatment of colon cancer

L18 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Specific protein markers useful for diagnosis of pancreatic cancer and screening methods

L18 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Gene expression profile in activated human CD4+ T cells useful for the diagnosis and treatment of immune-related diseases

L18 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

TI Differentially expressed nucleic acids and their encoded proteins and their uses for the diagnosis and treatment of tumor

L18 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Nucleic acid and encoded protein sequences that are differentially expressed in psoriatic skin and their use for diagnosis and treatment of psoriasis

L18 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Human protein and cDNA sequences for diagnostics and therapeutics

L18 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Methods of testing for bronchial asthma or chronic obstructive pulmonary disease, and drug screening for the same, using identified differentially expressed IL-13-stimulated marker genes

L18 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Genetic and protein manipulation of  $\beta$ ig-H3 for the treatment and cure of muscular dystrophies

L18 ANSWER 16 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer

L18 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Gene expression profiles useful for methods of diagnosis of cancer and screening for modulators of cancer

L18 ANSWER 18 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Nucleic acid markers for use in determining predisposition to neoplasm and/or adenoma

L18 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Gene expression profiles useful in methods of diagnosis of cancer compositions and methods of screening for modulators of cancer

L18 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer

L18 ANSWER 21 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Human cDNA sequences and their encoded proteins and diagnostic and therapeutic uses

L18 ANSWER 22 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Protein-protein interactions in human adipocyte cells and method for selecting modulators of these interactions

L18 ANSWER 23 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer

L18 ANSWER 24 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Tumor-associated proteins and their cDNA sequences and uses for immunotherapy and diagnosis of colon cancer

L18 ANSWER 25 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Nucleic acids and their encoded polypeptides from human tissues

L18 ANSWER 26 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Identification of colon cancer-associated proteins for immunotherapy and

diagnosis

L18 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Colon tumor-specific nucleic acids and proteins and their use for  
immunotherapy and diagnosis of colon cancer

=> d ibib abs 1

L18 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2007:788610 CAPLUS <<LOGINID::20080924>>  
DOCUMENT NUMBER: 147:158465  
TITLE: Use of  $\beta$ ig-h3 protein comprising fas-1 domains,  
EM1 domain and RGD motifs for treatment and prevention  
of angiogenesis-related disorders  
INVENTOR(S): Nam, Ju-Ock; Kim, Jung-Eun; Jeong, Ha-Won; Lee,  
Sung-Jin; Lee, Byung-Heon; Choi, Je-Yong; Park,  
Rang-Woon; Park, Jae-Yong; Kim, In-San; Son, Hye-Nam  
PATENT ASSIGNEE(S): Kyungpook National University Industry-Academic  
Cooperation Foundation, S. Korea  
SOURCE: U.S. Pat. Appl. Publ., 83pp., Cont.-in-part of U.S.  
Ser. No. 578,463.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070167369	A1	20070719	US 2007-712460	20070301
WO 2005099743	A1	20051027	WO 2004-KR851	20040413
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: WO 2004-KR851 W 20040413  
US 2006-578463 A2 20061013

AB The present invention relates to the novel use of cell adhesion mol.  $\beta$ ig-h3 comprising EM1 domain, four fas-1 domains and RGD protein motifs. More particularly, the invention relates to a method for the inhibition of the adhesion, migration and/or proliferation of endothelial cells, and/or for the inhibition of angiogenesis, using cell adhesion mol.  $\beta$ ig-h3, or functional equivalent thereof. Furthermore, the invention provides a method for treating or preventing angiogenesis-related diseases, using the polypeptides.

=> d hitseq 1

L18 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
IT 943948-05-8 943948-06-9 943948-07-0  
943948-08-1  
RL: BSU (Biological study, unclassified); PRP (Properties); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)  
(amino acid sequence; use of  $\beta$ ig-h3 protein comprising fas-1 domains, EM1 domain and RGD motifs for treatment and prevention of angiogenesis-related disorders)

RN 943948-05-8 CAPLUS

CN Cell adhesion molecule  $\beta$ ig-h3 (TGF- $\beta$ -induced gene h3) (human EM1 and Fas1 and RGD domains) (CA INDEX NAME)

SEQ 1 WYQRKICGKS TVISYECPPG YEKVPGKGC PAALPLSNLY ETLGVVGSTT  
51 TQLYTDRTEK LRPEMEGPGS FTIFAPSNEA WASLPAEVLD SLVSNVNIEL  
101 LNALRYHVMV RRVLTDELKH GMALTSMYQN SNIQIHHYPN GIVTVNCARL  
151 LKADHHAATNG VVHLIDKVIS TTNNIQQII EIEIDTFETLR AAVAASGLNT  
201 MLEGNQVTL LAPTNEAEFK IPSETNLRL GDPEALRDL NNHILKSAMC  
251 AEAIVAGLVL ETLEGTTLEV GCSGDMLTIN GKAIIISNKDI LATNGVIHYI  
301 DELLIPDSAK TLFELAAESD VSTAIDLFRQ AGLGNHLSGS ERLTLLAPLN  
351 SVFKDGTPI DAHTRNLLRN HIIKDLQASK YLYHGQTLT LGGKKLRFV  
401 YRNSLCIENS CAAAHDKRGR YTGLFTMDRM LTPPMGTVM VLKGDNRF  
451 LVAIAIQSAGL TETLNREGVY TVFAPTNNEAF QALPLGERNK LLGNAKELAN  
501 ILKYHVGDEI LVSGGIGALV RLKSLQGDKL EVSSKNNNVS VNKEPV  
551 IMATNGVVHV ITNVLQPPAN RPQERGDELA DSALEI

RN 943948-06-9 CAPLUS

CN Cell adhesion molecule  $\beta$ ig-h3 (TGF- $\beta$ -induced gene h3) (Sus scrofa EM1 and Fas1 and RGD domains) (CA INDEX NAME)

SEQ 1 WYQRKICGKS TVISYECPPG YEKVPGKGC PAVLPLSNLY ETLGVVGSTT  
51 TQLYTDRTEK LRPEMEGPGS FTIFAPSNEA WASLPAEVLD SLVSNVNIEL  
101 LNALRYHVMV RRVLTDELKH GMALTSMYQN SNIQIHHYPN GIVTVNCARL  
151 LKADHHAATNG VVHLIDKVIS TTNNIQQII EIEIDTFETLR AAVAASGLNT  
201 LLESDGQVTL LAPTNEAEFK IPSETNLRL GDPEALRDL NNHILKSAMC  
251 AEAIVAGLVL ETLEGTTLEV GCSGDMLTIN GKAIIISNKDV LATNGVIHF  
301 DELLIPDSAK TLFELAAESD VSTAIDLFRQ AGLGSHLSGN ERLTLLAPMN  
351 SVFKDGTPI DAHTRNLLRN HIIKDLQASK YLYHGQTLT LGGKKLRFV  
401 YRNSLCIENS CAAAHDKRGR YTGLFTMDRM LTPPMGTVM VLKGDNRF  
451 LVAIAIQSAGL TETLNREGVY TVFAPTNNEAF QALPLGERNK LLGNAKELAN  
501 ILKYHVGDEI LVSGGIGALV RLKSLQGDKL EVSSKNSLVT VNKEPV  
551 IMATNGVVHT INTVLRPPAN KPQERGDELA DSALEI

RN 943948-07-0 CAPLUS

CN Cell adhesion molecule  $\beta$ ig-h3 (TGF- $\beta$ -induced gene h3)  
(Oryctolagia cuniculus EM1 and Fas1 and RGD domains) (CA INDEX NAME)

SEQ 1 WYQRKICGKS TVISYECPPG YEKVPGERC PAALPLANLY ETLGVVGSTT  
51 TQLYTDRTEK LRPEMEGPGR FTIFAPSNEA WASLPAEVLD SLVSNVNIEL  
101 LNALRYHVMV RRVLTDELKH GMALTSMYQN SKFQIHHYPN GIVTVNCARL  
151 LKADHHAATNG VVHLIDKVIS TTNNIQQII EIEIDTFETLR AAVAASGLNT  
201 LLESDGQVTL LAPTNEAEFK IPSETNLRL GDPEALRDL NNHILKSAMC  
251 AEAIVAGLVL ETLEGTTLEV GCSGDMLTIN GKAIIISNKDV LATNGVIHF  
301 DELLIPDSAK TLSELAAGSD VSTAIDLFRQ AGLGTHLSGN ERLTLLAPLN  
351 SVFEEGAPPI DAHTRNLLRN HIIKDLQASK YLYHGQTLT LGGKKLRFV  
401 YRNSLCIENS CAAAHDKRGR YTGLFTMDRM LTPPMGTVM VLKGDNRF  
451 LVAIAIQFRRL TETLNREGVY TVFAPTNNEAF QALPPGELNK LLGNAKELAD  
501 ILKYHVGEEI LVSGGIGALV RLKSLQGDKL EVSSKNNNVS VNKEPV  
551 IMATNGVYVA ITSVLQPPAN RPQERGDELA DSALEI

RN 943948-08-1 CAPLUS  
CN Cell adhesion molecule  $\beta$ -big-h3 (TGF- $\beta$ -induced gene h3) (Mus  
musculus EM1 and Fasl and RGD domains) (CA INDEX NAME)

SEQ 1 WYQRKICGKS TVISYECPPG YEKVPGEKGC PAALPLSNLY ETMGVVGSTT  
51 TQLYIDRTEK LRPMEEGPGS FTIFAPSNEA WSSLPAEVLD SLVSNVIEL  
101 LNALRYHVMV RRVLTDELKH GMTLTSMYQN SNIQIHYPN GIVTVNCARL  
151 LKADHATNG VVHLIDKVIS TITNNIQQII EIEDTFETLRA AAVAASGLNT  
201 VLEGDGQFTL LAPTNEAFEK IPAETLNRL GDPEALRDL NNHLKSMC  
251 AEAIVAGMSM ETLLGGTILEV GCSDGKLTIN GKAIVISNKDI LATNGVIIHFI  
301 DELLIPDSAK TLLELAGESD VSTAIDILKQ AGLDTHLSGK EQLTFLAPLN  
351 SVFKDGVPRI DAQMKTLLLN HMVKEQLASK YLYSGQTLDT LGGKKLRLFV  
401 YRNSLCIENS CIIAHDKRGR FGTLFTMDRM LTTPPMGTVMDF VLKGDNRFMSM  
451 LVAAIQSAGL MEILNREGVY TVFAPTFNEAF QAMPPEELNK LLANAKELTN  
501 ILKYHIGDEI LVSGGIGALV RLKSLQGDKL EVSSKNNVVS VNKEPVAETD  
551 IMATNGVVYA INTVLQPPAN RPQERGDELA DSALEI

=> fil stng  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 30.23 224.93  
  
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL  
ENTRY SESSION  
CA SUBSCRIBER PRICE -0.80 -10.40

FILE 'STNGUIDE' ENTERED AT 15:13:52 ON 24 SEP 2008  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Sep 19, 2008 (20080919/UP).

=> log h  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 0.66 225.59  
  
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL  
ENTRY SESSION  
CA SUBSCRIBER PRICE 0.00 -10.40

SESSION WILL BE HELD FOR 120 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 15:20:32 ON 24 SEP 2008

Connecting via Winsock to STN

Welcome to STN International! Enter :::

LOGINID:SSPTACXB1654

PASSWORD:  
TERMINAL (ENTER 1, 2, 3, OR ?):2

\*\*\*\*\* \* Welcome to STN International \* \*\*\*\*\*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 APR 04 STN AnaVist, Version 1, to be discontinued  
NEWS 3 APR 15 WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats  
NEWS 4 APR 28 EMBASE Controlled Term thesaurus enhanced  
NEWS 5 APR 28 IMSRESEARCH reloaded with enhancements  
NEWS 6 MAY 30 INPAFAMDB now available on STN for patent family searching  
NEWS 7 MAY 30 DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option  
NEWS 8 JUN 06 EPFULL enhanced with 260,000 English abstracts  
NEWS 9 JUN 06 KOREPAT updated with 41,000 documents  
NEWS 10 JUN 13 USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications  
NEWS 11 JUN 19 CAS REGISTRY includes selected substances from web-based collections  
NEWS 12 JUN 25 CA/Cplus and USPAT databases updated with IPC reclassification data  
NEWS 13 JUN 30 AEROSPACE enhanced with more than 1 million U.S. patent records  
NEWS 14 JUN 30 EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations  
NEWS 15 JUN 30 STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in  
NEWS 16 JUN 30 STN AnaVist enhanced with database content from EPFULL  
NEWS 17 JUL 28 CA/Cplus patent coverage enhanced  
NEWS 18 JUL 28 EPFULL enhanced with additional legal status information from the epoline Register  
NEWS 19 JUL 28 IFICDB, IFIPAT, and IFIUDB reloaded with enhancements  
NEWS 20 JUL 28 STN Viewer performance improved  
NEWS 21 AUG 01 INFADOCDB and INPAFAMDB coverage enhanced  
NEWS 22 AUG 13 CA/Cplus enhanced with printed Chemical Abstracts page images from 1967-1998  
NEWS 23 AUG 15 CAOLD to be discontinued on December 31, 2008  
NEWS 24 AUG 15 Cplus currency for Korean patents enhanced  
NEWS 25 AUG 25 CA/Cplus, CASREACT, and IFI and USPAT databases enhanced for more flexible patent number searching  
NEWS 26 AUG 27 CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information  
NEWS 27 SEP 18 Support for STN Express, Versions 6.01 and earlier, to be discontinued  
NEWS 28 SEP 25 CA/Cplus current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances  
NEWS 29 SEP 26 WPIDS, WPINDEX, and WPIX coverage of Chinese and and Korean patents enhanced  
NEWS 30 SEP 29 IFICLS enhanced with new super search field  
NEWS 31 SEP 29 EMBASE and EMBAL enhanced with new search and display fields  
NEWS 32 SEP 30 CAS patent coverage enhanced to include exemplified prophetic substances identified in new Japanese-language patents

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 14:15:35 ON 02 OCT 2008

FILE 'REGISTRY' ENTERED AT 14:23:09 ON 02 OCT 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem

STRUCTURE FILE UPDATES: 1 OCT 2008 HIGHEST RN 1056151-32-6  
DICTIONARY FILE UPDATES: 1 OCT 2008 HIGHEST RN 1056151-32-6

New CAS Information Use Policies - enter HELP.USAGETERMS for details

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www-cas.org/support/stndgen/stndoc/properties.html>

⇒ *s iellpalvubmuvarvlt /sasp*

67 TELL-NAL-BYHMVGRBVLT/SOSE

⇒ [s.ealrd11nphilkksamca/sasp](http://s.ealrd11nphilkksamca/sasp)

84 EALBDLJNNHTLKSAMCA/SOESP

=> s\_dglasky\vhgat\et\lg/sasp

L3 58 DQLASKYLYHGQTLETLG/SQSP

=> s kelanilkhyigdeilvs/sqsp

L4 68 KELANILKYHIGDEILVS/SQSP

=> d his

(FILE 'HOME' ENTERED AT 14:15:35 ON 02 OCT 2008)

FILE 'REGISTRY' ENTERED AT 14:23:09 ON 02 OCT 2008

L1 67 S IELLNALRYHMVGRVLT/SQSP

L2 84 S EALRDLNNHILKSAMCA/SQSP

L3 58 S DQLASKYLYHGQTLETLG/SQSP

L4 68 S KELANILKYHIGDEILVS/SQSP

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	122.06	124.79

FILE 'CAPLUS' ENTERED AT 14:23:34 ON 02 OCT 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Oct 2008 VOL 149 ISS 14

FILE LAST UPDATED: 1 Oct 2008 (20081001/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>  
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> s 11 68 L1

=> s 12 68 L2

=> s 13 58 L3

=> s 14 58 L4

```
=> fil styng
'STYNG' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'CAPLUS'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available. If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
```

=> fil stng  
COST IN U.S. DOLLARS  
SINCE FILE ENTRY SESSION  
0.48 125.27  
FULL ESTIMATED COST

FILE 'STNGUIDE' ENTERED AT 14:24:26 ON 02 OCT 2008  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Sep 26, 2008 (20080926/UP).

→ a his

(FILE 'HOME' ENTERED AT 14:15:35 ON 02 OCT 2008)

FILE 'REGISTRY' ENTERED AT 14:23:09 ON 02 OCT 2008  
L1 67 S IELLNALRYHMMGVRVL/T/SQSP  
L2 84 S EAELRDLNNHILKSAMCA/SQSP  
L3 58 S DQLASKYLYHGTQTELGL/SQSP  
L4 68 S KEIANTILKYHIGDELTIV/SQSP

FILE 'CAPLUS' ENTERED AT 14:23:34 ON 02 OCT 2008  
L5 68 S L1  
L6 68 S L2  
L7 58 S L3  
L8 58 S L4

FILE 'STNGUIDE' ENTERED AT 14:24:26 ON 02 OCT 2008

=> s cancer

=> fil caplus  
COST IN U.S. DOLLARS  
SINCE FILE  
ENTRY SESSION  
0.12 125.39  
FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 14:25:26 ON 02 OCT 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is

strictly prohibited.

FILE COVERS 1907 - 2 Oct 2008 VOL 149 ISS 14  
FILE LAST UPDATED: 1 Oct 2008 (20081001/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>  
'OBI' IS DEFAULT SEARCH FIELD FOR 'CPLUS' FILE

=> s cancer  
L10 246905 CANCER/OBI

=> s carcinoma  
L11 155786 CARCINOMA/OBI

=> s onco?  
L12 45688 ONCO?/OBI

=> s neoplas?  
L13 546919 NEOPLAS?/OBI

=> s tumor or tumour  
L14 297654 TUMOR/OBI OR TUMOUR/OBI

=> s angiogen?  
L15 40146 ANGIOGEN?/OBI

=> s arterioscler?  
L16 11213 ARTERIOSCLER?/OBI

=> s sclerosis  
L17 25778 SCLEROSIS/OBI

=> s neovascular glaucoma  
L18 52 NEOVASCULAR GLAUCOMA/OBI

=> s diabetic retinopathy  
L19 5164 DIABETIC RETINOPATHY/OBI

=> s pterygium  
L20 227 PTERYGIUM/OBI

=> s retinal degeneration  
L21 1185 RETINAL DEGENERATION/OBI

=> s retrothal fibroplasia  
L22 617 RETROTHAL FIBROPLASIA/OBI

=> s granular conjunctivitis  
L23 1 GRANULAR CONJUNCTIVITIS/OBI

=> s rheumatoid arthritis  
L24 26118 RHEUMATOID ARTHRITIS/OBI

=> s lupus  
L25 17699 LUPUS/OBI

=> s thyroid?  
L26 71761 THYROID?/OBI

=> s psoriasis  
L27 15306 PSORIASIS/OBI

=> s pyogenic granuloma  
L28 28 PYOGENIC GRANULOMA/OBI

=> s seborrheic dermatitis  
L29 158 SEBORRHEIC DERMATITIS/OBI

=> s acne  
L30 7117 ACNE/OBI

=> d his

(FILE 'HOME' ENTERED AT 14:15:35 ON 02 OCT 2008)

FILE 'REGISTRY' ENTERED AT 14:23:09 ON 02 OCT 2008

L1 67 S IELLNALRYHMMVGRVLT/SQSP  
L2 84 S EALRDLNNHILKSAMCA/SQSP  
L3 58 S DQLASKYLYHGOTLETLG/SQSP  
L4 68 S KELANILKYHIGDEILVS/SQSP

FILE 'CAPLUS' ENTERED AT 14:23:34 ON 02 OCT 2008

L5 68 S L1  
L6 68 S L2  
L7 58 S L3  
L8 58 S L4

FILE 'STNGUIDE' ENTERED AT 14:24:26 ON 02 OCT 2008

L9 5 S CANCER

FILE 'CAPLUS' ENTERED AT 14:25:26 ON 02 OCT 2008

L10 246905 S CANCER  
L11 155786 S CARCINOMA  
L12 45688 S ONCO?  
L13 546919 S NEOPLAS?  
L14 297654 S TUMOR OR TUMOUR  
L15 40146 S ANGIOGEN?  
L16 11213 S ARTERIOSCLER?  
L17 25778 S SCLEROSIS  
L18 52 S NEOVASCULAR GLAUCOMA  
L19 5164 S DIABETIC RETINOPATHY  
L20 227 S PTERYGIUM  
L21 1185 S RETINAL DEGENERATION  
L22 617 S RETROLENTAL FIBROPLASIA  
L23 1 S GRANULAR CONJUNCTIVITIS  
L24 26118 S RHEUMATOID ARTHRITIS  
L25 17699 S LUPUS  
L26 71761 S THYROID?  
L27 15306 S PSORIASIS  
L28 28 S PYOGENIC GRANULOMA  
L29 158 S SEBORRHEIC DERMATITIS  
L30 7117 S ACNE

=> s l10-l30  
L31 914566 (L10 OR L11 OR L12 OR L13 OR L14 OR L15 OR L16 OR L17 OR L18 OR L19 OR L20 OR L21 OR L22 OR L23 OR L24 OR L25 OR L26 OR L27 OR

L28 OR L29 OR L30)

=> s 15-18

L32 78 (L5 OR L6 OR L7 OR L8)

=> s 132(1)131

L33 31 L32(L)31

=> s 133 and (pd<20030402 or ad<20030402 or prd<20030402)

L34 20 L33 AND (PD<20030402 OR AD<20030402 OR PRD<20030402)

=> d ti 1-20

L34 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

TI Expression profile of colon cancer specific genes and their use as biomarkers for diagnosis, therapy and drug screening

L34 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

TI Genes showing altered patterns of expression in colon cancer and their use in diagnosis and therapy

L34 ANSWER 3 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

TI Novel human genes and gene expression products and their use in diagnosis and treatment of colon cancer

L34 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

TI Method for detecting presence of colorectal cancer using TIMP1

L34 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

TI Specific protein markers useful for diagnosis of pancreatic cancer and screening methods

L34 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

TI Immunostimulatory cytokine or encoding nucleic acid in combination with antigen presenting cells for treating cancer, metastasis and infection

L34 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

TI Differentially expressed nucleic acids and their encoded proteins and their uses for the diagnosis and treatment of tumor

L34 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

TI Nucleic acid and encoded protein sequences that are differentially expressed in psoriatic skin and their use for diagnosis and treatment of psoriasis

L34 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

TI Genes showing altered patterns of expression in multiple sclerosis and their diagnostic and therapeutic uses

L34 ANSWER 10 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

TI Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer

L34 ANSWER 11 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

TI Differentially expressed genes for identification, assessment, prevention, and therapy of colon cancer

L34 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

TI Gene expression profiles useful for methods of diagnosis of cancer and screening for modulators of cancer

L34 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Nucleic acid markers for use in determining predisposition to neoplasm and/or adenoma

L34 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Gene expression profiles useful in methods of diagnosis of cancer compositions and methods of screening for modulators of cancer

L34 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer

L34 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Colon tumor proteins, antibodies and oligonucleotides for immunotherapy and diagnosis of colon cancer

L34 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer

L34 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Tumor-associated proteins and their cDNA sequences and uses for immunotherapy and diagnosis of colon cancer

L34 ANSWER 19 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Identification of colon cancer-associated proteins for immunotherapy and diagnosis

L34 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Colon tumor-specific nucleic acids and proteins and their use for immunotherapy and diagnosis of colon cancer

=> d ibib abs hitseq 1-20

L34 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2005:429532 CAPLUS <<LOGINID::20081002>>  
DOCUMENT NUMBER: 142:477160  
TITLE: Expression profile of colon cancer specific genes and their use as biomarkers for diagnosis, therapy and drug screening  
INVENTOR(S): Burgess, Christopher; Myerow, Susan; Thiagalingam, Arunthathi; Maimonis, Peter; Molino, Gary; Burgart, Lawrence; Boardman, Lisa Allyn; Thibodeau, Stephen; Lewis, Marcia  
PATENT ASSIGNEE(S): Bayer Healthcare LLC, USA; Mayo Foundation for Medical Education and Research  
SOURCE: PCT Int. Appl., 256 pp.  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005044990	A2	20050519	WO 2004-US36404	20041101
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,  
 SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
 NE, SN, TD, TG  
 US 2006018889 A1 20060824 US 2003-700439 20031104  
 US 20080233585 A1 20080925 US 2008-47358 20080313  
 US 20080194043 A1 20080814 US 2008-52760 20080321 <--  
 PRIORITY APPLN. INFO.: US 2003-700439 A 20031104  
 US 2002-43354P P 20021213 <--  
 US 2003-491397P P 20030731  
 US 2003-734564 A1 20031212

**AB** The present invention relates to novel marker sequences that are differentially expressed in cancer cells or tissue of a subject with cancerous conditions. The cDNA and protein sequences of 93 genes were disclosed. The present invention also relates to assays for diagnosis, prognosis, staging, monitoring, therapeutic treatment, and marker sequence related agents including probes, primers, antibodies, and therapeutic compns.

**IT** 851927-04-3

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (amino acid sequence; gene expression profile in colon cancer cells and use of genes as biomarkers for diagnosis, therapy and drug screening)

**RN** 851927-04-3 CAPLUS

**CN** Protein (human clone TGFBI colon cancer-specific) (9CI) (CA INDEX NAME)

**SEQ** 1 MALFVRLAL ALALALGPA TLAGPAKSPY QLVLQHSRLR GRQHGPNVCA  
 51 VQKVIGTNRK YFTNCKQWYQ RKIGKSTVI SYECCPGIEK VPGEKGCPAA  
 101 LPALSNLYETL GVGSTTQL YTDRTEKLRP EMEGPGSFTI FAPSNEAWAS  
 151 LPAAEVLDLSV SNNVNIELLNA LRYHMVGRV LTDELKHGMT LTSMYQNSNI  
 201 QIHHYPNGIV TVNCARLLKA DHHATNGVHH LIDKVISTIT NNIIQQIEIE  
 251 DTFETLRAAV AASGLNTMLE GNGQYTLLAP TNEAFEKIPS ETLNRLGDP  
 301 EALRLDNNHH ILKSAMCAEA IVAGLSVETL EGTTLEVGCs GDMLTINGKA  
 351 IIISNKDILAT NQVIIHYIDEL LIPDSAKTLF ELAAEESDVST AIDLFRQAGL  
 401 GNHLSGSERL TLLAPLNSVF KDGTPPIDAH TRNLLRNHII KDQLASKYLY  
 451 HQQTLETLLGG KKLRLRVFYRN SLCIENSCIA AHDKRGRYGT LFTMDRVLTP  
 501 PMGTVMDVNLK GDNRFSMLVA AIIQASGLTET LNREGVYITVF APTENEAFRAL  
 551 PPRERSRLLG DAKELANILK YHIGDEILVS GGIGALVRLK SLQGDKLEVS  
 601 LKNNVVSVNA EPVAEPDIMA TNGVVHVITN VLQPPANRPQ ERGDELADSA  
 651 LEIFKQASAF SRASQRSVRL APVIQKLLER MKH

L34 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2005:5166 CAPLUS <>LOGINID::20081002>>  
 DOCUMENT NUMBER: 142:91453  
 TITLE: Genes showing altered patterns of expression in colon  
 cancer and their use in diagnosis and therapy  
 INVENTOR(S): Martinez, Robert Vincent; Brown, Eugene; Liu, Wei  
 PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA  
 SOURCE: PCT Int. Appl., 167 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 11

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004061423	A2	20040722	WO 2004-XA35	20040106
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2004061423	A2	20040722	WO 2004-US35	20040106
WO 2004061423	A3	20041216		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
PRIORITY APPLN. INFO.:			US 2003-438000P	P 20030106
			WO 2004-US35	A 20040106

AB Sixty-three genes that show different patterns or levels of expression in normal colon and colon cancer are identified for use in diagnosis and therapy. The genes or gene products may be targets for drug therapy (no data) or as antigens in vaccines. Colon cancer genes of the present invention and their encoded products can be used as markers or prophylactic or therapeutic agents for the detection or treatment of colon cancer. Small interfering RNAs (siRNAs) designed to inhibit expression of the genes are also provided. [This abstract record is the first of eleven records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints].

L34 ANSWER 3 OF 20	CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:	2004:609831 CAPLUS <<LOGINID::20081002>>
DOCUMENT NUMBER:	141:155365
TITLE:	Novel human genes and gene expression products and their use in diagnosis and treatment of colon cancer
INVENTOR(S):	Astle, Jon H.; Boardman, Lisa Allyn; Burgart, Lawrence J.; Burgess, Christopher C.; Catino, Theodore J.; Dwivedi, Poornima; Lewis, Marcia E.; Molino, Gary A.; Myerow, Susan H.; Thiagalingam, Arunthathi; Thibodeau, Stephen N.
PATENT ASSIGNEE(S):	Bayer Healthcare LLC, USA; Mayo Foundation for Medical Education & Research
SOURCE:	U.S. Pat. Appl. Publ., 58 pp., Cont.-in-part of U.S. Ser. No. 871,161.
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	5
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040146879	A1	20040729	US 2003-610049	20030630 <--
US 6262333	B1	20010717	US 1999-328111	19990608 <--
US 6262334	B1	20010717	US 1999-385982	19990830 <--
US 20030097666	A1	20030522	US 2001-871161	20010531 <--
US 20020144298	A1	20021103	US 2001-879536	20010611 <--

EP 1494031	A2	20050105	EP 2004-253880	20040629
EP 1494031	A3	20071121		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2005046137	A	20050224	JP 2004-191089	20040629
US 1998-98639P P 19980831 <--				
US 1999-117393P P 19990127 <--				
US 1999-328111 A2 19990608 <--				
US 1999-385982 A1 19990830 <--				
US 2001-871161 A2 20010531 <--				
US 1998-88801P P 19980610 <--				
US 2003-610049 A 20030630				

PRIORITY APPLN. INFO.: AB This invention relates to novel human genes, to proteins expressed by the genes, and to variants of the proteins. The invention also relates to diagnostic assays and therapeutic agents related to the genes and proteins, including probes, antisense constructs, and antibodies. The subject nucleic acids have been found to be differentially regulated in tumor cells, particularly in colon cancer tissue.

IT 727761-71-9 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(amino acid sequence; human genes and gene expression products and their use in diagnosis and treatment of colon cancer)

RN 727761-71-9 CAPLUS

CN Protein (human colon cancer-specific gene) (9CI) (CA INDEX NAME)

SEQ 1 MALFVRLAL ALALALGPAA TLAGPAKSPY QLVLQHSRLR GRQHGPNVCA  
51 VQKVIGTNRK YFTNCQWYQ RKIGKSTVII SYECCPGYEK VPGEKGCPAA  
101 LPLSNLYETL GVVGSTTQL YTDRTEKLRP EMEGPGSFTI FAPSNEAWAS  
151 LPAEVLDLSV SNNVIELLNA LRYHMVGRVV LTDELKHGMT LTSMYQNSNI  
201 QIHYPNGIV TVNCARLLKA DHATNGVHH LIDKVISITIT NNIIQIIIEIE  
251 DTFFETLRAAV AASGLNTMLE GNGQYTLAP TNEAFEKIPS ETLNRILGDP  
301 EAALRDLNNH ILKSAAMCAEA IVAGLSVETL EGTTLEVGCS GDMLTINGKA  
351 IISNKDILAT NGVIHYIDEL LIPDSAKTFL ELAAESDVT AIDLFRQAGL  
401 GNHLSGSERL TLLAPLNSVF KDGTPPIDAH TRNLLRNHII KDQLASKYLY  
451 HQQTLETLGG KKLRLRVFYVRN SLCIENSCIA AHDKRGRYGT LFTMDRVLTP  
501 PMGTVMDVLK GDNRFSMLVA AIQSAGLTET LNREGVYTVF APTNEAFLAL  
551 PPRERSRLG DAKELANILK YHGEIELVS GGIGALVRKL SLLQGDKLEVS  
601 LKNNVSVSNK EPVAEPLDIMA TNGVVHVITN VLQPPANRPQ ERGDELADSA  
651 LEIFKQASAF SRASQRSVRL APVYQKLLER MKH

L34 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2004:569041 CAPLUS <<LOGINID::20081002>>  
DOCUMENT NUMBER: 141:118261  
TITLE: Method for detecting presence of colorectal cancer using TIMP1  
INVENTOR(S): Burgess, Christopher C.; Johnson, Karen Ann;  
Brown-Semelle, Cherill Lynn Andrea; Astle, John H.;  
Boardman, Lisa Elaine; Baggard, Lawrence J.; Catino,  
Theodore J.; Dwivedi, Poornima; Huntress, Mary Ann;  
Meimonis, Peter J.; Molino, Gary A.; Myerow, Susan H.;  
Thiagalingam, Arunthathi; Cibodo, Steven N.; Lewis,  
Marcia E.  
PATENT ASSIGNEE(S): Bayer Healthcare, LLC, USA; Mayo Foundation for  
Medical Education and Research  
SOURCE: Jpn. Kokai Tokkyo Koho, 90 pp.

DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004198419	A	20040715	JP 2003-414126	20031212 <--
US 20040157278	A1	20040812	US 2003-734564	20031212 <--
EP 1439393	A2	20040721	EP 2003-257868	20031215 <--
EP 1439393	A3	20040811		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 20080194043	A1	20080814	US 2008-52760 US 2002-433554P US 2003-491397P US 2003-700439 US 2003-734564	20080321 <-- P 20021213 <-- P 20030731 A1 20031104 A1 20031212
PRIORITY APPLN. INFO.:				

AB The present invention relates to a method for detecting the presence of colorectal cancer in an individual, wherein colorectal cancer is detected by detecting the presence of Regla or TIMP1 nucleic acid or amino acid mol. in a clin. sample obtained from the patient, wherein Regla or TIMP1 expression is indicative of the presence of colorectal cancer. The invention further relates to a method for detecting the presence of colorectal cancer in an individual, wherein colorectal cancer is detected by detecting the presence of Regla or TIMP1 nucleic acid or amino acid mol. in a clin. sample, in addition to detecting the presence of one or more addnl. colorectal cancer-associated markers.

IT 722554-69-0, protein (human TGFBI gene-coding)  
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)  
(amino acid sequence; method for diagnosing colorectal cancer using TIMP1 or Regla)

RN 722554-69-0 CAPLUS

CN protein (human TGFBI gene-coding) (9CI) (CA INDEX NAME)

SEQ

```
1 MALFVRLLL ALALALGPAA TLAGPAKSPY QLVLQHSRLR GRQHGPNVCA
51 VQKVIGTNRK YFTNCQWYQ RKICGKSTVI SYECCPGYEK VPGEKGCPAA
101 LPLSNLYETL GVGSTTTQL YTDRTEKLRP EMEGPGSFTI FAPSNEAWAS
151 LPAEVLDLSV SNVNIELLLNA LRYHMVGRRV LTDELKHGMT LTSMYQNSNI
201 QIHHYPNGIV TVNCARLLNA DHATNGVNH LIDKVISTIT NNIQQIEIE
251 DTFETLRAAV AASGLNTMLE GNGQYTLAA TNEAFEKIPS ETLNRILGDP
301 EAELRDLNNH ILKSAMCAEA IVAGLSVETL EGTTLEVGC3 GDMLTINGKA
351 IISNNDKDLAT NGVVIHYIDEL LIPDASKTLE ELAAESDVT AIDLFRQAGL
401 GNHLSGSERL TLLAPLNSVF KDGTTPIDAH TRNLLRNHII KDQLASKYLY
451 HGQTLETLLGG KKLLPLNSVF SLCIINSCIA AHDKRGRYAGT LFTMDRVLTP
501 PMGTVMDVLK GDNRFSMLVA AIQSGAGLTET LNRREGVYITV APTNEAFRAL
551 PPRERSRLLG DAKELANILK YHIGDEILVS GGIGALVRLK SLQGDKLEVS
601 LKNNVVSVNK EPVAEFDIMA TNQGVHVITN VLQPPANRQ ERGDELADSA
651 LEIFKQASAF SRASQRSVRL APVYQKLLER MKH
```

L34 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2004:534405 CAPLUS <<LOGINID::20081002>>

DOCUMENT NUMBER: 141:69775

TITLE: Specific protein markers useful for diagnosis of pancreatic cancer and screening methods

INVENTOR(S): Chen, Jie; Hu, Liping; Liu, Tong Hua; Lu, Zhao Hui;  
 Shen, Yan

PATENT ASSIGNEE(S): F. Hoffmann-La Roche Ag, Switz.; Sinogenomax Co. Ltd.  
 Chinese National Human Genomcenter

SOURCE: PCT Int. Appl., 381 pp.

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004055519	A2	20040701	WO 2003-EP14057	20031211 <--
WO 2004055519	A3	20041104		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003294828	A1	20040709	AU 2003-294828	20031211 <--
US 20040219572	A1	20041104	US 2003-733969	20031211 <--
CN 1726395	A	20060125	CN 2003-80106539	20031211 <--
PRIORITY APPLN. INFO.:			EP 2002-28058	A 20021217 <--
			EP 2003-25237	A 20031105
			WO 2003-EP14057	W 20031211

AB The present invention provides polypeptides which are up- or down-regulated in pancreatic cancer and which can be used as markers for diagnosis of pancreatic cancer. Thus, 110 protein markers are identified in pancreatic adenocarcinoma patients by 2-dimensional electrophoresis and MALDI-TOF mass spectrometry. The invention also provides an in vitro method for the diagnosis of pancreatic cancer and/or the susceptibility to pancreatic cancer comprising the steps of (a) obtaining a biol. sample; and (b) detecting and/or measuring the increase of one or more polypeptides as disclosed herein. Furthermore, screening methods relating to inhibitors and antagonists of the specific polypeptides disclosed herein are provided.

IT 712410-93-0

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (amino acid sequence; specific protein markers useful for diagnosis of pancreatic cancer and screening methods)

RN 712410-93-0 CAPLUS

CN Cell adhesion molecule  $\beta$ ig-h3 (TGF- $\beta$ -induced gene h3 (human precursor) (9CI) (CA INDEX NAME)

SEQ

1	MALFVRLLL ALALALGPAA TLAGPAKSPY QLVLQHSRLR GRQHGPNVCA
51	VQKVIGTNRK YFTNCQWYQ RKICGKSTVI SYECCPGYEK VPGEKGCPAA
101	LPLSNLYETL GVGSTTTQL YTDRTEKLRP EMEPGPSFTI FAPSNEAWAS
151	151 LPAEVLDLSV SNVNIELLNA LRYHMVGVRV LTDELKHGMT LTSMQNSNI
201	OIHMHYPNGIV TVNCARLLKA DHAHATNGVNH LIDKVISTIT NNHQOIEIE
251	251 DTFETLRAAV AASGLNTMLE GNQGQTLLAP TNEAEFKIPS ETILNRLGDP
301	301 EALRDLNNH ILLSAMCAEA VAGLSVETL EGTTILEVGCS GDMLTINGKA
351	351 IISNAKDLILAT NGVHYIDEL LIPDASAKTLE ELAAEESDVST AIDLFRQAGL
401	401 GNHLSGSERL TLLAPLNSVF KDGTPPIDAH TRNLLRNHII KDQLASKYLY

451 HQQTLETLLGG KKLRVVFVYRN SLCIENCIA AHDKRGRYGT LFTMDRVLTP  
 501 PMGTVMDVLK GDNRFSMLVA AIQSAGLTET LNREGVYTFV APTNEAFRAL  
 551 PPRERSRLLG DAKELANILK YHIGDEILVS GGIGALVRLK SLQGDKLEVS  
 601 LKNNVSVNK EPVAEPDIMA TNQGVHVITN VLQPPANRPQ ERGDELADSA  
 651 LEIFKQASAF SRASQRSVRL APVYQKLLER MKH

L34 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:354746 CAPLUS <<LOGINID::20081002>>  
 DOCUMENT NUMBER: 140:373912  
 TITLE: Immunostimulatory cytokine or encoding nucleic acid in  
 combination with antigen presenting cells for treating  
 cancer, metastasis and infection  
 INVENTOR(S): Lotze, Michael T.; Tahara, Hideaki  
 PATENT ASSIGNEE(S): University of Pittsburgh of the Commonwealth System of  
 Higher Education, USA  
 SOURCE: PCT Int. Appl., 169 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004034995	A2	20040429	WO 2003-US32827	20031015 <--
WO 2004034995	A9	20040610		
WO 2004034995	A3	20050120		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003290528	A1	20040504	AU 2003-290528	20031015 <--
US 20040247578	A1	20041209	US 2003-688845	20031015 <--
PRIORITY APPLN. INFO.:			US 2002-418865P	P 20021015 <--
			WO 2003-US32827	W 20031015

AB Methods and reagents for treating tumors, metastases, and infectious  
 lesions by coadministration of antigen presenting cells and  
 immunostimulatory cytokines or nucleic acid encoding an immunostimulatory  
 cytokine into or near the site of the tumor or infectious lesion are  
 described.

IT 683836-05-7

RL: PRP (Properties)  
 (unclaimed protein sequence; immunostimulatory cytokine or encoding  
 nucleic acid in combination with antigen presenting cells for treating  
 cancer, metastasis and infection)

RN 683836-05-7 CAPLUS

CN 11: PN: WO2004034995 SEQID: 77 unclaimed protein (9CI) (CA INDEX NAME)

SEQ 1 MALFVRLLL ALALALGPAA TLAGPAKSPY QLVLQHSRLR GRQHGPNVCA  
 51 VQKVIGTNRK YFTNCQWYQ RKICGKSTVI SYECCPGYEK VPGEKGPAA  
 101 LPLSNLYETL GVVGTTTQL YTDRTEKLRP EMEGPGSFTI FAPSNEAWAS

151 LPAEVLDLSV SNVNIELLNA LRYHMVGRRV LTDELKHGMT LTSMYQNSNI  
 201 QIHYPNGIV TVNCARLLKA DHAHNGVH DLDKVISTIT NNIQOIEIE  
 251 DTFETLRAAV AASGLNTMLE GNQGYTLLAP TNEAEFKIPS ETILNRLGDP  
 301 EAIRDLLNNH ILKSAMCAEA IVAGLSVETL EGTTILEVGCS GDMLTINGKA  
 351 IISNKKDILAT NGVIHYIDEL LIPDSAKTLE ELAAESDVT AIDLFRQAGL  
 401 GHQHLSGSERL TLLAPLNSVF KDGTPPIDAH TRNLLRNHII KDQLASKYLY  
 451 HQQTLETIGG KKLRFVYRN SLCIENSCIA AHDKRGRYGT LFTMDRVLTP  
 501 PMGTVMDVLK GDNRFSMLVA AIQSAGLTT LNREGVYTFV APTNEAFFAL  
 551 PPRERSRLG DAKELANILK YHIGDEILVS GGIGALVRLK SLQGDKLEVS  
 601 LKNNVVSVNK EPVAEPDIMA TNGVHVITN VLQPPANRPQ ERGDELADSA  
 651 LEIFKQASAF SRASQRSVRL APVYQKLLER MKH

L34 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:308357 CAPLUS <>LOGINID::20081002>>  
 DOCUMENT NUMBER: 140:333596  
 TITLE: Differentially expressed nucleic acids and their  
 encoded proteins and their uses for the diagnosis and  
 treatment of tumor  
 INVENTOR(S): Wu, Thomas D.; Zhang, Zemin; Zhou, Yan  
 PATENT ASSIGNEE(S): Genentech, Inc., USA  
 SOURCE: PCT Int. Appl., 7273 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004030615	A2	20040415	WO 2003-US28547	20030929
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2500687	A1	20040415	CA 2003-2500687	20030929
WO 2004030615	A2	20040415	WO 2003-XA28547	20030929
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003295328	A1	20040423	AU 2003-295328	20030929
EP 1594447	A2	20051116	EP 2003-786510	20030929
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006516089	T	20060622	JP 2004-541530	20030929
US 20070224201	A1	20070927	US 2005-529351	20050325

PRIORITY APPLN. INFO.:

US 2002-414971P P 20021002

WO 2003-US28547 W 20030929

AB The present invention provides a large number of specific cDNA sequences which are upregulated in certain tumor tissues as compared to their normal tissue counterparts and therefore useful for the diagnosis and treatment of tumor in mammals. An expressed sequence tag (EST) DNA database was searched and interesting EST sequences identified by GEPIS (gene expression profiling *in silico*), a bioinformatics tool that characterizes genes of interest for new cancer therapeutic targets. Using this type of screening bioinformatics, various tumor-associated antigenic target (TAT) proteins (and their encoding nucleic acid mols). were identified as being significantly overexpressed in particular type of cancer or certain cancers as compared to other cancers and/or normal non-cancerous tissues. [This abstract record is one of two records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

L34 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:290482 CAPLUS &lt;&lt;LOGINID::20081002&gt;&gt;

DOCUMENT NUMBER: 1401:316226

TITLE: Nucleic acid and encoded protein sequences that are differentially expressed in psoriatic skin and their use for diagnosis and treatment of psoriasis  
 INVENTOR(S): Bodary, Sarah; Clark, Hilary; Jackman, Janet; Schoenfeld, Jill; Williams, P. Mickey; Wood, William I.; Wu, Thomas D.

PATENT ASSIGNEE(S): Genentech, Inc., USA

SOURCE: PCT Int. Appl., 3068 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent  
 LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004028479	A2	20040408	WO 2003-US30907	20030925
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2499843	A1	20040408	CA 2003-2499843	20030925
AU 2003279084	A1	20040419	AU 2003-279084	20030925
EP 1585482	A2	20051019	EP 2003-770594	20030925
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006513700	T	20060427	JP 2004-540290	20030925
US 20070042945	A1	20070222	US 2005-529348	20050325
PRIORITY APPLN. INFO.:			US 2002-414006P	P 20020925
			WO 2003-US30907	W 20030925

AB The present invention provides a large number of cDNA and protein sequences that are differentially expressed in psoriatic tissue. Affymetrix microarrays are used to identify genes whose expression are up-regulated or down-regulated in psoriatic skin vs. non-lesional skin, thus comparing expression profiles of non-lesional skin and psoriatic skin from the same

patient, and also comparing against normal skin biopsies of normal healthy donors as a further control. The nucleic acid and protein compns. are useful in the diagnosis and/or treatment of psoriasis, and in screening for candidate inhibitors of psoriasis.

L34 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2003:913280 CAPLUS <>LOGINID::20081002>>  
DOCUMENT NUMBER: 139:379453  
TITLE: Genes showing altered patterns of expression in multiple sclerosis and their diagnostic and therapeutic uses  
INVENTOR(S): Dangond, Fernando; Hwang, Daehee  
PATENT ASSIGNEE(S): Brigham and Women's Hospital, Inc., USA  
SOURCE: PCT Int. Appl., 148 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003095618	A2	20031120	WO 2003-US14462	20030507
WO 2003095618	A3	20041021		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KE, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20040018522	A1	20040129	US 2003-430762	20030506
AU 2003228936	A1	20031111	AU 2003-228936	20030507
PRIORITY APPLN. INFO.:			US 2002-379284P	P 20020509
			US 2003-430762	A1 20030506
			WO 2003-US14462	W 20030507

AB The present invention identifies a number of gene markers whose expression is altered in multiple sclerosis (MS). These markers can be used to diagnose or predict MS in subjects, and can be used in the monitoring of therapies. In addition, these genes identify therapeutic targets, the modification of which may prevent MS development or progression. Genes were identified by determination of expression profiling. A large number of genes showing altered patterns of expression were identified, with the most discriminatory genes being those for: phosphatidylinositol transfer protein, inducible nitric oxide synthase, CIC-1 (CLCN1) muscle chloride channel protein, placental bikunin (AMBp), receptor kinase ligand LERK-3/Ephrin-A3, GATA-4, thymopoietin, transcription factor E2f-2, S-adenosylmethionine synthetase, carcinoembryonic antigen, the ret oncogene, a G protein-linked receptor (clone GPCR W), GTP- binding protein RALB, tyrosine kinase Syk, LERK-2/Ephrin-B1, ELK1 tyrosine kinase oncogene, transcription factor SL1, phospholipase C, gastricsin (progastricsin), and the D13S824E locus.

L34 ANSWER 10 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2003:747872 CAPLUS <>LOGINID::20081002>>  
DOCUMENT NUMBER: 139:256367  
TITLE: Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer  
INVENTOR(S): Xu, Jiangchun; Lodes, Michael J.; Sechrist, Heather;

Meagher, Madeleine Joy; Stolk, John; Benson, Darin R.;  
 Wang, Tongtong  
 PATENT ASSIGNEE(S): Corixa Corporation, USA  
 SOURCE: U.S., 140 pp., Cont.-in-part of U.S. Ser. No. 347,496.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 7  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6623923	B1	20030923	US 1999-401064	19990922 <--
US 6284241	B1	20010904	US 1998-221298	19981223 <--
CA 2356987	A1	20000629	CA 1999-2356987	19991223 <--
WO 2000037643	A2	20000629	WO 1999-US30909	19991223 <--
WO 2000037643	A3	20010809		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1144632	A2	20011017	EP 1999-967625	19991223 <--
EP 1144632	A3	20011107		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002533082	T	20021008	JP 2000-589697	19991223 <--
EP 1715043	A2	20061025	EP 2006-2432	19991223 <--
EP 1715043	A3	20070110		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
EP 1767636	A2	20070328	EP 2006-25304	19991223 <--
EP 1767636	A3	20070613		
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, AL, LT, LV, MK, RO, SI				
US 20020110547	A1	20020815	US 2001-833263	20010410 <--
US 20020076414	A1	20020620	US 2001-922217	20010803 <--
US 20020182191	A1	20021205	US 2001-25380	20011219 <--
US 20050260177	A1	20051124	US 2005-108172	20050415 <--
PRIORITY APPLN. INFO.:				
		US 1998-221298	A2 19981223 <--	
		US 1999-347496	A2 19990702 <--	
		US 1999-401064	A 19990922 <--	
		US 1999-444242	A 19991119 <--	
		US 1999-444252	A2 19991119 <--	
		US 1999-454150	A 19991202 <--	
		EP 1999-967625	A3 19991223 <--	
		WO 1999-US30909	W 19991223 <--	
		US 1999-476296	A2 19991230 <--	
		US 2000-480321	A2 20000110 <--	
		US 2000-504629	A2 20000215 <--	
		US 2000-519444	A2 20000306 <--	
		US 2000-444252	A2 20000410 <--	
		US 2000-575251	A2 20000519 <--	
		US 2000-609448	A2 20000629 <--	
		US 2000-649811	A2 20000828 <--	
		US 2001-833263	A2 20010410 <--	
		US 2001-922217	A2 20010803 <--	
		US 2001-25380	B1 20011219 <--	

AB Compns. and methods for the therapy and diagnosis of cancer, such as colon cancer, are disclosed. Compns. may comprise one or more colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a protein. Thus, polypeptides differentially expressed in colon tumors are isolated and characterized by PCR-based subtraction and microarray anal. of cDNA libraries, as well as mouse antisera. Such compns. may be used, for example, for the prevention and treatment of diseases such as colon cancer. Diagnostic methods based on detecting a colon tumor protein, or mRNA encoding such a protein, in a sample are also provided.

IT 603206-84-4P

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(amino acid sequence; tumor-associated nucleic acids and  
proteins for immunotherapy and diagnosis of colon cancer)

RN 603206-84-4 CAPLUS

CN Colon tumor-associated protein (human clone US6623923-SEQID-121) (9CI)  
(CA INDEX NAME)

SEQ 1 MALFVRLAL ALALALGPA ALAGPAKSPY QLVLQHSRLR GRQHGPNVCA  
51 VQKVIGTNRK YFTNCKQWYQ RKICGKSTVI SYECCPGYEK VPGEKGCPAA  
101 LPASNLYETL GVVGSTTQL YTDRTKELRP EMEPGPSFTI FAPSNEAWAS  
151 LPAEVLDSLV SNVNIELLNA LRYHMVGRV LTDELKHGMT LTSMYQNNSNI  
201 QIINHYPNGIV TVNCARLLKA DHATNGVHH LIDKVISTET NNIIQIIIEIE  
251 DTFETLRAAV AASGLNTMLE GNQYTL LAP TNEAEKIPS ETLNRLGDP  
301 EALARDLNNH ILKSAMCAEA IVAGLSVETL EGTTLEVGC GDMLTINGKA  
351 IISNKDILAT NGVIHYIDEL LIPDLSAKTFL ELAAEESDVST AIDLFRQAGL  
401 GNHLSGGSERL TLLAPLNSVF KDGTPPIDAH TRNLLRNHII KDLQLASKYLY  
451 HQQILETLLGG KKLRLVFVYRN SLCIENSCIA AHDKRGRYGT LFTMDRVLTP  
501 PMGTVMDVLK GDNRFSMLVA AIQASAGLTET LNREGVYTVF APTENEAFRAL  
551 PPRERSRLLG DAKELANILK YHIGDEILVS GGIGALVRLK SLQGDKLEVS  
601 LKNNVQSVNK EPVAEPDIMA TNGVVHVITN VLQPPANRPQ ERGDELADSA  
651 LEIFKQASAF SRASQRSVRL APVYQKLLER MKH

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 11 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2003:626612 CAPLUS <<LOGINID::20081002>>

Correction of: 2003:472599

DOCUMENT NUMBER: 139:129181

Correction of: 139:48232

TITLE: Differentially expressed genes for identification,  
assessment, prevention, and therapy of colon cancer  
INVENTOR(S): Berger, Allison; Guillemette, Tracy L.; Schlegel,  
Robert; Monahan, John E.; Kamatkar, Shubhangi;  
Thibodeau, Stephen; Burgart, Lawrence J.

PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., USA  
SOURCE: PCT Int. Appl., 88 pp.

DOCUMENT TYPE: Patent  
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003050243	A2	20030619	WO 2002-US37431	20021121 <--
WO 2003050243	A3	20040401		
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002357747	A1	20030623	AU 2002-357747	20021121 <--
US 20030148410	A1	20030807	US 2002-301822	20021121 <--
US 20050266493	A1	20051201	US 2005-186284	20050721 <--
PRIORITY APPLN. INFO.:			US 2001-339971P	P 20011210 <--
			US 2002-361978P	P 20020305 <--
			US 2002-381988P	P 20020520 <--
			US 2002-301822	B1 20021121 <--
			WO 2002-US37431	W 20021121 <--

AB The invention relates to newly discovered nucleic mols. and proteins that are up-regulated in colon cancer. The 114 markers were identified by transcriptional profiling with RNA derived from 21 normal colon samples, 4 adenomatous polyps, and 25 colon cancer samples using nylon arrays of 44,200 clones, including 30,000 IMAGE clones, 14,000 clones from cDNA libraries generated at Millennium Pharmaceuticals, Inc., and 200 control genes. Higher than normal levels of expression of any of these markers or combination of these markers correlates with the presence of colon cancer. Thus, compns., kits, and methods for detecting, characterizing, preventing, and treating human colon cancers are provided. The present invention claims a total of 228 sequences, but the Sequence Listing was not made available on publication of the patent application.

IT 568626-58-4

RL: PRP (Properties)

(unclaimed protein sequence; differentially expressed genes for identification, assessment, prevention, and therapy of colon cancer)

RN 568626-58-4 CAPLUS

CN 99: PN: WO03050243 SEQID: 201 unclaimed protein (9CI) (CA INDEX NAME)

SEQ 1 MALFVRLAL ALALALGPAA TLAGPAKSPY QLVLQHSRLR GRQHGPNVCA  
 51 VQKVGITGNRK YFTNCKQWYQ RKICGKSTVI SYECCPGYEK VPGBEKGCPAA  
 101 LPLSNLYETL GVVGSTTQL YTDRTEKLRP EMEGPGSFTI FAPSPNEAWAS  
 151 LPAEVLDLSV SNVNIELLNA LRYHMVGRVV LTDELKHGMT LTSMYQNSNI  
 201 QIHHYPNGIV TVNCARLLKA DHATNGVVH LIDKVISTIT NNIIQQIIIEIE  
 251 DTFETLRAAV AASGLNTMLE GNGQYTLLAP TNEAFEKIPS ETLNRLIGDP  
 301 EAFLRDLLNNH ILKSAMCAEA IVAGLSVETL EGTTILEVGCS GDMLTINGKA  
 351 IISNRKDILAT NGVHYIDEL LIPDSAKTLP ELAAESDVST AIDLFRQAGL  
 401 GNHLSGSERL TLLAPLNSVF KDGTPPIDAH TRNLLRNHII KDLQASLYLY  
 451 HGQTLLETLLGG KKLRVFWYRN SLCIENSCIA AHDKRGGRYGT LFTMDRVLTP  
 501 PMGTVMDVLK GDNRFSMLVA AIQSAGLTET LNREGVYTVF APTNEAFRAL  
 551 PPRERSRLLG DAKELANILK YHIGDEILVS GGIGALVRLK SLQGDKLEVS  
 601 LKNNVVSVNK EPVAEPDIMA TNGVVVHITN VLQPPANRPQ ERGDELADSA  
 651 LEIFKQASAF SRASQSRVLR APVYQKLLER MKH

L34 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2003:442069 CAPLUS <<LOGINID::20081002>>  
 DOCUMENT NUMBER: 139:18315  
 TITLE: Gene expression profiles useful for methods of  
 diagnosis of cancer and screening for modulators of  
 cancer  
 INVENTOR(S): Afar, Daniel; Aziz, Natasha; Ginsburg, Wendy M.; Gish,  
 Kurt C.; Glynne, Richard; Hevezzi, Peter A.; Mack,  
 David H.; Murray, Richard; Watson, Susan R.; Wilson,  
 Keith E.; Zlotnik, Albert  
 PATENT ASSIGNEE(S): Eos Biotechnology, Inc., USA  
 SOURCE: PCT Int. Appl., 1385 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 38  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003042661	A2	20030522	WO 2002-XK36810	20021113
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1721977	A2	20061115	EP 2006-7721	20020917
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SK, TR				
US 20070042360	A1	20070222	US 2002-245882	20020917
WO 2003042661	A2	20030522	WO 2002-US36810	20021113
WO 2003042661	A3	20041028		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20040197325	A1	20041007	US 2003-741657	20031219
US 7276372	B2	20071002		
US 20070059748	A1	20070315	US 2006-516476	20060906
US 20070154928	A1	20070705	US 2007-625458	20070122
PRIORITY APPLN. INFO.:				
US 2001-350666P P 20011113				
US 2001-335394P P 20011115				
US 2001-332464P P 20011121				
US 2001-334393P P 20011129				
US 2001-340376P P 20011214				
US 2002-347211P P 20020108				
US 2002-347349P P 20020110				
US 2002-356714P P 20020213				
US 2002-359077P P 20020220				
US 2002-368809P P 20020329				

US	2002-370110P	P	20020404
US	2002-372246P	P	20020412
US	2002-386614P	P	20020605
US	2002-396839P	P	20020716
US	2002-397775P	P	20020722
US	2002-397845P	P	20020722
US	2002-409450P	P	20020909
WO	2002-US36810	W	20021113
US	2001-299234P	P	20010618
US	2001-315287P	P	20010827
US	2001-323469P	P	20010917
US	2001-323887P	P	20010920
US	2001-325114P	P	20010925
US	2001-340944P	P	20011029
US	2002-355145P	P	20020208
US	2002-355257P	P	20020208
US	2002-369899P	P	20020404
US	2002-173999	A	20020617
EP	2002-766297	A3	20020917
US	2002-245882	A1	20020917
US	2002-435618P	P	20021220

AB Described herein are genes whose expression are up-regulated or down-regulated in specific cancers or other diseases, or are otherwise regulated in disease. Mol. profiles of various normal and cancerous tissues were determined and analyzed using the Affymetrix/Eos Hu3 GeneChip array comprising .apprx.58,680 probesets. Related methods and compns. that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of these selected conditions. [This abstract record is one of twelve records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

L34 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2003:242516 CAPLUS <<LOGINID::20081002>>  
 DOCUMENT NUMBER: 138:266955  
 TITLE: Nucleic acid markers for use in determining predisposition to neoplasm and/or adenoma  
 INVENTOR(S): James, Robert; Henry, Julianne; Kazenwadel, Jan; Van Host, Pellekaan Nick; MacPherson, Anne; O'Connor, Susan  
 PATENT ASSIGNEE(S): Medimolecular Pty. Ltd., Australia  
 SOURCE: PCT Int. Appl., 430 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
WO 2003025214	A1	20030327	WO 2002-AU1258	20020913 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,				

CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002325088	A1	20030401	AU 2002-325088	20020913 <--
AU 2002325088	B2	20070809		
EP 1438427	A1	20040721	EP 2002-757979	20020913 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
US 20050053967	A1	20050310	US 2004-800322	20040312 <--
AU 2007201611	A1	20070503	AU 2007-201611	20070412 <--
PRIORITY APPLN. INFO.:			US 2001-322288P	P 20010914 <--
			AU 2002-325088	A3 20020913 <--
			WO 2002-AU1258	W 20020913 <--

AB The present invention relates generally to novel nucleic acid mols., the levels and/or patterns of expression of which are indicative of the onset, predisposition to the onset and/or progression of a neoplasm and to derivs., homologs or analogs of said mols. More particularly, the present invention is directed to novel nucleic acid mols., the levels of expression of which are indicative of the onset and/or progression of a gastrointestinal tract neoplasm, such as an adenoma, and to derivs., homologs or analogs of said mols. The present invention is further directed to isolated proteins encoded thereby and to derivs., homologs, analogs, chemical equivalent and mimetics thereof. The identification of adenoma

markers and adenoma markers together with identification of their expression uplift levels and expression profile can now be correlated to disease stage and/or cancer invasiveness. The mols. of the present invention are useful in a range of prophylactic, therapeutic, and/or diagnostic applications including, but not limited to, those relating to the diagnosis and/or treatment of colorectal neoplasms such as colorectal adenomas. In a related aspect, the present invention is directed to a method of screening a subject for the onset, predisposition to the onset, and/or progression of a neoplasm by screening for modulation in the level of expression of one or more nucleic acid mol. markers.

IT 503193-38-2

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (amino acid sequence; nucleic acid markers for use in determining predisposition to neoplasm and/or adenoma)

RN 503193-38-2 CAPLUS

CN Adenoma-associated protein (human clone 4-1le) (9CI) (CA INDEX NAME)

SEQ 1 MALFVRLAL ALALALGPAA TLAGPAKSPY QLVLQHSRLL GRQHGPNVCA  
 51 VQKVIGTNRK YFTNCQWYQ RKIGCKSTVI SYECCPGYEK VPGEKGCPAA  
 101 LPLSNLYETL GVGSTTTQL YTDRTEKLRP EMEGPGSFTI FAPSNEAWAS  
 151 LPAVLDSLNS SNVNIELLKA DHAHNGVRRV LTDELKHGMT LTSMYQNSNI  
 201 QIHHYPNGIV TVNCARLLKA DHAHNGVRRV LIQKVISITI NNIQOIIIEIE  
 251 DTFETLRAAV AASGLNTMLE GNGQYTILLAP TNEAEFKIPS ETILNRILGDP  
 301 EALRDLLNNH ILKSAMCAEA IVAGLSVETL EGTTILEVGCS GDMLTINGKA  
 351 IIISNDILAT NGVIHYIDEL LIPDSAFTLF ELAAESDVST AIDLFRQAGL  
 401 GNHLSGSERL TLLAPLNSVF KDGTPPIDAH TRNLLRNHII KDQLASKYLY  
 451 HGQTLETIGG KKLRFVYRN SLCIENSCIA AHDKRGRYGT LFTMDRVLTP  
 501 PMGTVMDVLK GDNRFSMLVA AIQSGALIET LNREGVYTVF APTNEAFRAL  
 551 PPRERSRLLG DAKELANILK YHIGDEILVS GGIGALVRLK SIQGDKLEVS  
 601 LKNNVVSVNK EPVAEPDIMA TNQGVHVITN VLQPPANRPQ ERGDELADSA  
 651 LEIFKQASAF SRASQRSQLR APVYQKLLER MKH

REFERENCE COUNT:

11

THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2003:242452 CAPLUS <<LOGINID::20081002>>  
 DOCUMENT NUMBER: 138:282427  
 TITLE: Gene expression profiles useful in methods of  
 diagnosis of cancer compositions and methods of  
 screening for modulators of cancer  
 INVENTOR(S): Afar, Daniel; Aziz, Natasha; Gish, Kurt C.; Hevezzi,  
 Peter A.; Mack, David H.; Wilson, Keith E.; Zlotnik,  
 Albert  
 PATENT ASSIGNEE(S): EOS Biotechnology, Inc., USA  
 SOURCE: PCT Int. Appl., 767 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 38  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003025138	A2	20030327	WO 2002-US29560	20020917 <--
WO 2003025138	A3	20030508		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2459219	A1	20030327	CA 2002-2459219	20020917 <--
WO 2003025138	A2	20030327	WO 2002-XA29560	20020917 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2003025138	A2	20030327	WO 2002-XB29560	20020917 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2003025138	A2	20030327	WO 2002-XC29560	20020917 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2003025138 A2 20030327 WO 2002-XD29560 20020917 <--  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KE, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2003025138 A2 20030327 WO 2002-XE29560 20020917 <--  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KE, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2003025138 A2 20030327 WO 2002-XF29560 20020917 <--  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KE, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2003025138 A2 20030327 WO 2002-XG29560 20020917 <--  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KE, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2003025138 A2 20030327 WO 2002-XH29560 20020917 <--  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KE, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002330039 A1 20030401 AU 2002-330039 20020917 <--  
 EP 1434881 A2 20040707 EP 2002-766297 20020917 <--

R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005518782	T	20050630	JP 2003-529912	20020917 <--	
EP 1721977	A2	20061115	EP 2006-7721	20020917 <--	
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SK, TR				
US 20070042360	A1	20070222	US 2002-245882	20020917 <--	
US 20040197325	A1	20041007	US 2003-741657	20031219 <--	
US 7276372	B2	20071002			
US 20070059748	A1	20070315	US 2006-516476	20060906 <--	
US 20070154928	A1	20070705	US 2007-625458	20070122 <--	
PRIORITY APPLN. INFO.:					
		US 2001-323469P	P	20010917 <--	
		US 2001-323887P	P	20010920 <--	
		US 2001-350666P	P	20011113 <--	
		US 2002-355145P	P	20020208 <--	
		US 2002-355257P	P	20020208 <--	
		US 2002-372246P	P	20020412 <--	
		US 2001-299234P	P	20010618 <--	
		US 2001-315287P	P	20010827 <--	
		US 2001-325114P	P	20010925 <--	
		US 2001-340944P	P	20011029 <--	
		US 2002-369899P	P	20020404 <--	
		US 2002-173999	A	20020617 <--	
		EP 2002-766297	A3	20020517 <--	
		US 2002-245882	A1	20020917 <--	
		WO 2002-US29560	W	20020917 <--	
		US 2002-435618P	P	20021220 <--	

AB Described herein are genes whose expression are up-regulated or down-regulated in specific cancers, including acute lymphocytic leukemia, glioblastoma, glioblastoma multiforme, glioma, kidney cancer, stomach cancer, melanoma, and benign nevi. Mol. profiles of various normal and cancerous tissues were determined and analyzed using the Affymetrix/Eos Hu01 and Hu03 GeneChip microarrays containing 35,403 and 59,680 probe sets, resp. Related methods and compns. that can be used for diagnosis and treatment of those cancers are disclosed. Also described herein are methods that can be used to identify modulators of selected cancers. [This abstract record is one of nine records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT 503636-40-6

RL: ANT (Analyte); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(amino acid sequence; gene expression profiles useful in methods of diagnosis of cancer compns. and methods of screening for modulators of cancer)

RN 503636-40-6 CAPLUS

CN Tumor-associated protein (human clone WO03025138-SEQID-279) (9CI) (CA INDEX NAME)

SEQ 1 MALFVRLLL ALALALGPA TLAGPAKSPY QLVLQHSRLR GRQHGPNVCA  
 51 VQKVIGTNRK YFTNCKQWYQ RKICGKSTVI SYECCPGYEK VPGEKGGCPAA  
 101 LPLSNLYETL GVGSTTTQL YTDRTEKLRP EMEGPGSTI FAPSNEAWAS  
 151 LPAAEVLDLSV SNVNIELLNA LRYHMMGRRV LTDELKHGML LTSMYQNSNI  
 201 QIHHYNGCIV TVNCARLLKA DHATNGVHLL DLDKVISTIT NNIIQOIIIEIE  
 251 DTFETLRAAV AASGLNTMLE GNGQYTLAP TNEAFEKIPS ETLNRLILGDP  
 301 EALRDLNNH ILKSAMCAEA IVAGLSVETL EGTTLEVGS GDMLTINGKA  
 351 IISNKDILAT NGVIHAYIDEL LIPDPSAKTFL ELAAEESDVST AIDLFRQAGL  
 401 GNHLGSGSERL TLLAPLNSVF KDGTPSIDAH TRNLLRNHII KDQLASKEYLY  
 451 HGQTLETLGG KKLRVFVYRN SLCIENSCIA AHDKRGRYGT LFTMDRVLTP

501 PMGTVMVDLK GDNRFSMLVA AIQSAGLTET LNREGVYTVF APTNEAFRAL  
 551 PPRERSRLLG DAKELANILK YHIGDEILVS GIGALVRLK SLQGDKLEVS  
 601 LKNNVSVNK EPVAEPDIMA TNQVHVITN VLQPPANRPQ ERGDELADSA  
 651 LEIFKQASAF SRASQRSVRL APVYQKLLER MKH

L34 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2002:928019 CAPLUS <>LOGINID::20081002>>  
 DOCUMENT NUMBER: 138:1132  
 TITLE: Tumor-associated nucleic acids and proteins for  
 immunotherapy and diagnosis of colon cancer  
 INVENTOR(S): Xu, Jiangchun; Lodes, Michael J.; Sechrist, Heather;  
 Benson, Darin R.; Meagher, Madeleine Joy; Stolk, John  
 A.; Wang, Tongtong; Jiang, Yiqiu; Smith, Carole L.;  
 King, Gordon E.; Wang, Aijun; Clapper, Jonathan D.;  
 Skeiky, Yasir A. W.; Fanger, Gary R. C.; Vedvick,  
 Thomas S.; Carter, Darrick  
 PATENT ASSIGNEE(S): Corixa Corporation, USA  
 SOURCE: U.S. Pat. Appl. Publ., 52 pp., Cont.-in-part of U.S.  
 Ser. No. 922,217.  
 CODEN: USXSC0  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 7  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020182191	A1	20021205	US 2001-25380	20011219
US 6284241	B1	20010904	US 1998-221298	19981223
US 6623923	B1	20030923	US 1999-401064	19990922
WO 2000037643	A2	20000629	WO 1999-US30909	19991223
WO 2000037643	A3	20010809		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 20020110547	A1	20020815	US 2001-833263	20010410
US 20020076414	A1	20020620	US 2001-922217	20010803
WO 2002083070	A2	20021024	WO 2002-US11475	20020409
WO 2002083070	A3	20041111		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, QG, GW, ML, MR, NE, SN, TD, TG				
AU 2002256186	A1	20021028	AU 2002-256186	20020409
US 20050260177	A1	20051124	US 2005-108172	20050415
PRIORITY APPLN. INFO.:			US 1998-221298	A2 19981223
			US 1999-347496	A2 19990702
			US 1999-401064	A2 19990922

US 1999-444252	A2 19991119
US 1999-454150	B2 19991202
WO 1999-US30909	W 19991233
US 1999-476296	B2 19991230
US 2000-480321	B2 20000110
US 2000-504629	B2 20000215
US 2000-519444	B2 20000306
US 2000-575251	B2 20000519
US 2000-609448	A2 20000629
US 2000-649811	A2 20000828
US 2001-833263	A2 20010410
US 2001-922217	A2 20010803
US 1999-444242	A 19991119
US 2000-444252	A2 20000410
US 2001-25380	A 20011219
WO 2002-US11475	W 20020409

AB Compns. and methods for the therapy and diagnosis of cancer, such as colon cancer, are disclosed. Compns. may comprise one or more colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a protein. Thus, polypeptides differentially expressed in colon tumors are isolated and characterized by PCR-based subtraction and microarray anal. of cDNA libraries, as well as mouse antisera. Such compns. may be used, for example, for the prevention and treatment of diseases such as colon cancer. Diagnostic methods based on detecting a colon tumor protein, or mRNA encoding such a protein, in a sample are also provided.

L34 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESION NUMBER: 2002:813878 CAPLUS <<LOGINID::20081002>>  
 DOCUMENT NUMBER: 137:324213  
 TITLE: Colon tumor proteins, antibodies and oligonucleotides for immunotherapy and diagnosis of colon cancer  
 INVENTOR(S): Xu, Jiangchun; Lodes, Michael J.; Sechrist, Heather; Benson, Darin R.; Meagher, Madeleine Joy; Stolk, John A.; Wang, Tongtong; Jiang, Yuqiu; Smith, Carole L.; King, Gordon E.; Wang, Aijun; Clapper, Jonathan D.; Skeiky, Yasir Aw; Fanger, Gary R.; Vedvick, Thomas S.; Carter, Derrick  
 PATENT ASSIGNEE(S): Corixa Corporation, USA  
 SOURCE: PCT Int. Appl., 537 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 7  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083070	A2	20021024	WO 2002-US11475	20020409
WO 2002083070	A3	20041111		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

US 20020110547	A1	20020815	US 2001-833263	20010410
US 20020076414	A1	20020620	US 2001-922217	20010803
US 20020182191	A1	20021205	US 2001-25380	20011219
AU 2002256186	A1	20021028	AU 2002-256186	20020409
PRIORITY APPLN. INFO.:				
			US 2001-833263	A 20010410
			US 2001-922217	A 20010803
			US 2001-25380	A 20011219
			US 1998-221298	A2 19981223
			US 1999-347496	A2 19990702
			US 1999-401064	A2 19990922
			US 1999-444252	A2 19991119
			US 1999-454150	A2 19991202
			WO 1999-US30909	A2 19991223
			US 1999-476296	A2 19991230
			US 2000-480321	A2 20000110
			US 2000-504629	A2 20000215
			US 2000-519444	A2 20000306
			US 2000-444252	A2 20000410
			US 2000-575251	A2 20000519
			US 2000-609448	A2 20000629
			US 2000-649811	A2 20000828
			WO 2002-US11475	W 20020409

AB Compns. and methods for the therapy and diagnosis of cancer, such as colon cancer, are disclosed. Compns. may comprise one or more colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a protein. Such compns. may be used, for example, for the prevention and treatment of diseases such as colon cancer. Diagnostic methods based on detecting a colon tumor protein, or mRNA encoding such a protein, in a sample are also provided.

L34 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2002:616199 CAPLUS <<LOGINID::20081002>>  
 DOCUMENT NUMBER: 137:151147  
 TITLE: Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer  
 INVENTOR(S): Wang, Aijun; Clapper, Jonathan D.; Stolk, John A.; Meagher, Madeleine Joy  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 46 pp., Cont.-in-part of U.S. Ser. No. 649,811.  
 DOCUMENT TYPE: CODEN: USXKC0 Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 7  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020110547	A1	20020815	US 2001-833263	20010410
US 6284241	B1	20010904	US 1998-221298	19981223
US 6623923	B1	20030923	US 1999-401064	19990922
WO 2000037643	A2	20000629	WO 1999-US30909	19991223
WO 2000037643	A3	20010809		
W:	AB, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,			

DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 20020076414	A1	20020620	US 2001-922217	20010803
US 20020182191	A1	20021205	US 2001-25380	20011219
WO 2002083070	A2	20021024	WO 2002-US11475	20020409
WO 2002083070	A3	20041111		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002256186	A1	20021028	AU 2002-256186	20020409
US 20050260177	A1	20051124	US 2005-108172	20050415
PRIORITY APPLN. INFO.:				
		US 1998-221298	A2 19981223	
		US 1999-347496	A2 19990702	
		US 1999-401064	A2 19990522	
		US 1999-454150	A2 19991202	
		WO 1999-US30909	A2 19991223	
		US 1999-476296	A2 19991230	
		US 2000-480321	A2 20000110	
		US 2000-504629	A2 20000215	
		US 2000-519444	A2 20000306	
		US 2000-444252	A2 20000410	
		US 2000-575251	A2 20000519	
		US 2000-609448	A2 20000629	
		US 2000-649811	A2 20000828	
		US 1999-444242	A 19991119	
		US 1999-444252	A2 19991119	
		US 2001-833263	A2 20010410	
		US 2001-922217	A2 20010803	
		US 2001-25380	A 20011219	
		WO 2002-US11475	W 20020409	

AB Compns. and methods for the therapy and diagnosis of cancer, such as colon cancer, are disclosed. Compns. may comprise one or more colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a protein. Thus, polypeptides differentially expressed in colon tumors are isolated and characterized by PCR-based subtraction and microarray anal. of cDNA libraries, as well as mouse antisera. Such compns. may be used, for example, for the prevention and treatment of diseases such as colon cancer. Diagnostic methods based on detecting a colon tumor protein, or mRNA encoding such a protein, in a sample are also provided.

L34 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2002:466537 CAPLUS <<LOGINID::20081002>>  
 DOCUMENT NUMBER: 137:42650  
 TITLE: Tumor-associated proteins and their cDNA sequences and uses for immunotherapy and diagnosis of colon cancer  
 INVENTOR(S): Xu, Jiangchun; Lodes, Michael J.; Sechrist, Heather; Benson, Darin R.; Meagher, Madeleine Joy; Stolk, John A.; Wang, Tongtong; Jiang, Yugui; Smith, Carole L.; King, Gordon E.; Wang, Aijun; Clapper, Jonathan D.; Corixa Corporation, USA  
 PATENT ASSIGNEE(S): U.S. Pat. Appl. Publ., 50 pp., Cont.-in-part of U.S. Ser. No. 833,263.  
 SOURCE:

DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 7  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020076414	A1	20020620	US 2001-922217	20010803
US 6284241	B1	20010904	US 1998-221298	19981223
US 6623923	B1	20030923	US 1999-401064	19990922
WO 2000037643	A2	20000629	WO 1999-US30909	19991223
WO 2000037643	A3	20010809		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 20020110547	A1	20020815	US 2001-833263	20010410
US 20020182191	A1	20021205	US 2001-25380	20011219
WO 2002083070	A2	20021024	WO 2002-US11475	20020409
WO 2002083070	A3	20041111		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002256186	A1	20021028	AU 2002-256186	20020409
US 20050260177	A1	20051124	US 2005-108172	20050415
PRIORITY APPLN. INFO.:				
		US 1998-221298	A2 19981223	
		US 1999-347496	A2 19990702	
		US 1999-401064	A2 19990922	
		US 1999-454150	B2 19991202	
		WO 1999-US30909	W 19991223	
		US 1999-476296	A2 19991230	
		US 2000-480321	B2 20000110	
		US 2000-504629	A2 20000215	
		US 2000-519444	A2 20000306	
		US 2000-444252	A2 20000410	
		US 2000-575251	A2 20000519	
		US 2000-609448	A2 20000629	
		US 2000-649811	A2 20000828	
		US 2001-833263	A2 20010410	
		US 1999-444242	A 19991119	
		US 1999-444252	A2 19991119	
		US 2001-922217	A2 20010803	
		US 2001-25380	A 20011219	
		WO 2002-US11475	W 20020409	

AB Comps. and methods for the therapy and diagnosis of cancer, such as colon cancer, are disclosed. Thus, colon tumor-associated proteins are isolated by PCR-based subtraction and microarray anal., use of SCID mouse antisera, and conventional subtraction. Comps. may comprise one or more colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an

antigen presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a protein. Such compns. may be used, for example, for the prevention and treatment of diseases such as colon cancer. Diagnostic methods based on detecting a colon tumor protein, or mRNA encoding such a protein, in a sample are also provided.

L34 ANSWER 19 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2001:507728 CAPLUS <<LOGINID:20081002>>  
DOCUMENT NUMBER: 135121178  
TITLE: Identification of colon cancer-associated proteins for immunotherapy and diagnosis  
INVENTOR(S): Xu, Jiangchun; Lodes, Michael J.; Secrist, Heather; Benson, Darin R.; Meagher, Madeleine Joy; Stolk, John A.; King, Gordon E.; Wang, Tongtong; Jiang, Yuqiu  
PATENT ASSIGNEE(S): Corixa Corporation, USA  
SOURCE: PCT Int. Appl., 472 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 7  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001049716	A2	20010712	WO 2000-US35596	20001229 <--
WO 2001049716	A3	20020131		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2396036	A1	20010712	CA 2000-2396036	20001229 <--
EP 1242598	A2	20020925	EP 2000-989592	20001229 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:				
		US 1999-476296	A 19991230 <--	
		US 2000-480321	A 20000110 <--	
		US 2000-504629	A 20000215 <--	
		US 2000-519444	A 20000306 <--	
		US 2000-575251	A 20000519 <--	
		US 2000-609448	A 20000629 <--	
		US 2000-649811	A 20000828 <--	
		WO 2000-US35596	W 20001229 <--	

AB The authors disclose the use of a cDNA library and subtractive PCR to identify a number of genes, and their proteins, which are overexpressed in human colon tumors. In addition, soluble tumor proteins expressed in serum of colon tumor-bearing SCID mice were used to generate polyclonal antibodies for probing a cDNA expression library.

IT 148710-76-3, Protein (human clone  $\beta$ -ig-h3 transforming growth factor  $\beta$ -induced precursor reduced)

RL: ANT (Analyte); ARG (Analytical reagent use); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)  
(amino acid sequence; identification and immunogenicity of human colon tumor-associated antigens)

RN 148710-76-3 CAPLUS

CN Protein (human clone  $\beta$ ig-h3 transforming growth factor  $\beta$ -induced precursor reduced) (9CI) (CA INDEX NAME)

SEQ 1 MALFVRLAL ALALALGPA A TLAGPAKSPY QLVLQHSRLR GRQHGPNVCA  
51 VQKVIGTNRK YFTNCKQWYQ RKICGKSTVI SYECCPGYEK VPGEKGCPAA  
101 LPQLSNLYETL GVGSTTTQL YTDRTEKLRP EMEGGGSFTI FAPSNEAWAS  
151 LPAAEVLDLSV SNVNIELLNA LRYHMVGRV LTDELKHGMT LTSMYQNSNI  
201 QIHHYPNGIV TVNCARLLKA DHATNGVHH LIDKVISTIT NNIIQOIEIE  
251 DTFETLRAAV AASGLNTMLE GNGQYTLLAP TNEAEFKIPS ETLNRLILGDP  
301 EALRDLNNH ILKSAMCAEA IVAGLSVETL EGTTILEVGCS GDMLTINGKA  
351 IIISNKDILAT LIPDSAKTLEF ELAAEASDVST AIDLFRQAGL  
401 GNHLSGSGSERL TLLAPLNSVF KDGTPPIDAH TRNLLRNHII KDLQASKYLY  
451 HQQTLETLLGG KKLRLFVYRN SLCIENSCIA AHDKRGGRYGT LFTMDRVLTP  
501 PGPTVMDVLK GDNRFSMLVA AIQSAGLTET LNREGVYTVF APTEAFAFL  
551 PPRERSRLLG DAKELANILK YHIGDEILVS GIGALVRLK SLQGDKLEVS  
601 LKNNVSVSNK EPVVAEPDIMA TNGVHVITN VLQPPANRPQ ERGDELADSA  
651 LEIFKQASAF SRASQRSVRL APVYQKLLER MKH

L34 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:441937 CAPLUS <<LOGINID:20081002>>

DOCUMENT NUMBER: 133:85149

TITLE: Colon tumor-specific nucleic acids and proteins and their use for immunotherapy and diagnosis of colon cancer

INVENTOR(S): Xu, Jiangchun; Lodes, Michael J.; Sechrist, Heather; Benson, Darin R.; Meagher, Madeleine Joy; Stolk, John; Wang, Tongtong; Jiang, Yuqiu

PATENT ASSIGNEE(S): Corixa Corporation, USA

SOURCE: PCT Int. Appl., 229 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000037643	A2	20000629	WO 1999-US30909	19991223 <--
WO 2000037643	A3	20010809		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6284241	B1	20010904	US 1998-221298	19981223 <--
US 6623923	B1	20030923	US 1999-401064	19990922 <--
CA 2356987	A1	20000629	CA 1999-2356987	19991223 <--
EP 1144632	A2	20011017	EP 1999-967625	19991223 <--
EP 1144632	A3	20011107		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002533082	T	20021008	JP 2000-589697	19991223 <--
US 20020110547	A1	20020815	US 2001-833263	20010410 <--
US 20020076414	A1	20020620	US 2001-922217	20010803 <--

US 20020182191	A1	20021205	US 2001-25380	20011219 <--
US 20050260177	A1	20051124	US 2005-108172	20050415 <--
PRIORITY APPLN. INFO.:			US 1998-221298	A 19981223 <--
			US 1999-347496	A 19990702 <--
			US 1999-401064	A 19990922 <--
			US 1999-444242	A 19991119 <--
			US 1999-454150	A 19991202 <--
			US 1999-444252	A2 19991119 <--
			WO 1999-US30909	W 19991223 <--
			US 1999-476296	A2 19991230 <--
			US 2000-480321	A2 20000110 <--
			US 2000-504629	A2 20000215 <--
			US 2000-519444	A2 20000306 <--
			US 2000-444252	A2 20000410 <--
			US 2000-575251	A2 20000519 <--
			US 2000-609448	A2 20000629 <--
			US 2000-649811	A2 20000828 <--
			US 2001-833263	A2 20010410 <--
			US 2001-922217	A2 20010803 <--
			US 2001-25380	B1 20011219 <--

AB Over 470 nucleic acids that are overexpressed  $\geq 2$ -fold in human colon tumor tissues are provided. Complementary DNA libraries were constructed by subtracting a pool of colon tumors with a pool of normal colon and other tissues using PCR subtraction methodologies; clones from the cDNA subtracted library were submitted to PCR amplification, and mRNA expression levels for representative clones determined by microarray technol. This method recovers rare transcripts that are over-expressed in colon tumor tissue. Addnl. colon tumor-specific transcripts were obtained by (1) conventional cDNA subtraction, (2) use of mouse antisera to identify DNA sequences encoding colon tumor antigens, (3) and isolation of tumor polypeptides using SCID-passaged tumor RNA. Compns. and methods for the therapy and diagnosis of cancer, such as colon cancer, are disclosed. Compns. may comprise one or more colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen-presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a protein. Such compns. may be used, for example, for the prevention and treatment of diseases such as colon cancer. Diagnostic methods based on detecting a colon tumor protein, or mRNA encoding such a protein, in a sample are also provided.

IT 148710-76-3, Protein (human clone  $\beta$ ig-h3 transforming growth factor  $\beta$ -induced precursor reduced)

RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses) (amino acid sequence; colon tumor-specific nucleic acids and proteins and their use for immunotherapy and diagnosis of colon cancer)

RN 148710-76-3 CAPLOS

CN Protein (human clone  $\beta$ ig-h3 transforming growth factor  $\beta$ -induced precursor reduced) (9CI) (CA INDEX NAME)

SEQ 1 MALFVRLLL ALALALGPAA TLAGPAKSPY QLVLQHSRLR GRQHGPNVCA  
 51 VQKVIGTNRK YFTNCQWYQ RKICGKSTVI SYECCPGYEK VPGEKGCPAA  
 101 LPQLSNLYETL GVGSTTTQL YTDRTEKLRP EMEPGPGSFTI FAPSNEAWAS  
 151 LPAAEVLDLSV SNNVNIELLNA LRYHMVGRV LTDELKHGMT LTSMYQNSNI  
 201 QIHYPNGIV TVNCARLLKA DHHATNGVVH LIDKVISTIT NNIIQQIIIEIE  
 251 DTFETLRAAV AASGLNNTMLE GNQGYTLLAP TNEAEFKIPS ETLNRLIGDP  
 301 EALRDLNNHH ILKSMACMEEA IVAGLSVETL EGTTLEVGCs GDMLTNGKA  
 351 IISNKGDLAT NGVIHYIDEL LIPDASAKTLE ELAAESDVST AIDLFRQAGL

401 GNHLSGSERL TLLAPLNSVF KDGTPPIDAH TRNLLRNHII KDLQASKLY  
451 HGQTTLTGG KLLKRVFVYRN SLCIENSCIA HDAKRGRYGT LFTMDRVLTP  
501 PMGTCVMDVL GDNFRSMLVA AIQSAGLTET LNREGVYTVE APTNEAFRAL  
551 PPRERSRLIG DAKELANILK YHIGDEILVS GGIGALVRLK SLQGDKLEVS  
601 LKNNNRSVSLK EPVAEPDIMA TNGVHVITN VLQPPANRPQ ERGDELADSA  
651 LEIFKQASAF SRASRQSRSL APVYQKLLER MKH

```

=> fil stng
COST IN U.S. DOLLARS                               SINCE FILE      TOTAL
                                                ENTRY      SESSION
FULL ESTIMATED COST                           199.12      324.51

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                ENTRY      SESSION
CA SUBSCRIBER PRICE                         -16.00      -16.00

```

FILE 'STNGUIDE' ENTERED AT 14:31:27 ON 02 OCT 2008  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Sep 26, 2008 (20080926/UP).

```

=> fil caplus
COST IN U.S. DOLLARS                               SINCE FILE      TOTAL
                                                    ENTRY      SESSION
FULL ESTIMATED COST                           0.18      324.69

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                    ENTRY      SESSION
CA SUBSCRIBER PRICE                         0.00      -16.00

```

FILE 'CPLUS' ENTERED AT 14:33:20 ON 02 OCT 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Oct 2008 VOL 149 ISS 14  
FILE LAST UPDATED: 1 Oct 2008 (20081001/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>  
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> d his

(FILE 'HOME' ENTERED AT 14:15:35 ON 02 OCT 2008)

FILE 'REGISTRY' ENTERED AT 14:23:09 ON 02 OCT 2008  
L1        67 S IELLNALRYHMGVRVLT/SQSP  
L2        84 S EALRDLLNNHILKSAMCA/SQSP  
L3        58 S DQLASKLYHGGTLETLG/SQSP  
L4        68 S KELANILKYHIGDEILVS/SQSP

FILE 'CAPLUS' ENTERED AT 14:23:34 ON 02 OCT 2008  
L5        68 S L1  
L6        68 S L2  
L7        58 S L3  
L8        58 S L4

FILE 'STNGUIDE' ENTERED AT 14:24:26 ON 02 OCT 2008  
L9        5 S CANCER

FILE 'CAPLUS' ENTERED AT 14:25:26 ON 02 OCT 2008  
L10      246905 S CANCER  
L11      155786 S CARCINOMA  
L12      45688 S ONCO?  
L13      546919 S NEOPLAS?  
L14      297654 S TUMOR OR TUMOUR  
L15      40146 S ANGIOGEN?  
L16      11213 S ARTERIOSCLER?  
L17      25778 S SCLEROSIS  
L18      52 S NEOVASCULAR GLAUCOMA  
L19      5164 S DIABETIC RETINOPATHY  
L20      227 S PTERYGIUM  
L21      1185 S RETINAL DEGENERATION  
L22      617 S RETROLENATAL FIBROPLASIA  
L23      1 S GRANULAR CONJUNCTIVITIS  
L24      26118 S RHEUMATOID ARTHRITIS  
L25      17699 S LUPUS  
L26      71761 S THYROID?  
L27      15306 S PSORIASIS  
L28      28 S PYOGENIC GRANULOMA  
L29      158 S SEBORRHEIC DERMATITIS  
L30      7117 S ACNE  
L31      914566 S L10-L30  
L32      78 S L5-L8  
L33      31 S L32(L)L31  
L34      20 S L33 AND (PD<20030402 OR AD<20030402 OR PRD<20030402)

FILE 'STNGUIDE' ENTERED AT 14:31:27 ON 02 OCT 2008

FILE 'CAPLUS' ENTERED AT 14:33:20 ON 02 OCT 2008

=> s 131 and 132  
L35      47 L31 AND L32

=> s 135 and (pd<20030402 or ad<20030402 or prd<20030402)  
L36      32 L35 AND (PD<20030402 OR AD<20030402 OR PRD<20030402)

=> s 136 not 134  
L37      12 L36 NOT L34

=> d ti 1-12

L37 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Gene expression profile in activated human CD4+ T cells useful for the diagnosis and treatment of immune-related diseases

L37 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Binary prediction tree modeling with many predictors and its uses in clinical and genomic applications

L37 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Use of patterns of gene expression to identify tissue types and in disease diagnosis and prognosis

L37 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Methods of testing for bronchial asthma or chronic obstructive pulmonary disease, and drug screening for the same, using identified differentially expressed IL-13-stimulated marker genes

L37 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Genes expressed in atherosclerotic tissue and their use in diagnosis and pharmacogenetics

L37 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Method for measuring the amount of protein  $\beta$  ig-h3 and diagnostic kit using the same

L37 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Complexes of human and human papillomavirus proteins and their use in drug screening and diagnosis

L37 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Genes that are differentially expressed during erythropoiesis and their diagnostic and therapeutic uses

L37 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Human cDNA sequences and their encoded proteins and diagnostic and therapeutic uses

L37 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Transforming growth factor (TGF- $\beta$ )-induced expression of gene for protein  $\beta$ IG-H3 in human cells

L37 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN  
TI  $\beta$ ig-h3: a transforming growth factor- $\beta$ -responsive gene encoding a secreted protein that inhibits cell attachment in vitro and suppresses the growth of CHO cells in nude mice

L37 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Transforming growth factor  $\beta$  (TGF- $\beta$ )-induced gene expression

=> d ibib abs 1-12

L37 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2004:482032 CAPLUS <<LOGINID::20081002>>  
DOCUMENT NUMBER: 141:37605  
TITLE: Gene expression profile in activated human CD4+ T cells useful for the diagnosis and treatment of immune-related diseases

INVENTOR(S): Clark, Hilary; Hunte, Bridsell; Jackman, Janet; Schoenfeld, Jill; Williams, Mickey P.; Wood, William I.; Wu, Thomas D.; Bodary, Sarah

PATENT ASSIGNEE(S): Genentech, Inc., USA

SOURCE: PCT Int. Appl., 8598 pp.

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004047728	A2	20040610	WO 2003-XA35971	20031124 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2004047728	A2	20040610	WO 2003-US35971	20031124 <--
WO 2004047728	A3	20061130		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2002-429069P P 20021126 <--  
WO 2003-US35971 A 20031124

AB The present invention relates to compns. containing novel proteins and methods of using those compns. for the diagnosis and treatment of immune-related diseases. Microarray anal. of human CD4+ T-cells activated with an anti-CD3 antibody together with either ICAM-1 or anti-CD28 antibody provides genes that are differentially expressed in comparison to resting CD4+ T-cells. [This abstract record is one of two records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

L37 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:449883 CAPLUS <<LOGINID::20081002>>  
 DOCUMENT NUMBER: 140:402911  
 TITLE: Binary prediction tree modeling with many predictors and its uses in clinical and genomic applications  
 INVENTOR(S): Nevins, Joseph R.; West, Mike; Huang, Andrew T.  
 PATENT ASSIGNEE(S): Duke University, USA  
 SOURCE: PCT Int. Appl., 886 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 5  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004038376	A2	20040506	WO 2003-XA33946	20031024 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2004038376	A2	20040506	WO 2003-US33946	20031024 <--
WO 2004038376	A3	20040826		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:				
		US 2002-420729P	P 20021024 <--	
		US 2002-421062P	P 20021025 <--	
		US 2002-421102P	P 20021025 <--	
		US 2002-424701P	P 20021108 <--	
		US 2002-424715P	P 20021108 <--	
		US 2002-424718P	P 20021108 <--	
		US 2002-425256P	P 20021112 <--	
		US 2003-448461P	P 20030221 <--	
		US 2003-448462P	P 20030221 <--	
		US 2003-457877P	P 20030327 <--	
		US 2003-458373P	P 20030331 <--	
		WO 2003-US33946	A 20031024	

AB The statistical anal. described and claimed is a predictive statistical tree model that overcomes several problems observed in prior statistical models and regression analyses, while ensuring greater accuracy and predictive capabilities. Although the claimed use of the predictive statistical tree model described herein is directed to the prediction of a disease in individuals, the claimed model can be used for a variety of applications including the prediction of disease states, susceptibility of disease states or any other biol. state of interest, as well as other applicable non-biol. states of interest. This model first screens genes to reduce noise, applies kmeans correlation-based clustering targeting a large number of clusters, and then uses singular value decompns. (SVD) to extract the single dominant factor (principal component) from each cluster. This generates a statistically significant number of cluster-derived singular factors, that are referred to as metagenes, that characterize multiple patterns of expression of the genes across samples. The strategy aims to extract multiple such patterns while reducing dimension and smoothing out gene-specific noise through the aggregation within clusters. Formal predictive anal. then uses these metagenes in a Bayesian classification tree anal. This generates multiple recursive partitions of the sample into subgroups (the 'leaves' of the classification tree), and assoc. Bayesian predictive probabilities of outcomes with each subgroup. Overall predictions for an individual sample are then generated by averaging predictions, with appropriate wts., across many such tree models. The model includes the use of iterative out-of-sample, cross-validation

predictions leaving each sample out of the data set one at a time, refitting the model from the remaining samples and using it to predict the hold-out case. This rigorously tests the predictive value of a model and mirrors the real-world prognostic context where prediction of new cases as they arise is the major goal.

L37 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2004:219931 CAPLUS <<LOGINID::20081002>>  
DOCUMENT NUMBER: 1401:248186  
TITLE: Use of patterns of gene expression to identify tissue  
types and in disease diagnosis and prognosis  
INVENTOR(S): Glinskii, Guennadi V.  
PATENT ASSIGNEE(S): Sidney Kimmel Cancer Center, USA  
SOURCE: U.S. Pat. Appl. Publ., 209 pp., which which which  
which  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040053317	A1	20040318	US 2003-660434	20030910 <--
CA 2498418	A1	20040325	CA 2003-2498418	20030910 <--
WO 2004025258	A2	20040325	WO 2003-US28707	20030910 <--
WO 2004025258	A3	20050519		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003274970	A1	20040430	AU 2003-274970	20030910 <--
EP 1552293	A2	20050713	EP 2003-759240	20030910 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 20050142573	A1	20050630	US 2004-861003	20040603 <--
PRIORITY APPLN. INFO.:			US 2002-410018P	P 20020910 <--
			US 2002-411155P	P 20020916 <--
			US 2002-429168P	P 20021125 <--
			US 2003-444348P	P 200303131 <--
			US 2003-460826P	P 20030403
			US 2003-660434	A1 20030910
			WO 2003-US28707	W 20030910

AB Methods of using quant. anal. of array hybridizations to identify normal and diseased tissue in the diagnosis and prognosis of disease are described. The methods segregate individual samples into distinct classes using quant. measurements of expression values for selected sets of genes in individual samples compared to a reference standard. Samples displaying pos. and neg. correlations of the gene expression values with the reference standard samples exhibit distinct behaviors and pathohistol. features. Also disclosed are methods for identifying sets of genes whose expression patterns are correlated with a phenotype. Such sets are useful for characterizing cellular differentiation pathways and states and for identifying potential

drug discovery targets. Panels for diagnosis and determination of risk of invasive and metastatic forms of lung, prostate and breast cancer are identified. Similarly, panels indicating recurrence of the cancers and poor prognostic outcomes are identified.

L37 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2004:181844 CAPLUS <>LOGINID::20081002>>  
DOCUMENT NUMBER: 140:233978  
TITLE: Methods of testing for bronchial asthma or chronic obstructive pulmonary disease, and drug screening for the same, using identified differentially expressed IL-13-stimulated marker genes  
INVENTOR(S): Ohtani, Noriko; Sugita, Yuji; Yamaya, Mutsuo; Kubo, Hiroshi; Nagai, Hiroichi; Izuhara, Kenji  
PATENT ASSIGNEE(S): Genox Research, Inc., Japan  
SOURCE: Eur. Pat. Appl., 241 pp.  
CODEN: EPXXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1394274	A2	20040303	EP 2003-254857	20030804 <--
EP 1394274	A3	20040526		
R: AI, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2004121218	A	20040422	JP 2003-77212	20030320 <--
US 20050208496	A1	20050922	US 2003-631467	20030731 <--
			JP 2002-229312	A 20020806 <--
			JP 2003-77212	A 20030320 <--

PRIORITY APPLN. INFO.:

AB An objective of the present invention is to provide a method of testing for bronchial asthma or chronic obstructive pulmonary disease, a method of screening for candidate compds. for treating bronchial asthma or chronic obstructive pulmonary disease, and a pharmaceutical agent for treating bronchial asthma or chronic obstructive pulmonary disease. The present invention identified genes whose expression levels varied between respiratory epithelial cells that had been stimulated by IL-13 to induce the goblet cell differentiation, and unstimulated respiratory epithelial cells. The respiratory epithelial cells were cultured according to the air interface method. The genes were revealed to be useful as markers for testing for bronchial asthma or chronic obstructive pulmonary disease and screening for therapeutic agents for such diseases. Specifically, the present invention provides methods of testing for bronchial asthma or chronic obstructive pulmonary disease and methods of screening for compds. to treat the diseases based on the comparison of the expression levels of marker genes identified as described above.

L37 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2003:942764 CAPLUS <>LOGINID::20081002>>  
DOCUMENT NUMBER: 140:3792  
TITLE: Genes expressed in atherosclerotic tissue and their use in diagnosis and pharmacogenetics  
INVENTOR(S): Nevins, Joseph; West, Mike; Goldschmidt, Pascal  
PATENT ASSIGNEE(S): Duke University, USA  
SOURCE: PCT Int. Appl., 408 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 5

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003091391	A2	20031106	WO 2002-XA38221	20021112 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2003091391	A2	20031106	WO 2002-US38221	20021112 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2002-374547P	P 20020423 <--
			US 2002-420784P	P 20021024 <--
			US 2002-421043P	P 20021025 <--
			US 2002-424680P	P 20021108 <--
			WO 2002-US38221	A 20021112 <--

AB Genes whose expression is correlated with an determinant of an atherosclerotic phenotype are provided. Also provided are methods of using the subject atherosclerotic determinant genes in diagnosis and treatment methods, as well as drug screening methods. In addition, reagents and kits thereof that find use in practicing the subject methods are provided. Also provided are methods of determining whether a gene is correlated with a disease phenotype, where correlation is determined using a Bayesian anal.

L37 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2003:856144 CAPLUS <<LOGINID::20081002>>  
 DOCUMENT NUMBER: 139:347737  
 TITLE: Method for measuring the amount of protein  $\beta$  ig-h3 and diagnostic kit using the same  
 INVENTOR(S): Kim, In-San; Bae, Jong-Sub  
 PATENT ASSIGNEE(S): Regen Biotech, Inc., S. Korea  
 SOURCE: PCT Int. Appl., 95 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003089935	A1	20031030	WO 2002-KR1975	20021022 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,				

UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,  
 CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 KR 2002082421 A 20021031 KR 2002-21488 20020419 <--  
 AU 2002348583 A1 20031103 AU 2002-348583 20021022 <--  
 AU 2002348583 B2 20061207  
 EP 1502114 A1 20050202 EP 2002-781971 20021022 <--  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK  
 BR 2002015700 A 20050503 BR 2002-15700 20021022 <--  
 CN 1625687 A 20050608 CN 2002-828782 20021022 <--  
 CN 100374864 C 20080312  
 JP 2005527813 T 20050915 JP 2003-586617 20021022 <--  
 RU 2281512 C2 20060810 RU 2004-133806 20021022 <--  
 US 20050164197 A1 20050728 US 2004-511719 20041126 <--  
 PRIORITY APPLN. INFO.: KR 2002-21488 A 20020419 <--  
 KR 2001-20991 A 20010419 <--  
 WO 2002-KR1975 W 20021022 <--

AB The present invention relates to the method for measuring the amount of  $\beta$  ig-h3 protein and diagnostic kit using the same. The  $\beta$  ig-h3 protein is an extracellular matrix protein involved in cell adhesion, is induced by TGF- $\beta$  in many kinds of cells, and contains fas-1 domains composed of 110-140 amino acids containing two very conserved branches composed of 10 amino acids each. Particularly, the invention relates to the method for measuring the amount of  $\beta$  ig-h3 protein in the body fluids by specific binding reaction between  $\beta$  ig-h3 protein or recombinant proteins of the fas-1 domain in  $\beta$  ig-h3 protein (including their fragments or their derivs.) and their ligands, in particular an antigen-antibody reaction. Sensitive diagnostic kits for renal diseases, hepatic diseases, rheumatoid arthritis, or cardiovascular diseases are thus provided. Standard protein can be any of human  $\beta$  ig-h3, mouse  $\beta$  ig-h3, recombinant  $\beta$  ig-h3 D-IV(1x) which is a monomer of the fourth fas-1 domain, ig-h3 D-IV(2x), ig-h3 D-IV(3x) and  $\beta$  ig-h3 D-IV(4x), and either anti-human  $\beta$  ig-h3 antibody or anti-mouse  $\beta$  ig-h3 antibody can be used as the primary antibody. The preferable coating concn of std protein is 0.1-2.0  $\mu$ g/mL and 0.5-1.0  $\mu$ g/mL is more preferable; and the preferable diluting ratio of the primary and the secondary antibody is 1:400-1:3200 and 1:2000 is more preferable.  
 REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L37 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2003:656897 CAPLUS <<LOGINID::20081002>>  
 DOCUMENT NUMBER: 139:193297  
 TITLE: Complexes of human and human papillomavirus proteins and their use in drug screening and diagnosis  
 INVENTOR(S): Jackson, Amanda; Ooi, Chean Eng; Lewin, David A.; Cuthill, Scott  
 PATENT ASSIGNEE(S): Curagen Corporation, USA; Hoffmann-La Roche Inc.  
 SOURCE: PCT Int. Appl., 156 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003068940	A2	20030821	WO 2003-US4594	20030214 <--

WO 2003068940 A3 20031127  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,  
 PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,  
 UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 AU 200315244 A1 20030904 AU 2003-215244 20030214 --<  
 US 20050100554 A1 20050512 US 2003-367057 20030214 --<  
 PRIORITY APPLN. INFO.: US 2002-356911P P 20020214 --<  
 WO 2003-US4594 W 20030214 --<

AB Complexes of human papillomavirus (HPV) proteins E1-E7, L1, and L2 with human proteins are disclosed. These complexes may be used to screen for agents which disrupt the complexes. These agents may be used for treatment of HPV infections. A method of detecting these complexes may be used in screening for pre-cancerous cervical lesions and for classifying HPV infections. Thus, yeast two-hybrid assays were used to identify interactions of HPV-1a, HPV-11, and HPV-16 proteins with human proteins.

L37 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2003:409169 CAPLUS <<LOGINID::20081002>>  
 DOCUMENT NUMBER: 138:380506  
 TITLE: Genes that are differentially expressed during erythropoiesis and their diagnostic and therapeutic uses  
 INVENTOR(S): Brissette, William H.; Neote, Kuldeep S.; Zagouras, Panayiotis; Zenke, Martin; Lemke, Britt; Hacker, Christine  
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA; Max-Delbrueck-Centrum Fuer Molekulare Medizin  
 SOURCE: PCT Int. Appl., 285 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003038130	A2	20030508	WO 2002-XA34888	20021031 --<
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2003038130	A2	20030508	WO 2002-US34888	20021031 --<
WO 2003038130	A3	20040212		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,				

UA, UG, US, UZ, VN, YU, ZA, ZM, ZW  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,  
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-335048P P 20011031 <--  
US 2001-335183P P 20011102 <--  
WO 2002-US34888 A 20021031 <--

AB The present invention provides mol. targets that regulate erythropoiesis. Groups of genes or their encoded gene products comprise panels of the invention and may be used in therapeutic intervention, therapeutic agent screening, and in diagnostic methods for diseases and/or disorders of erythropoiesis. The panels were discovered using gene expression profiling of erythroid progenitors with Affymetrix HU6800 and HG-U95Av2 chips. Cells from an *in vitro* growth and differentiation system of SCF-Epo dependent human erythroid progenitors, E-cadherin+/CD36<sup>+</sup> progenitors, cord blood, or CD34<sup>+</sup> peripheral blood stem cells were analyzed. The HU6800 chip contains probes from 13,000 genes with a potential role in cell growth, proliferation, and differentiation and the HG-U95Av2 chip contains 12,000 full-length, functionally-characterized genes. [This abstract record is one of two records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

L37 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2002:869107 CAPLUS <<LOGINID::20081002>>  
DOCUMENT NUMBER: 137:364443  
TITLE: Human cDNA sequences and their encoded proteins and diagnostic and therapeutic uses  
INVENTOR(S): Alsobrook, John P.; Anderson, David W.; Boldog, Ferenc L.; Burgess, Catherine E.; Casman, Stacie J.; Edinger, Schlotmit R.; Ellerman, Karen; Gangolli, Esha A.; Gerlach, Valerie L.; Gorman, Linda; Gunther, Erik; Herrmann, John L.; Ji, Weizhen; Lepley, Denise M.; Lewin, David A.; Li, Li; Macdougall, John R.; Malyankar, Uriel M.; Mezes, Peter D.; Padigaru, Muralidhara; Paturajan, Meera; Peyman, John A.; Rastelli, Luca; Rieger, Daniel K.; Rothenberg, Mark E.; Shenoy, Suresh G.; Smithson, Glenn; Spytek, Kimberly A.; Stone, David J.; Taupier, Raymond J., Jr.; Tchernev, Velizar T.; Vernet, Corine A. M.; Voss, Edward Z.; Zerhusen, Bryan D.; Zhong, Haihong; Miller, Charles E.  
PATENT ASSIGNEE(S): Curagen Corporation, USA  
SOURCE: PCT Int. Appl., 491 pp.  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 175  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
WO 2002090568	A2	20021114	WO 2002-US14341	20020502 <--
WO 2002090568	A3	20050421		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,  
 CT, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 CA 2446427 A1 20021114 CA 2002-2446427 20020502 <--  
 AU 2002314769 A1 20021118 AU 2002-314769 20020502 <--  
 JP 2005504514 T 20050217 JP 2002-587627 20020502 <--  
 EP 1539806 A2 20050615 EP 2002-741692 20020502 <--  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
 AU 2005200106 A1 20050210 AU 2005-200106 20050112 <--  
 AU 2006201467 A1 20060504 AU 2006-201467 20060407 <--  
 AU 2007202935 A1 20070719 AU 2007-202935 20070626 <--  
 PRIORITY APPLN. INFO.:  
 US 2001-288935P P 20010503 <--  
 US 2001-289087P P 20010507 <--  
 US 2001-289620P P 20010508 <--  
 US 2001-289621P P 20010508 <--  
 US 2001-289817P P 20010509 <--  
 US 2001-289818P P 20010509 <--  
 US 2001-290194P P 20010511 <--  
 US 2001-290753P P 20010514 <--  
 US 2001-291189P P 20010515 <--  
 US 2001-291243P P 20010516 <--  
 US 2001-292001P P 20010518 <--  
 US 2001-292374P P 20010521 <--  
 US 2001-292587P P 20010522 <--  
 US 2001-293107P P 20010523 <--  
 US 2001-293589P P 20010524 <--  
 US 2001-293747P P 20010525 <--  
 US 2001-294110P P 20010529 <--  
 US 2001-294434P P 20010530 <--  
 US 2001-312192P P 20010814 <--  
 US 2001-313173P P 20010817 <--  
 US 2001-313187P P 20010817 <--  
 US 2001-318728P P 20010912 <--  
 US 2001-318744P P 20010912 <--  
 US 2001-335910P P 20011115 <--  
 US 2001-333891P P 20011128 <--  
 US 2001-333942P P 20011128 <--  
 US 2002-345776P P 20020103 <--  
 US 2002-345220P P 20020104 <--  
 US 2002-136071 A 20020501 <--  
 AU 2000-37360 A3 20000309 <--  
 AU 2000-78680 A3 20001006 <--  
 AU 2001-247294 A3 20010305 <--  
 AU 2001-47294 T0 20010305 <--  
 US 2001-288395P P 20010503 <--  
 WO 2002-US14341 W 20020502 <--

AB Disclosed herein are 62 cDNA sequences that encode novel human polypeptides that are members of the following protein families: trypsin, germline oligomeric matrix protein, neuromedin U25, caldecrin, neural cell adhesion protein, ADAMTS 12, CASPR4, ADAMS-TS3, gliacolin, aminopeptidase N, adiponectin, trypsin III, tissue kallikrein,  $\beta$ -transforming growth factor, diphthamide synthesis protein, WECH, lungkine, ADAM-TS7, palmitoyl-protein thioesterase-21, betacellulin, small inducible cytokine A23, granulocyte colony-stimulating factor, platelet basic protein 2, brain natriuretic peptide, serine protease, acyl-CoA-binding protein, elastase IV, collagen, viral receptor, and cathepsin L2. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivs., variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic,

diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

L37 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 1995:810958 CAPLUS <<LOGINID::20081002>>  
DOCUMENT NUMBER: 123:219300  
ORIGINAL REFERENCE NO.: 123:38838h  
TITLE: Transforming growth factor (TGF- $\beta$ )-induced expression of gene for protein  $\beta$ IG-H3 in human cells  
INVENTOR(S): Purchio, Anthony F.; Skonier, John E.; Neubauer, Michael G.  
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA  
SOURCE: U.S., 23 pp. Cont.-in-part of U.S. Ser. No. 833,835, abandoned.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5444164	A	19950822	US 1992-878960	19920504 <--
CA 2088804	A1	19930806	CA 1993-2088804	19930204 <--
ES 2073327	T3	19950801	ES 1993-300809	19930204 <--
JP 07133296	A	19950523	JP 1993-18705	19930205 <--

PRIORITY APPLN. INFO.: US 1992-833835 B2 19920205 <--  
AB Expression of the gene for protein  $\beta$ IG-H3 by TGF- $\beta$  in human lung adenocarcinoma cells A549 and H2981 is described, its cDNA isolated, and amino acid sequence deduced. The 683-amino-acid protein contains 4 homologous repeats and may represent a cell surface recognition mol. The TGF- $\beta$ -induced protein shown to inhibit the growth of tumor cells.

L37 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 1994:571807 CAPLUS <<LOGINID::20081002>>  
DOCUMENT NUMBER: 121:171807  
ORIGINAL REFERENCE NO.: 121:31007a,31010a  
TITLE:  $\beta$ ig-h3: a transforming growth factor- $\beta$ -responsive gene encoding a secreted protein that inhibits cell attachment in vitro and suppresses the growth of CHO cells in nude mice  
AUTHOR(S): Skonier, John; Bennett, Kelly; Rothwell, Victoria; Kosowski, Steve; Plowman, Greg; Wallace, Phil; Edelhoff, Susanne; Disteche, Christine; Neubauer, Mike; et al.  
CORPORATE SOURCE: Pharmaceutical Research Institute, Bristol-Myers Squibb, Seattle, WA, 98121, USA  
SOURCE: DNA and Cell Biology (1994), 13(6), 571-584  
CODEN: DCEBEB; ISSN: 1044-5498  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB  $\beta$ ig-h3 is a novel gene first discovered by differential screening of a cDNA library made from A549 human lung adenocarcinoma cells treated with transforming growth factor- $\beta$ 1 (TGF- $\beta$ 1). It encodes a 683-amino-acid protein containing a secretory signal sequence and four homologous internal domains. Here the authors show that treatment of several types of cells, including human melanoma cells, human mammary epithelial cells, human keratinocytes, and human fibroblasts, with TGF- $\beta$  resulted in a significant increase in  $\beta$ ig-h3 RNA. A

portion of the  $\beta$ ig-h3 coding sequence was expressed in bacteria, and antisera against the bacterially produced protein was raised in rabbits. This antisera was used to demonstrate that several cell lines secreted a 68-kD  $\beta$ IG-H3 protein after treatment with TGF- $\beta$ . Transfection of  $\beta$ IG-H3 expression plasmids into Chinese hamster ovary (CHO) cells led to a marked decrease in the ability of these cells to form tumors in nude mice. The  $\beta$ IG-H3 protein was purified from media conditioned by recombinant CHO cells, characterized by immunoblotting and protein sequencing and shown to function in an anti-adhesion assay in that it inhibited the attachment of A549, HeLa, and WI-38 cells to plastic in serum-free media. Sequencing of cDNA clones encoding murine  $\beta$ ig-H3 indicated 90.6% conservation at the amino acid level between the murine and human proteins. Finally, the  $\beta$ ig-h3 gene was localized to human chromosome 5q31, a region frequently deleted in preleukemic myelodysplasia and leukemia. The corresponding mouse  $\beta$ ig-h3 gene was mapped to mouse chromosome 13 region B to C1, which confirms a region of conservation on human chromosome 5 and mouse chromosome 13. The authors suggest that this protein be named p68 $\beta$ ig-h3.

L37 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1993:618358 CAPLUS <LOGINID::20081002>>  
 DOCUMENT NUMBER: 119:218358  
 ORIGINAL REFERENCE NO.: 119:38717a,38720a  
 TITLE: Transforming growth factor  $\beta$  (TGF- $\beta$ )-induced  
 gene expression  
 INVENTOR(S): Purchio, Anthony F.; Neubauer, Michael G.; Skonier,  
 John E.  
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA  
 SOURCE: Eur. Pat. Appl., 23 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 555989	A1	19930818	EP 1993-300809	19930204 <--
EP 555989	B1	19950524		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CA 2088804	A1	19930806	CA 1993-2088804	19930204 <--
ES 2073327	T3	19950801	ES 1993-300809	19930204 <--
JP 07133296	A	19950523	JP 1993-18705	19930205 <--
PRIORITY APPLN. INFO.:			US 1992-833835	A 19920205 <--
AB	TGF- $\beta$ -induced gene expression is observed in a few cultured mammalian cell lines such as the cell lines derived from human adenocarcinoma cells, the embryonic palatal mesenchyme cells, and prostate adenocarcinoma cells. The cDNA encoding the induced protein is isolated from the TGF- $\beta$ 1-treated human lung adenocarcinoma-derived cell line A549 and its amino acid sequence deduced. The protein designated $\beta$ IG-H3 consists of 4 homologous repeat regions with a total of 683 amino acids. An Arg-Gly-Asp motif at positions 642-644, that may function as a ligand recognition sequence for several integrins, is also noted. Methods for production and identification of the proteins are also claimed.			

=> fil stng  
 COST IN U.S. DOLLARS  
 FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
47.04	371.73

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	-9.60	-25.60

FILE 'STNGUIDE' ENTERED AT 14:35:15 ON 02 OCT 2008  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Sep 26, 2008 (20080926/UP).

=>  
=> log h

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	3.00	374.73

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	0.00	-25.60

SESSION WILL BE HELD FOR 120 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 15:04:59 ON 02 OCT 2008